



Samaritan  
Health Plans

# Prior Authorization Criteria

InterCommunity Health Network

Puede obtener este documento en otro idioma, otro formato o en letra grande o pedir un intérprete sin costo alguno para usted. Llámenos al 800-832-4580 (TTY 800-735-2900) para pedir una copia de este documento o un intérprete.

You can get this document in another language, format, large print or ask for an interpreter at no cost to you. Please call us at 800-832-4580 (TTY 800-735-2900) to request a copy of this document or an interpreter

**PLEASE READ: This document contains information about the criteria for coverage for this plan.**

Updated on 07/1/2024. For more recent information or other questions, please contact Pharmacy Services at 541-768-4550 or toll free 800-832-4580 (TTY 800-735-2900) or visit [samhealthplans.org](https://www.samhealthplans.org). Pharmacy Services is available Monday through Friday, from 8 a.m. to 5 p.m.

## **Abatacept (ORENCIA)**

---

**Products Affected**

- ORENCIA

- ORENCIA CLICKJECT

PA Criteria	Criteria Details
<b>Required Medical Information</b>	<p><b>All diagnoses:</b></p> <ul style="list-style-type: none"><li>• Initial testing for latent TB and treatment, if necessary, before starting treatment.</li><li>• No current active infection at initiation of therapy.</li><li>• Risks and benefits documented in cases of chronic or recurrent infection.</li><li>• Will NOT be used in combination with another biologic or Otezla</li></ul> <p><b>Juvenile Idiopathic Arthritis (JIA):</b></p> <ul style="list-style-type: none"><li>• Documentation of juvenile idiopathic arthritis with active systemic features of JIA, with a physician global assessment of 5 or higher (or any systemic activity in the absence of active joint involvement) or JIA without active systemic features</li><li>• The member is transitioning to the requested treatment from a different biologic product previously approved by the plan OR documented failure of the following:<ul style="list-style-type: none"><li>○ NSAIDs for 3 months at maximum recommended or tolerated anti-inflammatory dose unless contraindicated, AND</li><li>○ At least 6 months of 2 of Methotrexate, leflunomide, sulfasalazine, hydroxychloroquine, or systemic corticosteroids</li></ul></li><li>• Documented intolerance or contraindication to DMARDs OR DMARD will be continued</li><li>• Trial and failure of both infliximab and adalimumab</li></ul> <p><b>Psoriatic Arthritis (PsA):</b></p> <ul style="list-style-type: none"><li>• Documentation of psoriatic arthritis based on at least 3 out of 5 of the following:<ul style="list-style-type: none"><li>○ Psoriasis (1 point for personal or family history, 2 points for current)</li><li>○ Psoriatic nail dystrophy</li><li>○ Negative test result for RF</li><li>○ Dactylitis (current or history)</li><li>○ Radiological evidence of juxta-articular new bone formation</li></ul></li><li>• The member is transitioning to the requested treatment from a different biologic product previously approved by the plan OR documented failure of conventional therapy with both of the following:<ul style="list-style-type: none"><li>○ NSAIDs for 3 months at maximum recommended or tolerated anti-inflammatory dose unless contraindicated, AND</li></ul></li></ul>

PA Criteria	Criteria Details
	<ul style="list-style-type: none"> <li>○ Methotrexate or other DMARD such as leflunomide, sulfasalazine, or cyclosporine</li> <li>• Trial and failure of both infliximab and adalimumab</li> </ul> <p><b>Rheumatoid Arthritis (RA):</b></p> <ul style="list-style-type: none"> <li>• Documentation of a baseline of moderate to high disease activity of rheumatoid arthritis measured as such by an accepted assessment instrument (PAS, PASII, RAPID3, CDAI, DAS28, SDAI)</li> <li>• The member is transitioning to the requested treatment from a different biologic product previously approved by the plan OR documented failure of nonbiologic DMARD therapy: methotrexate (dosed at least 20mg per week for at least 8 weeks), leflunomide or sulfasalazine</li> <li>• Trial and failure of both infliximab and adalimumab</li> </ul>
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	<p><b>Psoriatic Arthritis:</b> Dermatologist or Rheumatologist.  <b>Rheumatoid Arthritis, Juvenile Idiopathic Arthritis:</b> Rheumatologist.</p>
<b>Coverage Duration</b>	<b>Initial:</b> 6 months. <b>Renewal:</b> 12 months.
<b>Renewal Criteria</b>	<p><b>JIA:</b> Evidence of 20% or greater improvement in tender joint count and swollen joint count or has there been an improvement in functional ability.</p> <p><b>PsA:</b> Evidence of a 20% or greater improvement in tender joint count and swollen joint count.</p> <p><b>RA:</b> Evidence of a 20% or greater improvement in tender joint count and swollen joint count.</p>

Effective Date:	9/1/2023
P&T Approval Date:	7/11/2023
P&T Revision Date:	



# Acne Combo Products

---

## Products Affected

- Clindamycin/Benzoyl Peroxide 1-5% Gel
- Erythromycin/Benzoyl Peroxide 3-5% Gel

PA Criteria	Criteria Details
<b>Required Medical Information</b>	Documentation of trial and failure, intolerance, or contraindication to clindamycin/benzoyl peroxide 1.2-5% gel
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	<b>Initial:</b> 12 months; <b>Renewal:</b> 12 months
<b>Renewal Criteria</b>	Documentation of positive clinical response to therapy

Effective Date:	02/01/2023
P&T Approval Date:	01/10/2023
P&T Revision Date:	01/10/2023

# Acne Medication – Isotretinoin

## Products Affected

- Amnesteem capsules 10mg, 20mg, 40mg
- Claravis capsules 10mg, 20mg, 30mg 40mg
- Isotretinoin capsules 10mg, 20mg, 25mg, 30mg, 35mg, 40mg
- Myorisan capsules 10mg, 20mg, 30mg, 40mg
- Zenetane capsules 10mg, 20mg, 30mg, 40mg

PA Criteria	Criteria Details
<b>Required Medical Information</b>	Diagnosis of Severe nodulocystic acne <b>AND</b> documentation of trial and failure, intolerance, or contraindication to oral antibiotic with topical combination therapy (BP + Abx, retinoid + BP, or retinoid + BP + Abx)
<b>Age Restrictions</b>	12 years and older
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	<b>Initial:</b> 20 weeks
<b>Renewal Criteria</b>	No Renewals

Effective Date:	02/01/2023
P&T Approval Date:	01/10/2023
P&T Revision Date:	01/10/2023

# Acne Medication – Tretinoin

## Products Affected

- Tretinoin **0.025% cream**
- Tretinoin **0.05% cream**
- Tretinoin **0.1% cream**
- Tretinoin **0.01% gel**
- Tretinoin **0.025% gel**

PA Criteria	Criteria Details
<b>Required Medical Information</b>	Documentation of trial and failure, intolerance, or contraindication to a topical product containing benzoyl peroxide.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	<b>Initial:</b> 12 months, <b>Renewal:</b> 12 months
<b>Renewal Criteria</b>	Documentation of positive clinical response to therapy.

Effective Date:	02/01/2023
P&T Approval Date:	01/10/2023
P&T Revision Date:	01/10/2023



# Adalimumab & Biosimilars

## Products Affected

- Adalimumab-adaz- **40 MG/0.4ML (auto-injector and prefilled syringe)**
- Adalimumab-fkjp - **40MG/0.8ML, 20 MG/0.4ML, (auto-injector and prefilled syringe)**
- Hadlima **40/0.4M, 40/0.8ML (auto-injector and prefilled syringe)**
- Yusimry **40/0.8ML**

PA Criteria	Criteria Details
<p><b>Required Medical Information</b></p>	<p><b>All diagnoses</b></p> <ul style="list-style-type: none"> <li>• Initial testing for latent TB and treatment, if necessary, before starting treatment.</li> <li>• No current active infection at initiation of therapy.</li> <li>• Risks and benefits documented in cases of chronic or recurrent infection.</li> <li>• Will NOT be used in combination with another biologic or Otezla</li> </ul> <p><b>Ankylosing Spondylitis/Axial Spondyloarthritis (AS/SpA):</b></p> <ul style="list-style-type: none"> <li>• Documentation of moderate-to-severe ankylosing spondylitis or axial spondyloarthritis as defined by:               <ul style="list-style-type: none"> <li>○ Back pain and stiffness for more than 3 months AND</li> <li>○ Signs of active inflammation on MRI OR radiological evidence of sacroiliitis OR HLA-B27 positive AND</li> <li>○ BASDAI score of <math>\geq 4</math></li> </ul> </li> <li>• The member is transitioning to the requested treatment from a different biologic product previously approved by the plan <b>OR</b> Documented failure of conventional therapy with both of the following:               <ul style="list-style-type: none"> <li>○ At least two NSAIDs for 3 months at maximum recommended or tolerated anti-inflammatory dose unless contraindicated <b>AND</b></li> <li>○ Physical therapy/exercise program</li> </ul> </li> </ul> <p><b>Crohn’s Disease (CD):</b></p> <ul style="list-style-type: none"> <li>• Documentation of moderate-to-severe Crohn’s Disease</li> <li>• The member is transitioning to the requested treatment from a different biologic product previously approved by the plan OR Documented trial and failure of at least 1 of the following: 6-mercaptopurine, azathioprine, corticosteroid, methotrexate</li> </ul> <p><b>Hidradenitis Suppurativa (HS):</b></p>

PA Criteria	Criteria Details
	<ul style="list-style-type: none"> <li>• Documentation of a diagnosis of moderate to severe hidradenitis suppurativa (Hurley Stage II or Hurley Stage III)</li> <li>• The member is transitioning to the requested treatment from a different biologic product previously approved by the plan OR Documented failure of conventional therapy (e.g. oral antibiotics)</li> </ul> <p><b>Juvenile Idiopathic Arthritis (JIA):</b></p> <ul style="list-style-type: none"> <li>• Documentation of juvenile idiopathic arthritis with active systemic features of JIA, with a physician global assessment of 5 or higher (or any systemic activity in the absence of active joint involvement) or JIA without active systemic features</li> <li>• The member is transitioning to the requested treatment from a different biologic product previously approved by the plan OR documented failure of the following: <ul style="list-style-type: none"> <li>○ NSAIDs for 3 months at maximum recommended or tolerated anti-inflammatory dose unless contraindicated, AND</li> <li>○ At least 6 months of 2 of Methotrexate, leflunomide, sulfasalazine, hydroxychloroquine, or systemic corticosteroids</li> </ul> </li> <li>• Documented intolerance or contraindication to DMARDs OR DMARD will be continued with adalimumab</li> </ul> <p><b>Plaque Psoriasis (PP):</b></p> <ul style="list-style-type: none"> <li>• Documentation of severe plaque psoriasis, defined as having functional impairment as indicated by Dermatology Life Quality Index (DLQI) = 11 or Children's Dermatology Life Quality Index (CDLQI) = 13 (or severe score on other validated tool) AND one or more of the following: <ul style="list-style-type: none"> <li>○ At least 10% of body surface area involved</li> <li>○ Hand, foot, face, or mucous membrane involvement</li> </ul> </li> <li>• The member is transitioning to the requested treatment from a different biologic product previously approved by the plan OR documented failure of all the following: <ul style="list-style-type: none"> <li>○ High-potency topical corticosteroids (augmented betamethasone, clobetasol, etc.)</li> <li>○ At least one other topical agent (calcipotriene, tazarotene, anthralin, tar, etc.)</li> <li>○ PUVA or UVB Phototherapy</li> <li>○ Methotrexate</li> <li>○ At least 1 other second line systemic agent such as cyclosporine or acitretin</li> </ul> </li> </ul> <p><b>Psoriatic Arthritis (PsA):</b></p>

PA Criteria	Criteria Details
	<ul style="list-style-type: none"> <li>• Documentation of psoriatic arthritis based on at least 3 out of 5 of the following: <ul style="list-style-type: none"> <li>○ Psoriasis (1 point for personal or family history, 2 points for current)</li> <li>○ Psoriatic nail dystrophy</li> <li>○ Negative test result for RF</li> <li>○ Dactylitis (current or history)</li> <li>○ Radiological evidence of juxta-articular new bone formation</li> </ul> </li> <li>• The member is transitioning to the requested treatment from a different biologic product previously approved by the plan OR documented failure of conventional therapy with both of the following: <ul style="list-style-type: none"> <li>○ NSAIDs for 3 months at maximum recommended or tolerated anti-inflammatory dose unless contraindicated, AND</li> <li>○ Methotrexate or other DMARD such as leflunomide, sulfasalazine, or cyclosporine</li> </ul> </li> </ul> <p><b>Rheumatoid Arthritis (RA):</b></p> <ul style="list-style-type: none"> <li>• Documentation of a baseline of moderate to high disease activity of rheumatoid arthritis measured as such by an accepted assessment instrument (PAS, PASII, RAPID3, CDAI, DAS28, SDAI)</li> <li>• The member is transitioning to the requested treatment from a different biologic product previously approved by the plan OR documented failure of nonbiologic DMARD therapy: methotrexate (dosed at least 20mg per week for at least 8 weeks), leflunomide or sulfasalazine</li> </ul> <p><b>Ulcerative Colitis (UC):</b></p> <ul style="list-style-type: none"> <li>• Documentation of moderate-to-severe ulcerative colitis</li> <li>• The member is transitioning to the requested treatment from a different biologic product previously approved by the plan OR documented failure of at least 1 of the following: <ul style="list-style-type: none"> <li>○ Mesalamine, sulfasalazine OR</li> <li>○ Mercaptopurine, azathioprine, OR</li> <li>○ Corticosteroids (prednisone, methylprednisolone)</li> </ul> </li> </ul> <p><b>Uveitis:</b></p> <ul style="list-style-type: none"> <li>• Documentation of non-infectious, intermediate-, posterior- or pan-uveitis</li> <li>• Documented failure of all the following: <ul style="list-style-type: none"> <li>○ Topical glucocorticoids for at least 1 month OR periocular steroid injection, AND</li> <li>○ Oral corticosteroids, AND</li> </ul> </li> </ul>

PA Criteria	Criteria Details
	<ul style="list-style-type: none"> <li>○ At least one of the following: mycophenolate, tacrolimus, cyclosporine, azathioprine, or methotrexate</li> </ul>
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	<p><b>Crohns Disease and Ulcerative Colitis:</b> Gastroenterologist.  <b>Hidradenitis Suppurativa and Plaque Psoriasis:</b> Dermatologist.  <b>Psoriatic Arthritis:</b> Dermatologist or Rheumatologist.  <b>Rheumatoid Arthritis, Juvenile Idiopathic Arthritis:</b> Rheumatologist.  <b>Ankylosing Spondylitis, Axial Spondyloarthritis:</b> Rheumatologist.  <b>Uveitis:</b> Ophthalmologist or Rheumatologist.</p>
<b>Coverage Duration</b>	<b>Initial:</b> 6 months. <b>Renewal:</b> 12 months.
<b>Renewal Criteria</b>	<p><b>AS/SpA:</b> Evidence of significant improvement in signs and symptoms of AS/SpA and/or functioning, such as ASAS40 or 2-point improvement in BASDAI.</p> <p><b>CD:</b> Evidence of a decrease in symptoms, reduction in enterocutaneous fistulas or clinical remission.</p> <p><b>HS:</b> Evidence of a reduction of 25% or more of the total abscess and inflammatory nodule count and no increase in abscesses and draining fistulas.</p> <p><b>JIA:</b> Evidence of 20% or greater improvement in tender joint count and swollen joint count or has there been an improvement in functional ability.</p> <p><b>PP:</b> Evidence of positive clinical response to therapy as evidenced by ONE of the following: reduction of body surface area (BSA) involvement from baseline, improvement in symptoms (e.g. pruritus, inflammation) from baseline, or evidence of functional improvement.</p> <p><b>PsA:</b> Evidence of a 20% or greater improvement in tender joint count and swollen joint count.</p> <p><b>RA:</b> Evidence of a 20% or greater improvement in tender joint count and swollen joint count.</p> <p><b>UC:</b> Evidence of a significant response such as a decrease in bloody stools per day or elimination of signs of toxicity.</p>

PA Criteria	Criteria Details
	<b>Uveitis:</b> Evidence that that disease activity has been controlled, such as a lack of inflammation, no new inflammatory vascular lesions, no vitreous haze or decreases in visual acuity.

Effective Date:	11/1/2023
P&T Approval Date:	7/11/2023
P&T Revision Date:	

# Alirocumab (PRALUENT)

## Products Affected

- Praluent

PA Criteria	Criteria Details
<b>Required Medical Information</b>	<p><b>Clinical ASCVD:</b> Documented history of clinical ASCVD or has experienced a cardiovascular event <b>AND</b> Documentation of a current LDL greater than or equal to 70 mg/dl <b>AND</b> documentation of at least one of the following: Patient is receiving maximally tolerated statin therapy (or is statin intolerant) <b>AND</b> is receiving ezetimibe or documented intolerance to ezetimibe .</p> <p><b>Primary or familial hyperlipidemia:</b> Documentation of an untreated (i.e., prior to lipid lowering therapy) LDL greater than 190 mg/dL <b>AND</b> documentation of current LDL greater than 100 mg/dL <b>AND</b> documentation of at least one of the following: Patient is receiving maximally tolerated statin therapy (or is statin intolerant) <b>AND</b> is receiving ezetimibe or documented intolerance to ezetimibe.</p> <p><b>Homozygous Familial Hyperlipidemia:</b> Documentation of an untreated (i.e., prior to lipid lowering therapy) LDL greater than 190 mg/dL <b>AND</b> documentation of current LDL greater than 100 mg/dL <b>AND</b> documentation of at least one of the following: Patient is receiving maximally tolerated statin therapy (or is statin intolerant) <b>AND</b> is receiving ezetimibe or documented intolerance to ezetimibe</p>
<b>Age Restrictions</b>	18 years of age or older
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a cardiologist
<b>Coverage Duration</b>	<b>Initial:</b> 12 months. <b>Renewal:</b> 12 months.
<b>Renewal Criteria</b>	Documented positive clinical response to therapy

Effective Date:	02/01/2022
P&T Approval Date:	01/11/2022
P&T Revision Date:	01/11/2022

# Alpelisib (VIJOICE)

**Products Affected**

- Vjoyce TAB

PA Criteria	Criteria Details
<b>Required Medical Information</b>	Confirmed diagnosis of PROS <b>AND</b> has at least one severe clinical manifestation of PROS <b>AND</b> has a PIK3CA mutation that is confirmed by genetic testing.
<b>Age Restrictions</b>	At least 2 years of age.
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a provider who specializes in treatment of genetic disorders.
<b>Coverage Duration</b>	<b>Initial:</b> 24 weeks. <b>Renewal:</b> 6 months.
<b>Renewal Criteria</b>	Documentation of a reduction in volume from baseline in at least one lesion <b>AND</b> an improvement in at least one symptom of PROS from baseline

Effective Date:	10/01/2022
P&T Approval Date:	09/13/2022
P&T Revision Date:	

# Ambrisentan (LETAIRIS)

## Products Affected

- AMBRISENTAN

PA Criteria	Criteria Details
<b>Required Medical Information</b>	Diagnosis of pulmonary arterial hypertension (PAH) World Health Organization (WHO Group 1) confirmed by right heart catheterization <b>OR</b> patient is currently on any therapy for the diagnosis of PAH. Documented failure or incomplete response to or being co-prescribed with tadalafil.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a cardiologist or pulmonologist.
<b>Coverage Duration</b>	<b>Initial:</b> 6 months. <b>Renewal:</b> 12 months.
<b>Renewal Criteria</b>	Documentation of positive clinical response to therapy.  <b>Note:</b> Letairis (ambrisentan) has a black box warning for embryo-fetal toxicity. Because of the risks of birth defects, Letairis is available for females only through a special restricted distribution program under a Risk Evaluation and Mitigation Strategy (REMS).

Effective Date:	
P&T Approval Date:	
P&T Revision Date:	



# Anakinra (KINERET)

## Products Affected

- KINERET 100 MG/0.67ML

PA Criteria	Criteria Details
<b>Required Medical Information</b>	<p><b>All diagnoses:</b></p> <ul style="list-style-type: none"> <li>• Initial testing for latent TB and treatment, if necessary, before starting treatment.</li> <li>• No current active infection at initiation of therapy.</li> <li>• Risks and benefits documented in cases of chronic or recurrent infection.</li> <li>• Will NOT be used in combination with another biologic or Otezla</li> </ul> <p><b>Rheumatoid Arthritis (RA):</b></p> <ul style="list-style-type: none"> <li>• Documentation of a baseline of moderate to high disease activity of rheumatoid arthritis measured as such by an accepted assessment instrument (PAS, PASII, RAPID3, CDAI, DAS28, SDAI)</li> <li>• The member is transitioning to the requested treatment from a different biologic product previously approved by the plan OR documented failure of nonbiologic DMARD therapy: methotrexate (dosed at least 20mg per week for at least 8 weeks), leflunomide or sulfasalazine</li> <li>• Trial and failure of both infliximab and adalimumab</li> </ul>
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	<b>Rheumatoid Arthritis:</b> Rheumatologist.
<b>Coverage Duration</b>	<b>Initial:</b> 6 months. <b>Renewal:</b> 12 months.
<b>Renewal Criteria</b>	<b>RA:</b> Evidence of a 20% or greater improvement in tender joint count and swollen joint count.

Effective Date:	9/1/2023
P&T Approval Date:	7/11/2023
P&T Revision Date:	

# Apremilast (OTEZLA)

## Products Affected

- OTEZLA TAB 30MG, TAB 10/20/30

PA Criteria	Criteria Details
<b>Required Medical Information</b>	<p><b>All diagnoses:</b></p> <ul style="list-style-type: none"> <li>• Initial testing for latent TB and treatment, if necessary, before starting treatment.</li> <li>• No current active infection at initiation of therapy.</li> <li>• Risks and benefits documented in cases of chronic or recurrent infection.</li> <li>• Will NOT be used in combination with another biologic or Otezla</li> </ul> <p><b>Plaque Psoriasis (PP):</b></p> <ul style="list-style-type: none"> <li>• Documentation of severe plaque psoriasis, defined as having functional impairment as indicated by Dermatology Life Quality Index (DLQI) = 11 or Children's Dermatology Life Quality Index (CDLQI) = 13 (or severe score on other validated tool) AND one or more of the following:               <ul style="list-style-type: none"> <li>○ At least 10% of body surface area involved</li> <li>○ Hand, foot, face, or mucous membrane involvement</li> </ul> </li> <li>• The member is transitioning to the requested treatment from a different biologic product previously approved by the plan OR documented failure of all the following:               <ul style="list-style-type: none"> <li>○ High-potency topical corticosteroids (augmented betamethasone, clobetasol, etc.)</li> <li>○ At least one other topical agent (calcipotriene, tazarotene, anthralin, tar, etc.)</li> <li>○ PUVA or UVB Phototherapy</li> <li>○ Methotrexate</li> <li>○ At least 1 other second line systemic agent such as cyclosporine or acitretin</li> </ul> </li> <li>• Trial and failure of both infliximab and adalimumab</li> </ul> <p><b>Psoriatic Arthritis (PsA):</b></p> <ul style="list-style-type: none"> <li>• Documentation of psoriatic arthritis based on at least 3 out of 5 of the following:               <ul style="list-style-type: none"> <li>○ Psoriasis (1 point for personal or family history, 2 points for current)</li> <li>○ Psoriatic nail dystrophy</li> </ul> </li> </ul>

PA Criteria	Criteria Details
	<ul style="list-style-type: none"> <li>○ Negative test result for RF</li> <li>○ Dactylitis (current of history)</li> <li>○ Radiological evidence of juxta-articular new bone formation</li> <li>● The member is transitioning to the requested treatment from a different biologic product previously approved by the plan OR documented failure of conventional therapy with both of the following: <ul style="list-style-type: none"> <li>○ NSAIDs for 3 months at maximum recommended or tolerated anti-inflammatory dose unless contraindicated, AND</li> <li>○ Methotrexate or other DMARD such as leflunomide, sulfasalazine, or cyclosporine</li> </ul> </li> <li>● Trial and failure of both infliximab and adalimumab</li> </ul>
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	<b>Plaque Psoriasis:</b> Dermatologist. <b>Psoriatic Arthritis:</b> Dermatologist or Rheumatologist.
<b>Coverage Duration</b>	<b>Initial:</b> 6 months. <b>Renewal:</b> 12 months.
<b>Renewal Criteria</b>	<b>PP:</b> Evidence of positive clinical response to therapy as evidenced by ONE of the following: reduction of body surface area (BSA) involvement from baseline, improvement in symptoms (e.g. pruritus, inflammation) from baseline, or evidence of functional improvement.  <b>PsA:</b> Evidence of a 20% or greater improvement in tender joint count and swollen joint count.

Effective Date:	9/1/2023
P&T Approval Date:	7/11/2023
P&T Revision Date:	07/11/2023, 01/11/2022

# Aprepitant (EMEND)

## Products Affected

- APREPITANT

PA Criteria	Criteria Details
<b>Required Medical Information</b>	Prevention of acute nausea and vomiting associated with initial and repeat courses of highly emetogenic chemotherapy in conjunction with other antiemetic agents, such as dexamethasone and ondansetron. Prevention of delayed nausea and vomiting associated with highly emetogenic chemotherapy in conjunction with dexamethasone. Documentation of patient receiving treatment with a moderate to highly emetogenic chemotherapy agent. Documentation patient is receiving concurrent treatment with IV or oral ondansetron (Zofran), granisetron (Kytril) or palonosetron (Aloxi) and dexamethasone.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	<b>Initial:</b> 12 months. <b>Renewal:</b> 12 months.
<b>Renewal Criteria</b>	Documented positive clinical response to therapy

Effective Date:	
P&T Approval Date:	
P&T Revision Date:	

# Baricitinib (OLUMIANT)

## Products Affected

- Olumiant **TAB 1MG, 2MG, 4MG,**

PA Criteria	Criteria Details
<b>Required Medical Information</b>	<p><b>All diagnoses:</b></p> <ul style="list-style-type: none"> <li>• Initial testing for latent TB and treatment, if necessary, before starting treatment.</li> <li>• No current active infection at initiation of therapy.</li> <li>• Risks and benefits documented in cases of chronic or recurrent infection.</li> <li>• Will NOT be used in combination with another biologic or Otezla</li> </ul> <p><b>Rheumatoid Arthritis (RA):</b></p> <ul style="list-style-type: none"> <li>• Documentation of a baseline of moderate to high disease activity of rheumatoid arthritis measured as such by an accepted assessment instrument (PAS, PASII, RAPID3, CDAI, DAS28, SDAI)</li> <li>• The member is transitioning to the requested treatment from a different biologic product previously approved by the plan OR documented failure of nonbiologic DMARD therapy: methotrexate (dosed at least 20mg per week for at least 8 weeks), leflunomide or sulfasalazine</li> <li>• Trial and failure of both infliximab and adalimumab</li> <li>• Trial and failure of Actemra, Cimzia, Kineret, Orencia, and rituximab</li> </ul>
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	<b>Rheumatologist</b>
<b>Coverage Duration</b>	<b>Initial:</b> 6 months. <b>Renewal:</b> 12 months.
<b>Renewal Criteria</b>	Evidence of a 20% or greater improvement in tender joint count and swollen joint count.

Effective Date:	9/1/2023
P&T Approval Date:	7/11/2023
P&T Revision Date:	07/11/2023, 01/11/2022

# Belzutifan (WELIREG)

**Products Affected**

- WELIREG

PA Criteria	Criteria Details
<b>Required Medical Information</b>	Confirmed diagnosis of Von Hippel-Lindau disease with VHL alteration confirmation <b>AND</b> require therapy for either associated renal cell carcinoma, associated pancreatic neuroendocrine tumors, or associated CNS hemangioblastoma <b>AND</b> confirmation that patient is not eligible currently for surgery <b>AND</b> Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
<b>Age Restrictions</b>	18 years of age or older
<b>Prescriber Restrictions</b>	Prescribed by oncologist
<b>Coverage Duration</b>	<b>Initial:</b> 3 months. <b>Renewal:</b> 3 months
<b>Renewal Criteria</b>	Documented positive clinical response to therapy

Effective Date:	
P&T Approval Date:	
P&T Revision Date:	

# Beumosudil (REZUROCK)

**Products Affected**

- Rezurock

PA Criteria	Criteria Details
<b>Required Medical Information</b>	Diagnosed with chronic graft-versus-host disease (cGVHD) <b>AND</b> who have tried and failed of at least two prior lines of systemic therapy for cGVHD <b>AND</b> not currently taking Imbruvica (ibrutinib)
<b>Age Restrictions</b>	Patient must be 12 years or older.
<b>Prescriber Restrictions</b>	Prescribed by an oncologist or transplant specialist
<b>Coverage Duration</b>	<b>Initial:</b> 3 months. <b>Renewal:</b> 6 months.
<b>Renewal Criteria</b>	<b>Renewal Criteria:</b> Documented positive clinical response to therapy

Effective Date:	04/01/2022
P&T Approval Date:	03/08/2022
P&T Revision Date:	03/08/2022

# Bimekizumab-bkzx (BIMZELX)

## Products Affected

- Bimzelx

PA Criteria	Criteria Details
<b>Required Medical Information</b>	<ul style="list-style-type: none"> <li>○ Severe plaque psoriasis, defined as having functional impairment as indicated by Dermatology Life Quality Index (DLQI) = 11 or Children's Dermatology Life Quality Index (CDLQI) = 13 (or severe score on other validated tool)</li> <li>○ One or more of the following:               <ul style="list-style-type: none"> <li>○ At least 10% of body surface area involved</li> <li>○ Hand, foot, face, or mucous membrane involvement</li> </ul> </li> </ul> <p style="text-align: center;"><b>OR</b></p> <ul style="list-style-type: none"> <li>• Is the patient on a current biologic product and experiencing intolerable side effects?</li> <li>○ The patient tried and failed or have contraindications to ALL of the following?               <ul style="list-style-type: none"> <li>• High-potency topical corticosteroids (augmented betamethasone, clobetasol, etc.)</li> <li>• At least one other topical agent: calcipotriene, tazarotene, anthralin, tar, etc.</li> <li>• PUVA or UVB Phototherapy</li> <li>• Methotrexate</li> <li>• At least 1 other second line systemic agent such as cyclosporine or acitretin</li> </ul> </li> <li>○ The patient tried and failed BOTH first line agents (infliximab or biosimilar AND Humira or biosimilar)</li> </ul>
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	<b>Initial:</b> 6 months. <b>Renewal:</b> 12 months.
<b>Renewal Criteria</b>	<b>Renewal Criteria: Documentation of positive clinical response to therapy as evidenced by ONE of the following:</b> <ul style="list-style-type: none"> <li>• Reduction of body surface area (BSA) involvement from baseline</li> </ul>



PA Criteria	Criteria Details
	<ul style="list-style-type: none"><li data-bbox="516 275 1338 352">• Improvement in symptoms (e.g. pruritus, inflammation) from baseline</li><li data-bbox="516 359 1024 394">• Evidence of functional improvement</li></ul>

Effective Date:	7/1/2024
P&T Approval Date:	5/13/2024
P&T Revision Date:	5/13/2024

# Bosentan (TRACLEER)

**Products Affected**

- BOSENTAN

PA Criteria	Criteria Details
<b>Required Medical Information</b>	<b>Pulmonary arterial hypertension (PAH):</b> Diagnosed with PAH WHO Group 1 confirmed by right heart catheterization <b>AND</b> documentation of NYHA Functional Classification II, III, or IV symptoms <b>AND</b> documented normal liver function tests prior to initiation.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a cardiologist or pulmonologist.
<b>Coverage Duration</b>	<b>Initial:</b> 12 months. <b>Renewal:</b> 12 months.
<b>Renewal Criteria</b>	Documented positive clinical response to therapy

Effective Date:	
P&T Approval Date:	
P&T Revision Date:	

# Bosutinib (Bosulif)

## Products Affected

- Bosulif capsules
- Bosulif tablets

PA Criteria	Criteria Details
<b>Required Medical Information</b>	<p><b>Chronic Myelogenous/Myeloid Leukemia:</b></p> <ul style="list-style-type: none"> <li>• Diagnosis of Philadelphia chromosome-positive chronic myelogenous/myeloid leukemia (Ph+ CML) AND</li> <li>• One of the following:               <ul style="list-style-type: none"> <li>○ Disease is in the accelerated or blast phase OR</li> <li>○ Disease is in the chronic phase and patient is 1 year of age or older</li> </ul> </li> <li>• One of the following:               <ul style="list-style-type: none"> <li>○ Trial and failure or intolerance to generic imatinib</li> <li>○ Continuation of prior therapy</li> </ul> </li> </ul>
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Oncologist or hematologist
<b>Coverage Duration</b>	<b>Initial:</b> 12 months. <b>Renewal:</b> 12 months.
<b>Renewal Criteria</b>	Patient does not show evidence of progressive disease while on therapy

Effective Date:	5/1/2024
P&T Approval Date:	3/12/2024
P&T Revision Date:	

# BUPRENORPHINE PATCH

## Products Affected

- BUPRENORPHINE PATCH

PA Criteria	Criteria Details
<b>Required Medical Information</b>	<p><b>Cancer or End-of-Life Care:</b> Patient is being treated for cancer related pain or pain associated with end-of-life <b>AND</b> documented trial and failure of scheduled short-acting opioid therapy <b>AND</b> documented trial and failure of, contraindication to long-acting morphine sulfate therapy <b>AND</b> documented trial/failure of, or reason why fentanyl is not appropriate.</p> <p><b>Other Chronic Pain:</b> Documented above the line diagnosis, FDA indicated, or guideline supported condition <b>AND</b> documented severe chronic pain (greater than 3mo) that is severe enough to require around the clock analgesic therapy <b>AND</b> documented trial and failure or contraindication to short-acting opioid therapy <b>AND</b> documented trial and failure of, or contraindication to long-acting morphine sulfate therapy <b>AND</b> documented trial and failure of, or reason why fentanyl is not appropriate.</p>
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	<p><b>Initial cancer/end of life:</b> 12 months. <b>Renewal:</b> 12 months.  <b>Initial non-cancer/end of life:</b> 6 months. <b>Renewal:</b> 12 months.</p>
<b>Renewal Criteria</b>	Documented positive clinical response to therapy

Effective Date:	
P&T Approval Date:	
P&T Revision Date:	

# Certolizumab Pegol SC (CIMZIA)

**Products Affected**

- CIMZIA
- CIMZIA PREFILLED
- CIMZIA STARTER KIT

PA Criteria	Criteria Details
<p><b>Required Medical Information</b></p>	<p><b>All diagnoses:</b></p> <ul style="list-style-type: none"> <li>• Initial testing for latent TB and treatment, if necessary, before starting treatment.</li> <li>• No current active infection at initiation of therapy.</li> <li>• Risks and benefits documented in cases of chronic or recurrent infection.</li> <li>• Will NOT be used in combination with another biologic or Otezla</li> </ul> <p><b>Ankylosing Spondylitis/Axial Spondyloarthritis (AS/SpA):</b></p> <ul style="list-style-type: none"> <li>• Documentation of moderate-to-severe ankylosing spondylitis or axial spondyloarthritis as defined by:               <ul style="list-style-type: none"> <li>○ Back pain and stiffness for more than 3 months AND</li> <li>○ Signs of active inflammation on MRI OR radiological evidence of sacroiliitis OR HLA-B27 positive AND</li> <li>○ BASDAI score of <math>\geq 4</math></li> </ul> </li> <li>• The member is transitioning to the requested treatment from a different biologic product previously approved by the plan OR Documented failure of conventional therapy with both of the following:               <ul style="list-style-type: none"> <li>○ At least two NSAIDs for 3 months at maximum recommended or tolerated anti-inflammatory dose unless contraindicated, AND</li> <li>○ Physical therapy/exercise program</li> </ul> </li> <li>• Trial and failure of both infliximab and adalimumab</li> </ul> <p><b>Crohn's Disease (CD):</b></p> <ul style="list-style-type: none"> <li>• Documentation of moderate-to-severe Crohn's Disease</li> <li>• The member is transitioning to the requested treatment from a different biologic product previously approved by the plan OR Documented trial and failure of at least 1 of the following: 6-mercaptopurine, azathioprine, corticosteroid, methotrexate</li> <li>• Trial and failure of both infliximab and adalimumab</li> </ul> <p><b>Plaque Psoriasis (PP):</b></p> <ul style="list-style-type: none"> <li>• Documentation of severe plaque psoriasis, defined as having functional impairment as indicated by Dermatology Life Quality Index (DLQI) = 11 or Children's Dermatology Life Quality Index (CDLQI) = 13</li> </ul>

PA Criteria	Criteria Details
	<p>(or severe score on other validated tool) AND one or more of the following:</p> <ul style="list-style-type: none"> <li>○ At least 10% of body surface area involved</li> <li>○ Hand, foot, face, or mucous membrane involvement</li> <li>● The member is transitioning to the requested treatment from a different biologic product previously approved by the plan OR documented failure of all the following: <ul style="list-style-type: none"> <li>○ High-potency topical corticosteroids (augmented betamethasone, clobetasol, etc.)</li> <li>○ At least one other topical agent (calcipotriene, tazarotene, anthralin, tar, etc.)</li> <li>○ PUVA or UVB Phototherapy</li> <li>○ Methotrexate</li> <li>○ At least 1 other second line systemic agent such as cyclosporine or acitretin</li> </ul> </li> <li>● Trial and failure of both infliximab and adalimumab</li> </ul> <p><b>Psoriatic Arthritis (PsA):</b></p> <ul style="list-style-type: none"> <li>● Documentation of psoriatic arthritis based on at least 3 out of 5 of the following: <ul style="list-style-type: none"> <li>○ Psoriasis (1 point for personal or family history, 2 points for current)</li> <li>○ Psoriatic nail dystrophy</li> <li>○ Negative test result for RF</li> <li>○ Dactylitis (current or history)</li> <li>○ Radiological evidence of juxta-articular new bone formation</li> </ul> </li> <li>● The member is transitioning to the requested treatment from a different biologic product previously approved by the plan OR documented failure of conventional therapy with both of the following: <ul style="list-style-type: none"> <li>○ NSAIDs for 3 months at maximum recommended or tolerated anti-inflammatory dose unless contraindicated, AND</li> <li>○ Methotrexate or other DMARD such as leflunomide, sulfasalazine, or cyclosporine</li> </ul> </li> <li>● Trial and failure of both infliximab and adalimumab</li> </ul> <p><b>Rheumatoid Arthritis (RA):</b></p> <ul style="list-style-type: none"> <li>● Documentation of a baseline of moderate to high disease activity of rheumatoid arthritis measured as such by an accepted assessment instrument (PAS, PASII, RAPID3, CDAI, DAS28, SDAI)</li> <li>● The member is transitioning to the requested treatment from a different biologic product previously approved by the plan OR documented failure of nonbiologic DMARD therapy: methotrexate</li> </ul>

PA Criteria	Criteria Details
	(dosed at least 20mg per week for at least 8 weeks), leflunomide or sulfasalazine <ul style="list-style-type: none"> <li>• Trial and failure of both infliximab and adalimumab</li> </ul>
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	<b>Crohns Disease:</b> Gastroenterologist. <b>Plaque Psoriasis:</b> Dermatologist. <b>Psoriatic Arthritis:</b> Dermatologist or Rheumatologist. <b>Rheumatoid Arthritis, Juvenile Idiopathic Arthritis:</b> Rheumatologist. <b>Ankylosing Spondylitis, Axial Spondyloarthritis:</b> Rheumatologist.
<b>Coverage Duration</b>	<b>Initial:</b> 6 months. <b>Renewal:</b> 12 months.
<b>Renewal Criteria</b>	<p><b>AS/SpA:</b> Evidence of significant improvement in signs and symptoms of AS/SpA and/or functioning, such as ASAS40 or 2-point improvement in BASDAI.</p> <p><b>CD:</b> Evidence of a decrease in symptoms, reduction in enterocutaneous fistulas or clinical remission.</p> <p><b>PP:</b> Evidence of positive clinical response to therapy as evidenced by ONE of the following: reduction of body surface area (BSA) involvement from baseline, improvement in symptoms (e.g. pruritus, inflammation) from baseline, or evidence of functional improvement.</p> <p><b>PsA:</b> Evidence of a 20% or greater improvement in tender joint count and swollen joint count.</p> <p><b>RA:</b> Evidence of a 20% or greater improvement in tender joint count and swollen joint count.</p>

Effective Date:	9/1/2023
P&T Approval Date:	7/11/2023
P&T Revision Date:	

# Chloroquine Phosphate (ARALEN)

**Products Affected**

- CHLOROQUINE PHOSPHATE

PA Criteria	Criteria Details
<b>Required Medical Information</b>	Treatment of Malaria or Extraintestinal amebiasis.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	<b>Initial:</b> 3 months.
<b>Renewal Criteria</b>	

Effective Date:	
P&T Approval Date:	
P&T Revision Date:	



# Cinacalcet Hydrochloride (SENSIPAR)

**Products Affected**

- CINACALCET HCL

PA Criteria	Criteria Details
<b>Required Medical Information</b>	<p>Treatment of secondary hyperparathyroidism in patients with chronic kidney disease (CKD) on dialysis.</p> <p>Treatment of hypercalcemia in patients with parathyroid carcinoma.</p> <p>Treatment of severe hypercalcemia in patients with primary hyperparathyroidism who are unable to undergo parathyroidectomy.</p>
<b>Age Restrictions</b>	Patients 18 years of age and older.
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	<b>Initial:</b> 12 months. <b>Renewal:</b> 12 months.
<b>Renewal Criteria</b>	Documented positive clinical response to therapy

Effective Date:	
P&T Approval Date:	
P&T Revision Date:	

# Conjugated Estrogens (Premarin Tablets)

---

## Products Affected

- Premarin Tablets

PA Criteria	Criteria Details
Required Medical Information	All FDA indicated or guideline supported diagnoses- <ul style="list-style-type: none"><li>• Trial and failure of generic estradiol tablets and patches.</li></ul>
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Lifetime
Renewal Criteria	

Effective Date:	03/01/2024
P&T Approval Date:	01/09/2024
P&T Revision Date:	

# Conjugated estrogens and medroxyprogesterone acetate (Prempro/Premphase)

**Products Affected**

- Prempro
- Premphase

PA Criteria	Criteria Details
<b>Required Medical Information</b>	<p><b>All FDA indicated or guideline supported diagnoses-</b></p> <ul style="list-style-type: none"> <li>• Trial and failure of generic combination products OR estradiol tablets/patches used in combination with medroxyprogesterone capsules.</li> </ul>
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	<b>Lifetime</b>
<b>Renewal Criteria</b>	

Effective Date:	03/01/2024
P&T Approval Date:	01/09/2024
P&T Revision Date:	

# Compounds (standard criteria for all compounded medications)

**Products Affected**

- All compounded medications

PA Criteria	Criteria Details
<p><b>Required Medical Information</b></p>	<ul style="list-style-type: none"> <li>• The requested medication being used to treat an above the line diagnosis on the OHA Prioritized list OR the member has an above the line comorbid condition that will be treated indirectly by the requested medication OR the member under the age of 21.</li> <li>• Each active ingredient in the compounded drug is FDA-approved or national compendia* supported for the condition being treated.</li> <li>• The requested amounts are supported by national compendia* or two peer-reviewed literature for the condition being treated in the requested route of delivery.</li> <li>• If any prescription ingredients require prior authorization and/or step therapy, all drug-specific criteria must be also met.</li> <li>• The patient has tried and failed therapy or had an intolerance to two FDA-approved commercially-available prescription therapeutic alternatives, one of which is the same route of administration as the requested compound, unless one of the following criteria are met:             <ul style="list-style-type: none"> <li>○ Patient has a contraindication to commercially available products</li> <li>○ Only one or no other therapeutic alternatives are commercially available</li> <li>○ Prepared strength(s) is/are not commercially available or currently in short supply</li> <li>○ Prepared in a different dosage form for a patient who is unable to take the commercially available formulation (mixing or reconstituting commercially available products based on the manufacturer's instructions or the product's approved labeling does NOT meet this criteria).</li> <li>○ Patient has an allergy or sensitivity to inactive ingredients (e.g. dyes, preservatives, sugars, etc.) that are found in commercially available products.</li> </ul> </li> </ul>
<p><b>Age Restrictions</b></p>	

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	<b>Initial:</b> 6 months. <b>Renewal:</b> 12 months.
<b>Renewal Criteria</b>	Documented positive clinical response to therapy

Effective Date:	
P&T Approval Date:	
P&T Revision Date:	

# Clobazam (ONFI)

## Products Affected

- Clobazam 10mg Tablets
- Clobazam 20mg Tablets
- Clobazam 2.5mg/mL suspension

PA Criteria	Criteria Details
<b>Required Medical Information</b>	<p><b>Lennox-Gastaut Syndrome</b></p> <ul style="list-style-type: none"> <li>• Confirmed diagnosis.</li> </ul> <p><b>Refractory Seizures</b></p> <ul style="list-style-type: none"> <li>• Documentation showing appropriate trial of 2 or more tolerated anticonvulsant therapies.</li> </ul>
<b>Age Restrictions</b>	<b>Suspension:</b> ≥2 years of age and <10 years of age (or unable to use tablets)
<b>Prescriber Restrictions</b>	Neurologist
<b>Coverage Duration</b>	<b>Initial:</b> 12 months. <b>Renewal:</b> 12 months.
<b>Renewal Criteria</b>	Documentation of positive clinical response to therapy.
Effective Date:	5/1/2024
P&T Approval Date:	3/12/2024
P&T Revision Date:	7/11/2023



## Continuous Glucose Monitors (CGM)

PA Criteria	Criteria Details
<p><b>Required Medical Information</b></p>	<p><b>Type 1 Diabetes Mellitus:</b></p> <ul style="list-style-type: none"> <li>• Use of continuous insulin infusion via pump <b>OR</b> child or adolescent under the age of 21 <b>OR</b> member is pregnant or plans to become pregnant within 6 months <b>OR</b> using short or intermediate acting insulin <b>AND</b> the criteria listed under “applies to all requests” has been met.</li> </ul> <p><b>Type 2 Diabetes Mellitus OR Gestational Diabetes:</b></p> <ul style="list-style-type: none"> <li>• Using short or intermediate acting insulin <b>AND</b> the criteria listed under “applies to all requests” has been met.</li> </ul> <p><b>Applies to all requests</b></p> <ul style="list-style-type: none"> <li>• Must meet at least one of the following: <ul style="list-style-type: none"> <li>○ Baseline HbA1c levels great than or equal to 8.0%</li> <li>○ Frequent or severe hypoglycemia</li> <li>○ Impaired awareness of hypoglycemia (including presence of these conditions prior to initiation of CGM</li> <li>○ Diabetes related complications (e.g. peripheral neuropathy, end-organ damage, ect.)</li> </ul> </li> <li>• Member has received or will receive diabetes education specific to the use of the CGM device.</li> </ul> <p>**If the request is for a <b>Dexcom</b> device the additional questions apply, must meet one of the following criteria:</p> <ul style="list-style-type: none"> <li>○ Use of an insulin pump compatible with the requested Dexcom</li> <li>○ Pediatric member under the age of 16 years old</li> <li>○ Inability to use preferred Freestyle CGM device</li> </ul>
<p><b>Age Restrictions</b></p>	
<p><b>Prescriber Restrictions</b></p>	
<p><b>Coverage Duration</b></p>	<p><b>Initial:</b> 6 months. <b>Renewal:</b> 12 months.</p>
<p><b>Renewal Criteria</b></p>	<p>Use of CGM device for at least 50% of the time for a 90-day period by the time of their first follow-up visit (within 3-6 months) and provider visits</p>



<b>PA Criteria</b>	<b>Criteria Details</b>
	within the last 6 months. **Note: two trials per yar of CGM are allowed to meet adherence for continuation of coverage.

Effective Date:	06/01/2022
P&T Approval Date:	05/08/2022
P&T Revision Date:	



# Cyclosporine (GENGRAF) (NEORAL)

**Products Affected**

- CYCLOSPORINE
- GENGRAF
- CYCLOSPORINE MODIFIED
- SANDIMMUNE

PA Criteria	Criteria Details
<b>Required Medical Information</b>	Treatment of Solid Organ Transplant, Rheumatoid arthritis, or Psoriasis.
<b>Age Restrictions</b>	<b>Liquid only:</b> Member is under age 10 or unable to use tablets/capsules
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	<b>Initial:</b> 12 months. <b>Renewal:</b> 12 months.
<b>Renewal Criteria</b>	<b>Renewal Criteria:</b> Documented positive clinical response to therapy

Effective Date:	5/1/2024
P&T Approval Date:	3/12/2024
P&T Revision Date:	3/12/2024

# Deferasirox (EXJADE)

## Products Affected

- DEFERASIROX

PA Criteria	Criteria Details
<b>Required Medical Information</b>	Patient has one of the following diagnoses: Chronic iron overload due to blood transfusion <b>OR</b> non-transfusion-dependent thalassemia syndromes <b>AND</b> patient has a creatinine clearance of greater than or equal to 40 mL/minute <b>OR</b> serum creatinine less than or equal to 2 times the age-appropriate level <b>AND</b> patient has a serum ferritin levels consistently greater than 1,000 mcg/L (as demonstrated with at least two lab values within the previous two months) <b>AND</b> patient has had a failure or contraindication to deferoxamine injection.
<b>Age Restrictions</b>	Patient is 2 years of age or older.
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	<b>Initial:</b> 12 months. <b>Renewal:</b> 12 months.
<b>Renewal Criteria</b>	Documented positive clinical response to therapy

Effective Date:	
P&T Approval Date:	
P&T Revision Date:	



# Desmopressin (STIMATE)

## Products Affected

- Desmopressin Acetate Nasal Spray & Injections

PA Criteria	Criteria Details
<b>Required Medical Information</b>	<b>Being used for one of the following:</b> <ul style="list-style-type: none"> <li>• Diabetes Insipidus</li> <li>• Maintenance of hemostasis and control of bleeding in hemophilia A with factor VIII coagulant activity levels greater than 5%</li> <li>• Mild-to-moderate classic von Willebrand's disease (type 1) with factor VIII coagulant activity greater than 5%.</li> </ul>
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	<b>Initial:</b> 12 months; <b>Renewal:</b> 12 months
<b>Renewal Criteria</b>	Documentation of positive clinical response to therapy.

Effective Date:	9/1/2023
P&T Approval Date:	7/11/2023
P&T Revision Date:	

# Deutetrabenazine (AUSTEDO)

**Products Affected**

- Austedo 6mg TAB
- Austedo 9mg TAB
- Austedo 12mg TAB

PA Criteria	Criteria Details
<b>Required Medical Information</b>	<p><b>Chorea associated with Huntington’s Disease:</b> Documentation of the degree of chorea present and the impact on functional ability and/or quality of life <b>AND</b> documentation of mental status, specifically depression and suicidality.</p> <p><b>Tardive Dyskinesia:</b> Clinical documentation of tardive dyskinesia including 1) At least one month of past or current exposure to a dopamine receptor blocker, 2) Dyskinetic or dystonic involuntary movements, 3) Exclusion of other causes of abnormal movements <b>AND</b> clear documentation that tardive dyskinesia causes functional impairment <b>AND</b> documentation of the degree of tardive dyskinesia with the AIMS scale as a baseline. <b>AND</b> discontinuation of the medication precipitating TD <b>OR</b> documentation that the patient has tried and failed an 8-week trial of at least 2 other agents within the same therapeutic category at a clinically effective and maximally tolerated dose for the patient’s primary neuropsychiatric diagnosis <b>OR</b> evidence the medications precipitating tardive dyskinesia are medically necessary <b>AND</b> trial and failure or contraindication to clonazepam and amantadine.</p>
<b>Age Restrictions</b>	Age 18 and older
<b>Prescriber Restrictions</b>	<b>Huntington’s Disease:</b> neurologist <b>Tardive Dyskinesia:</b> neurologist or psychiatrist
<b>Coverage Duration</b>	<b>Initial:</b> 3 months. <b>Renewal:</b> 12 months.
<b>Renewal Criteria</b>	<p><b>Huntington’s Chorea:</b> clinical response such as improvement in chorea, ability to perform ADLs, reduction in falls, or increase in quality of life. <b>AND</b> documentation of continued monitoring of mental status specifically for depression and suicidality.</p> <p><b>Tardive Dyskinesia:</b> Follow-up AIMS assessment showing improvement from Baseline <b>AND</b> documented improvement in functioning such as ability to perform ADLs, reduction in falls and increase in quality of life.</p>

Effective Date:	07/01/2023
-----------------	------------

P&T Approval Date:	05/09/2023
P&T Revision Date:	05/09/2023



# Dihydroergotamine (MIGRANAL)

---

## Products Affected

- DIHYDROERGOTAMINE MESYLATE INJ

PA Criteria	Criteria Details
<b>Required Medical Information</b>	Treatment of migraine headache with or without aura <b>OR</b> treatment of cluster headaches <b>AND</b> patient has tried and failed or has a contraindication to a formulary serotonin 5-HT <sub>1B</sub> , 1D receptor agonist.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	<b>Initial:</b> 12 months. <b>Renewal:</b> 12 months.
<b>Renewal Criteria</b>	Documented positive clinical response to therapy

Effective Date:	
P&T Approval Date:	
P&T Revision Date:	

# Dimethyl Fumarate (TECFIDERA)

---

## Products Affected

- DIMETHYL FUMARATE
- DIMETHYL FUMARATE STARTER PACK

PA Criteria	Criteria Details
Required Medical Information	<b>Multiple sclerosis:</b> Patient is diagnosed with relapsing forms of multiple sclerosis.
Age Restrictions	
Prescriber Restrictions	Must be prescribed by a neurologist.
Coverage Duration	<b>Initial:</b> 6 months. <b>Renewal:</b> 12 months.
Renewal Criteria	Documented positive clinical response to therapy

Effective Date:	02/01/2023
P&T Approval Date:	01/10/2023
P&T Revision Date:	01/10/2023

# Direct-Acting Antivirals (use in Hepatitis C)

## Products Affected

- MAVYRET
- SOFOSBUVIR-VELPATASVIR
- VOSEVI

PA Criteria	Criteria Details																			
<b>Required Medical Information</b>	<p>PA is only required if the patient has previously been treated for hepatitis C.</p> <p>Treatment of Hepatitis C infection:</p> <ul style="list-style-type: none"> <li>• Appropriate pre-treatment testing               <ul style="list-style-type: none"> <li>○ Genotype testing in the past 3 years is required if the patient has decompensated cirrhosis, prior treatment experience with DAA regimen, and if prescribed a regimen which is not pan-genotypic</li> <li>○ History of previous HCV treatment, viral load after treatment, and outcome are required only if there is documentation of treatment experience</li> </ul> </li> <li>• Has the patient been treated with a direct acting antiviral regimen previously</li> <li>• Did patient achieve a sustained virological response (SVR) at week 12 or longer following the completion of their last DAA regimen</li> <li>• Is this likely a reinfection, indicated by at least one of the following:               <ul style="list-style-type: none"> <li>○ Does the patient have ongoing risk factors for hepatitis C reinfection (e.g. sexually active men who have sex with men, persons who inject drugs), <b>OR</b></li> <li>○ Is the hepatitis C infection due a different genotype than previous</li> </ul> </li> <li>• If the request is for elbasvir/grazoprevir for GT 1a, ledipasvir/sofosbuvir for GT 1a treatment experienced or sofosbuvir for GT 3 with cirrhosis or treatment experience has the patient had a baseline NS5a resistance test. (Note: baseline NS5A resistance testing is required per OHA in this situation)</li> <li>• The prescribed drug regimen a recommended regimen based on the patient's genotype, age, treatment status (retreatment or treatment naïve) and cirrhosis status (see table 1 and 2)?</li> </ul> <p><i>*Per OHA: treatment experienced are patients who received more than 4 weeks of HCV DAA therapy.</i></p> <p><b>Table 1. Recommended Regimens for Adults and adolescents 12 years of age and older</b></p> <table border="1"> <thead> <tr> <th>Treatment History</th> <th>Cirrhosis Status</th> <th>Recommended Regimen</th> </tr> </thead> <tbody> <tr> <td colspan="3"><b>Treatment Naïve (Genotype 1-6)</b></td> </tr> <tr> <td rowspan="3">Treatment naïve</td> <td>Non-cirrhotic</td> <td>SOF/VEL x 12 weeks G/P x 8 weeks</td> </tr> <tr> <td>Compensated cirrhosis</td> <td>G/P x 8 weeks SOF/VEL x 12 weeks (baseline resistance testing recommended for GT3)</td> </tr> <tr> <td>Decompensated cirrhosis</td> <td>SOF/VEL + RBV x 12 weeks SOF/VEL x 24 weeks (if RBV ineligible)</td> </tr> <tr> <td colspan="3"><b>Treatment Experienced (Genotype 1-6)</b></td> </tr> <tr> <td><u>Sofobuvir based regimen treatment failures, including: sofosbuvir + ribavirin Ledipasvir/Sofobuvir Velpatasvir/sofosbuvir</u></td> <td>Non-cirrhotic or compensated cirrhosis</td> <td>SOF/VEL/VOX x 12 weeks G/P x16 weeks (except GT3)</td> </tr> </tbody> </table>	Treatment History	Cirrhosis Status	Recommended Regimen	<b>Treatment Naïve (Genotype 1-6)</b>			Treatment naïve	Non-cirrhotic	SOF/VEL x 12 weeks G/P x 8 weeks	Compensated cirrhosis	G/P x 8 weeks SOF/VEL x 12 weeks (baseline resistance testing recommended for GT3)	Decompensated cirrhosis	SOF/VEL + RBV x 12 weeks SOF/VEL x 24 weeks (if RBV ineligible)	<b>Treatment Experienced (Genotype 1-6)</b>			<u>Sofobuvir based regimen treatment failures, including: sofosbuvir + ribavirin Ledipasvir/Sofobuvir Velpatasvir/sofosbuvir</u>	Non-cirrhotic or compensated cirrhosis	SOF/VEL/VOX x 12 weeks G/P x16 weeks (except GT3)
Treatment History	Cirrhosis Status	Recommended Regimen																		
<b>Treatment Naïve (Genotype 1-6)</b>																				
Treatment naïve	Non-cirrhotic	SOF/VEL x 12 weeks G/P x 8 weeks																		
	Compensated cirrhosis	G/P x 8 weeks SOF/VEL x 12 weeks (baseline resistance testing recommended for GT3)																		
	Decompensated cirrhosis	SOF/VEL + RBV x 12 weeks SOF/VEL x 24 weeks (if RBV ineligible)																		
<b>Treatment Experienced (Genotype 1-6)</b>																				
<u>Sofobuvir based regimen treatment failures, including: sofosbuvir + ribavirin Ledipasvir/Sofobuvir Velpatasvir/sofosbuvir</u>	Non-cirrhotic or compensated cirrhosis	SOF/VEL/VOX x 12 weeks G/P x16 weeks (except GT3)																		

PA Criteria	Criteria Details																				
	<table border="1"> <tr> <td>Elbasvir/grazoprevir treatment failures</td> <td>Non-cirrhotic or compensated cirrhosis</td> <td>SOF/VEL/VOX x 12 weeks</td> </tr> <tr> <td>Glecaprevir/pibrentasvir treatment failures</td> <td>Non-cirrhotic or compensated cirrhosis</td> <td>G/P + SOF + RBV x 16 weeks SOF/VEL/VOX x 12 weeks (plus RBV if compensated cirrhosis)</td> </tr> <tr> <td><u>Multiple DAA Treatment Failures, including:</u> Sofobuvir/velpatasvir/voxilaprevir Glecaprevir/pibrentasvir + sofosbuvir</td> <td>Non-Cirrhotic or compensated cirrhosis</td> <td>G/P + SOF + RBV x 16-24 weeks SOF/VEL/VOX x24 weeks</td> </tr> </table> <p><b>Table 2. Recommended Regimens for children 3-12 years of age</b></p> <table border="1"> <thead> <tr> <th>Treatment History</th> <th>Cirrhosis Status</th> <th>Recommended Regimen</th> </tr> </thead> <tbody> <tr> <td colspan="3"><b>Treatment Naïve (Genotype 1-6)</b></td> </tr> <tr> <td rowspan="2">Treatment Naïve</td> <td>Non-cirrhotic or compensated cirrhosis</td> <td>SOF/VEL x 12 weeks G/P x 8 weeks</td> </tr> <tr> <td>Decompensated cirrhosis</td> <td>SOF/VEL + RBV x 12 weeks</td> </tr> </tbody> </table> <p>Abbreviations: DAA = direct acting antiviral; EBV/GZR = elbasvir/grazoprevir; G/P = glecaprevir and pibrentasvir; PEG = pegylated interferon; RBV = ribavirin; SOF = sofosbuvir; SOF/VEL = sofosbuvir/velpatasvir; SOF/VEL/VOX = sofosbuvir/velpatasvir/voxilaprevir</p> <p>There is limited data supporting DAA regimens in treatment- experienced patients with decompensated cirrhosis. These patients should be handled on a case by case basis with the patient, prescriber, and CCO or FFS medical director</p> <p>Ribavirin ineligible/intolerance may include: 1) neutrophils &lt; 750 mm<sup>3</sup>, 2) hemoglobin &lt; 10 g/dl, 3) platelets &lt;50,000 cells/mm<sup>3</sup>, autoimmune hepatitis or other autoimmune condition, hypersensitivity or allergy to ribavirin</p>	Elbasvir/grazoprevir treatment failures	Non-cirrhotic or compensated cirrhosis	SOF/VEL/VOX x 12 weeks	Glecaprevir/pibrentasvir treatment failures	Non-cirrhotic or compensated cirrhosis	G/P + SOF + RBV x 16 weeks SOF/VEL/VOX x 12 weeks (plus RBV if compensated cirrhosis)	<u>Multiple DAA Treatment Failures, including:</u> Sofobuvir/velpatasvir/voxilaprevir Glecaprevir/pibrentasvir + sofosbuvir	Non-Cirrhotic or compensated cirrhosis	G/P + SOF + RBV x 16-24 weeks SOF/VEL/VOX x24 weeks	Treatment History	Cirrhosis Status	Recommended Regimen	<b>Treatment Naïve (Genotype 1-6)</b>			Treatment Naïve	Non-cirrhotic or compensated cirrhosis	SOF/VEL x 12 weeks G/P x 8 weeks	Decompensated cirrhosis	SOF/VEL + RBV x 12 weeks
Elbasvir/grazoprevir treatment failures	Non-cirrhotic or compensated cirrhosis	SOF/VEL/VOX x 12 weeks																			
Glecaprevir/pibrentasvir treatment failures	Non-cirrhotic or compensated cirrhosis	G/P + SOF + RBV x 16 weeks SOF/VEL/VOX x 12 weeks (plus RBV if compensated cirrhosis)																			
<u>Multiple DAA Treatment Failures, including:</u> Sofobuvir/velpatasvir/voxilaprevir Glecaprevir/pibrentasvir + sofosbuvir	Non-Cirrhotic or compensated cirrhosis	G/P + SOF + RBV x 16-24 weeks SOF/VEL/VOX x24 weeks																			
Treatment History	Cirrhosis Status	Recommended Regimen																			
<b>Treatment Naïve (Genotype 1-6)</b>																					
Treatment Naïve	Non-cirrhotic or compensated cirrhosis	SOF/VEL x 12 weeks G/P x 8 weeks																			
	Decompensated cirrhosis	SOF/VEL + RBV x 12 weeks																			
<b>Age Restrictions</b>																					
<b>Prescriber Restrictions</b>																					
<b>Coverage Duration</b>	8-24 weeks																				
<b>Renewal Criteria</b>																					

Effective Date:	12/01/2022
P&T Approval Date:	11/08/2022
P&T Revision Date:	

# Disposable Insulin Pump (Omnipod)

## Products Affected

- Omnipod 5
- Omnipod Dash

PA Criteria	Criteria Details
<b>Required Medical Information</b>	<p><b>Insulin dependent diabetes mellitus – pediatric (under age 18)</b></p> <ul style="list-style-type: none"> <li>• Documentation of Type 1 Diabetes Mellitus or Diabetes with C-reactive protein levels indicating insulin dependence.</li> <li>• On intensive insulin therapy (&gt;3 daily insulin injections) requiring frequent self-adjustments for at least 6 months prior to initiation of the insulin pump.</li> <li>• Documentation self-testing of blood glucose at least 4 times per day during the previous 2 months</li> <li>• Evidence of completion of a comprehensive diabetes education program in the last 12 months (member or caregiver/parent).</li> </ul> <p><b>Insulin dependent diabetes mellitus – adult</b></p> <ul style="list-style-type: none"> <li>• All of the above pediatric requirements AND</li> <li>• Documentation of 1 of the following: <ul style="list-style-type: none"> <li>○ HbA1c &gt;7%</li> <li>○ History of recurring hypoglycemia</li> <li>○ Wide fluctuations in blood glucose before mealtime</li> <li>○ Dawn phenomenon with fasting blood sugars frequently exceeding 200mg/dL</li> <li>○ History of severe glycemic excursions</li> </ul> </li> <li>• Inability to use a traditional (non-disposable) insulin pump.</li> </ul>
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	<b>Initial:</b> 6 months. <b>Renewal:</b> 12 months
<b>Renewal Criteria</b>	Clinical documentation of positive clinical response to therapy and in-person visit with provider within the last 6 months.

Effective Date:	03/01/2024
P&T Approval Date:	01/09/2024
P&T Revision Date:	

# Donepezil Hydrochloride (ARICEPT)

---

## Products Affected

- DONEPEZIL HCL

PA Criteria	Criteria Details
<b>Required Medical Information</b>	Treatment of mild, moderate, or severe dementia of the Alzheimer's type. Alzheimer's disease, Prophylaxis - Impaired cognition (Mild). Multi-infarct dementia.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	<b>Initial:</b> 12 months. <b>Renewal:</b> 12 months.
<b>Renewal Criteria</b>	Documented positive clinical response to therapy

Effective Date:	
P&T Approval Date:	
P&T Revision Date:	

# Dronabinol (MARINOL)

**Products Affected**

- DRONABINOL

PA Criteria	Criteria Details
<b>Required Medical Information</b>	<p><b>Nausea and Vomiting Associated with Cancer Chemotherapy (CINV):</b>            Failure, contraindication, or intolerance to one 5HT-3 receptor antagonist (eg, Anzemet [dolasetron], Kytril [granisetron], or Zofran [ondansetron]) <b>AND</b> failure, contraindication, or intolerance to one of the following: Compazine (prochlorperazine), Decadron (dexamethasone), Haldol (haloperidol), Zyprexa (olanzapine).</p> <p><b>AIDS anorexia:</b> Diagnosis of anorexia with weight loss in patients with AIDS <b>AND</b> patient is on antiretroviral therapy.</p>
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	<b>Initial:</b> 12 months. <b>Renewal:</b> 12 months.
<b>Renewal Criteria</b>	<b>Renewal Criteria:</b> Documented positive clinical response to therapy

Effective Date:	
P&T Approval Date:	
P&T Revision Date:	



# Dupilumab (DUPIXENT)

## Products Affected

- DUPIXENT

PA Criteria	Criteria Details
<p><b>Required Medical Information</b></p>	<p><b>Moderate to severe Asthma</b> with inadequate control of asthma symptoms with one of the following: inhaled corticosteroids and long acting beta2 agonist <b>OR</b> inhaled corticosteroids and long-acting muscarinic antagonist.</p> <p><b>Atopic Dermatitis:</b> Diagnosed with severe atopic dermatitis defined as having functional impairment as indicated by Dermatology Life Quality Index (DLQI) <math>\geq 11</math> or Children's Dermatology Life Quality Index (CDLQI) <math>\geq 13</math> (or severe score on other validated tool) <b>AND</b> one or more of the following: At least 10% of body surface area involvement <b>OR</b> hand, foot or mucous membrane involvement <b>AND</b> documented contraindication or failed trial to ALL of the following: Moderate-high potency corticosteroid (e.g., clobetasol, fluocinonide, fluticasone) <b>AND</b> Topical calcineurin inhibitor (e.g. tacrolimus) <b>AND</b> Oral immunomodulator therapy (e.g. cyclosporine, methotrexate, azathioprine, mycophenolate mofetil, oral corticosteroids).</p> <p><b>Eosinophilic Esophagitis:</b> Confirmed diagnosis of EoE <b>AND</b> Weight <math>\geq 40</math> kg (88lbs) <b>AND</b> Two or more episodes of dysphagia per week <b>AND</b> inadequate response (8-week trial) or intolerance/contraindication to high-dose PPI therapy <b>AND</b> inadequate response (8- to 12- week trial), intolerance, or contraindication to swallowed inhaled respiratory corticosteroid therapy.</p> <p><b>CRSwNP:</b> Diagnosis of CRSwNP, which includes objective evidence of the presence of bilateral nasal polyps <b>AND</b> not used in combination with other biologics for eosinophilic indications <b>AND</b> failure to adequately reduce symptoms after at least 2 months of saline nasal irrigations and INCS use at doses appropriate for nasal polyp treatment <b>AND</b> systemic corticosteroid treatment for NPs at least once within the last 2 years or prior NP removal surgery <b>AND</b> concomitant use of an INCS (unless not tolerated or contraindicated) while on biologic therapy</p> <p><b>Prurigo Nodularis:</b> Funded comorbid condition which would benefit from therapy <b>AND</b> diagnosis of PN verified by a dermatologist <b>AND</b> has had the diagnosis of PN for at least 3 months <b>AND</b> severe or very severe itch (WI-NRS score <math>\geq 7</math>) reported within the past week <b>AND</b> at least 20 PN lesions in total on both legs and/or both arms and/or trunk.</p>
<p><b>Age Restrictions</b></p>	<p><b>Moderate to Severe Asthma:</b> 6 years and older</p>

<b>PA Criteria</b>	<b>Criteria Details</b>
	<b>Atopic Dermatitis:</b> 6 months and older <b>Eosinophilic Esophagitis:</b> 12 years and older <b>CRSwNP &amp; Prurigo Nodularis:</b> 18 years and older
<b>Prescriber Restrictions</b>	<b>Atopic dermatitis:</b> Prescribed by a Dermatologist <b>Eosinophilic Esophagitis:</b> Prescribed by Gastroenterologist or Immunologist <b>CRSwNP:</b> Prescribed by ENT or Immunologist <b>Prurigo Nodularis:</b> Prescribed by Dermatologist
<b>Coverage Duration</b>	<b>Initial:</b> 6 months. <b>Renewal:</b> 12 months.
<b>Renewal Criteria</b>	Documented positive clinical response to therapy

Effective Date:	12/01/2022
P&T Approval Date:	11/08/2022
P&T Revision Date:	

# Elagolix (ORLISSA)

## Products Affected

- ORLISSA TAB 150MG

- ORLISSA TAB 200MG

PA Criteria	Criteria Details
<b>Required Medical Information</b>	<p>Diagnosis of moderate to severe pain associated with endometriosis <b>AND</b> trial and failure, contraindication, or intolerance to a 3-month trial of prescription strength NSAIDs <b>AND</b> trial and failure, contraindication, or intolerance to two 3-month trials of hormonal therapies (eg combined oral contraceptives, progestins, or levonorgestrel IUD, etc.).</p> <p><b>Additional info required for 200 mg tablet twice daily:</b> documentation of coexisting dyspareunia</p>
<b>Age Restrictions</b>	At least 18 years old but not yet through menopause
<b>Prescriber Restrictions</b>	Prescribed by obstetrician or gynecologist
<b>Coverage Duration</b>	<p><b>200MG dose: Initial:</b> 6 months; <b>Renewal:</b> No <b>Renewals</b> allowed</p> <p><b>150MG dose: Initial:</b> 6 months; <b>Renewal:</b> 18months</p>
<b>Renewal Criteria</b>	<b>150MG ONLY:</b> Documentation of positive clinical response to therapy <b>AND</b> total therapy durations is less than 24 months.

Effective Date:	02/01/2023
P&T Approval Date:	01/10/2023
P&T Revision Date:	01/10/2023



# Ellexacaftor-tezacaftor-ivacaft (TRIKAFTA)

---

## Products Affected

- TRIKAFTA

PA Criteria	Criteria Details
<b>Required Medical Information</b>	Clinical documentation of cystic fibrosis diagnosis with at least one F508del mutation (heterozygous or homozygous).
<b>Age Restrictions</b>	12 years of age and older
<b>Prescriber Restrictions</b>	Prescribed by pulmonologist
<b>Coverage Duration</b>	<b>Initial:</b> 3 months <b>Renewal:</b> 6 months
<b>Renewal Criteria</b>	Documented positive clinical response to therapy

Effective Date:	
P&T Approval Date:	
P&T Revision Date:	



# Epoetin Alpha (PROCRIT) (EPOGEN)

**Products Affected**

- EPOGEN
- PROCRIT

PA Criteria	Criteria Details
<b>Required Medical Information</b>	<p><b>Anemia due to Chronic Kidney Disease (CKD):</b> Anemia with hematocrit less than 30% or hemoglobin less than 10g/dL within 30 days of request <b>AND</b> patient is on dialysis <b>OR</b> patient is not on dialysis but the rate of hemoglobin decline indicates the likelihood of requiring a red blood cell (RBC) transfusion and reducing the risk of alloimmunization and/or other RBC transfusion-related risks is a goal.</p> <p><b>Anemia in HIV Patients:</b> Anemia with hematocrit less than 36% or hemoglobin is less than 12 g/dL collected within 30 days of request, Serum erythropoietin less than or equal to 500mU/mL. Patient is receiving zidovudine therapy or diagnosed with HIV.</p> <p><b>Anemia due to Chemotherapy:</b> Anemia with hematocrit less than 30% &amp; hemoglobin less than 10 g/dL collected within the prior 2 weeks of request. All other causes of anemia have been ruled out, cancer is a non-myeloid malignancy <b>AND</b> patient is concurrently on chemo <b>OR</b> will receive concomitant chemo for a minimum of 2 months <b>OR</b> anemia is caused by cancer chemo (will not be approved if patient is not receiving cancer chemotherapy).</p> <p><b>Preoperative for reduction of allogeneic blood transfusion:</b> Patient scheduled for an elective, non-cardiac, non-vascular surgery. Perioperative hemoglobin is greater than 10 to less than or equal to 13 g/dL <b>AND</b> patient is at high risk of blood loss <b>AND</b> patient is unwilling or unable to donate autologous blood pre-operatively.</p> <p><b>Anemia in Myelodysplastic Syndrome (MDS):</b> Diagnosis of MDS. Serum erythropoietin less than or equal to 500mU/mL <b>OR</b> diagnosis of transfusion-dependent MDS.</p>
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Coverage Duration</b>	<b>Initial:</b> 3 months. <b>Preop Initial:</b> 1 month.
<b>Renewal Criteria</b>	Patient has a documented continued need for therapy demonstrated by an improvement in the hematocrit and hemoglobin levels or by a significant decrease in transfusion requirements.

Effective Date:	
P&T Approval Date:	
P&T Revision Date:	



# Erenumab (AIMOVIG)

**Products Affected**

- AIMOVIG 70 mg/mL
- AIMOVIG 140 mg/mL

PA Criteria	Criteria Details
<b>Required Medical Information</b>	<b>Migraine prophylaxis:</b> Experiences at least 4 migraines per month <b>AND</b> trial and failure (defined as at least an 8-week trial) of 3 prophylactic medications from at least 2 different therapeutic classes including beta blockers, antidepressants, and anticonvulsants (e.g. propranolol, amitriptyline, topiramate). If the member has a diagnosis of chronic migraine ( $\geq$ 15 headache days & 8 migraine episodes per month) then trial and failure or intolerance to Botox.
<b>Age Restrictions</b>	18 years of age or older
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a neurologist
<b>Coverage Duration</b>	<b>Initial:</b> 3 months. <b>Renewal:</b> 6 months.
<b>Renewal Criteria</b>	Shows reduction in monthly headache days by at least 2 days from pre-CGRP treatment baseline. Clinical documented improvement in migraine-related disability.

Effective Date:	12/01/2022
P&T Approval Date:	11/08/2022
P&T Revision Date:	12/01/2022, 01/11/2022,

# Erythromycin Gel & Solution

## Products Affected

- Erythromycin 2% gel
- Erythromycin 2% solution

PA Criteria	Criteria Details
<b>Required Medical Information</b>	Documentation of trial and failure, intolerance, or contraindication to clindamycin 1% gel or solution
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	<b>Initial:</b> 12 months. <b>Renewal:</b> 12 months.
<b>Renewal Criteria</b>	Documented positive clinical response to therapy

Effective Date:	
P&T Approval Date:	
P&T Revision Date:	

# Estradiol (ESTRING)

---

## Products Affected

- Estring 2MG Vaginal Ring

PA Criteria	Criteria Details
Required Medical Information	Trial and failure of estradiol vaginal cream and estradiol vaginal tablet
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	<b>Initial:</b> 6 months. <b>Renewal:</b> 12 months.
Renewal Criteria	Documented positive clinical response to therapy

Effective Date:	07/01/2023
P&T Approval Date:	05/09/2023
P&T Revision Date:	05/09/2023

# Etrasimod arginine (Velsipity)

## Products Affected

- Velsipity tabletes

PA Criteria	Criteria Details
<b>Required Medical Information</b>	<b>Ulcerative Colitis (UC):</b> <ul style="list-style-type: none"> <li>• Documentation of moderate-to-severe ulcerative colitis</li> <li>• The member is transitioning to the requested treatment from a different biologic product previously approved by the plan OR documented failure of at least 1 of the following:               <ul style="list-style-type: none"> <li>○ Mesalamine, sulfasalazine OR</li> <li>○ Mercaptopurine, azathioprine, OR</li> <li>○ Corticosteroids (prednisone, methylprednisolone)</li> </ul> </li> <li>• Trial and failure of both infliximab and adalimumab</li> </ul>
<b>Age Restrictions</b>	Must be at least 18 years of age
<b>Prescriber Restrictions</b>	Prescribed by or in collaboration with a Gastroenterologist
<b>Coverage Duration</b>	<b>Initial:</b> 6 months. <b>Renewal:</b> 12 months.
<b>Renewal Criteria</b>	Evidence of a decrease in symptoms, reduction in enterocutaneous fistulas or clinical remission.

Effective Date:	03/01/2024
P&T Approval Date:	01/09/2024
P&T Revision Date:	

# Etanercept (ENBREL)

## Products Affected

- ENBREL 25/0.5ML, 50MG/ML
- ENBREL SURECLICK 50MG/ML

PA Criteria	Criteria Details
<p><b>Required Medical Information</b></p>	<p><b>All diagnoses:</b></p> <ul style="list-style-type: none"> <li>• Initial testing for latent TB and treatment, if necessary, before starting treatment.</li> <li>• No current active infection at initiation of therapy.</li> <li>• Risks and benefits documented in cases of chronic or recurrent infection.</li> <li>• Will NOT be used in combination with another biologic or Otezla</li> </ul> <p><b>Ankylosing Spondylitis/Axial Spondyloarthritis (AS/SpA):</b></p> <ul style="list-style-type: none"> <li>• Documentation of moderate-to-severe ankylosing spondylitis or axial spondyloarthritis as defined by:               <ul style="list-style-type: none"> <li>○ Back pain and stiffness for more than 3 months AND</li> <li>○ Signs of active inflammation on MRI OR radiological evidence of sacroiliitis OR HLA-B27 positive AND</li> <li>○ BASDAI score of <math>\geq 4</math></li> </ul> </li> <li>• The member is transitioning to the requested treatment from a different biologic product previously approved by the plan OR Documented failure of conventional therapy with both of the following:               <ul style="list-style-type: none"> <li>○ At least two NSAIDs for 3 months at maximum recommended or tolerated anti-inflammatory dose unless contraindicated, AND</li> <li>○ Physical therapy/exercise program</li> <li>○ Trial and failure of both infliximab and adalimumab</li> </ul> </li> </ul> <p><b>Plaque Psoriasis (PP):</b></p> <ul style="list-style-type: none"> <li>• Documentation of severe plaque psoriasis, defined as having functional impairment as indicated by Dermatology Life Quality Index (DLQI) = 11 or Children's Dermatology Life Quality Index (CDLQI) = 13 (or severe score on other validated tool) AND one or more of the following:               <ul style="list-style-type: none"> <li>○ At least 10% of body surface area involved</li> <li>○ Hand, foot, face, or mucous membrane involvement</li> </ul> </li> <li>• The member is transitioning to the requested treatment from a different biologic product previously approved by the plan OR documented failure of all the following:</li> </ul>

PA Criteria	Criteria Details
	<ul style="list-style-type: none"> <li>○ High-potency topical corticosteroids (augmented betamethasone, clobetasol, etc.)</li> <li>○ At least one other topical agent (calcipotriene, tazarotene, anthralin, tar, etc.)</li> <li>○ PUVA or UVB Phototherapy</li> <li>○ Methotrexate</li> <li>○ At least 1 other second line systemic agent such as cyclosporine or acitretin</li> <li>● Trial and failure of both infliximab and adalimumab</li> </ul> <p><b>Psoriatic Arthritis (PsA):</b></p> <ul style="list-style-type: none"> <li>● Documentation of psoriatic arthritis based on at least 3 out of 5 of the following: <ul style="list-style-type: none"> <li>○ Psoriasis (1 point for personal or family history, 2 points for current)</li> <li>○ Psoriatic nail dystrophy</li> <li>○ Negative test result for RF</li> <li>○ Dactylitis (current or history)</li> <li>○ Radiological evidence of juxta-articular new bone formation</li> </ul> </li> <li>● The member is transitioning to the requested treatment from a different biologic product previously approved by the plan OR documented failure of conventional therapy with both of the following: <ul style="list-style-type: none"> <li>○ NSAIDs for 3 months at maximum recommended or tolerated anti-inflammatory dose unless contraindicated, AND</li> <li>○ Methotrexate or other DMARD such as leflunomide, sulfasalazine, or cyclosporine</li> </ul> </li> <li>● Trial and failure of both infliximab and adalimumab</li> </ul> <p><b>Rheumatoid Arthritis (RA):</b></p> <ul style="list-style-type: none"> <li>● Documentation of a baseline of moderate to high disease activity of rheumatoid arthritis measured as such by an accepted assessment instrument (PAS, PASII, RAPID3, CDAI, DAS28, SDAI)</li> <li>● The member is transitioning to the requested treatment from a different biologic product previously approved by the plan OR documented failure of nonbiologic DMARD therapy: methotrexate (dosed at least 20mg per week for at least 8 weeks), leflunomide or sulfasalazine</li> <li>● Trial and failure of both infliximab and adalimumab</li> </ul>
<b>Age Restrictions</b>	

PA Criteria	Criteria Details
<b>Prescriber Restrictions</b>	<b>Plaque Psoriasis:</b> Dermatologist. <b>Psoriatic Arthritis:</b> Dermatologist or Rheumatologist. <b>Rheumatoid Arthritis:</b> Rheumatologist. <b>Ankylosing Spondylitis, Axial Spondyloarthritis:</b> Rheumatologist.
<b>Coverage Duration</b>	<b>Initial:</b> 6 months. <b>Renewal:</b> 12 months.
<b>Renewal Criteria</b>	<p><b>AS/SpA:</b> Evidence of significant improvement in signs and symptoms of AS/SpA and/or functioning, such as ASAS40 or 2-point improvement in BASDAI.</p> <p><b>PP:</b> Evidence of positive clinical response to therapy as evidenced by ONE of the following: reduction of body surface area (BSA) involvement from baseline, improvement in symptoms (e.g. pruritus, inflammation) from baseline, or evidence of functional improvement.</p> <p><b>PsA:</b> Evidence of a 20% or greater improvement in tender joint count and swollen joint count.</p> <p><b>RA:</b> Evidence of a 20% or greater improvement in tender joint count and swollen joint count.</p>

Effective Date:	9/1/2023
P&T Approval Date:	7/11/2023
P&T Revision Date:	07/11/2023, 01/11/2022

# Evolocumab (REPATHA)

**Products Affected**

- REPATHA
- REPATHA SURECLICK
- REPATHA PUSHTRONEX SYSTEM

PA Criteria	Criteria Details
<b>Required Medical Information</b>	<p><b>Clinical ASCVD:</b> Documented history of clinical ASCVD or has experienced a cardiovascular event <b>AND</b> documentation of a current LDL greater than or equal to 70 mg/dl <b>AND</b> documentation of at least one of the following: Patient is receiving maximally tolerated statin therapy <b>AND</b> is receiving ezetimibe or documented intolerance to ezetimibe, Patient is statin intolerant <b>AND</b> is receiving ezetimibe or documented intolerance to ezetimibe.</p> <p><b>Primary or familial hyperlipidemia:</b> Documentation of an untreated (i.e., prior to lipid lowering therapy) LDL greater than 190 mg/dL <b>AND</b> Documentation of current LDL greater than 100 mg/dL <b>AND</b> Documentation of at least one of the following: Patient is receiving maximally tolerated statin therapy <b>AND</b> is receiving ezetimibe or documented intolerance to ezetimibe, Patient is statin intolerant <b>AND</b> is receiving ezetimibe or documented intolerance to ezetimibe.</p>
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a cardiologist
<b>Coverage Duration</b>	<b>Initial:</b> 12 months. <b>Renewal:</b> 12 months.
<b>Renewal Criteria</b>	Documented positive clinical response to therapy

Effective Date:	
P&T Approval Date:	
P&T Revision Date:	



# Fezolinetant (VEOZAH)

## Products Affected

- Veozah TAB 45MG

PA Criteria	Criteria Details
<b>Required Medical Information</b>	<b>Vasomotor Symptoms (VMS):</b> <ul style="list-style-type: none"> <li>• Diagnosis of moderate-to-severe VMS due to menopause</li> <li>• Documented contraindication, intolerance, or inadequate response to at least 2 hormonal therapies AND</li> <li>• Documented contraindication, intolerance, or inadequate response to two nonhormonal therapies (e.g., one SNRI and one SSRI).</li> </ul>
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Gynecologist
<b>Coverage Duration</b>	<b>Initial:</b> 3 months. <b>Renewal:</b> 12 months.
<b>Renewal Criteria</b>	Documentation of at least 50% reduction in VMS from baseline.

Effective Date:	9/1/2023
P&T Approval Date:	7/11/2023
P&T Revision Date:	

# Filgrastim (NEUPOGEN)

**Products Affected**

- NEUPOGEN

PA Criteria	Criteria Details
<p><b>Required Medical Information</b></p>	<p><b>Bone marrow/stem cell transplant (BMSCT):</b> Prescribed for non-myeloid malignancies &amp; undergoing myeloablative chemotherapy followed by autologous or allogeneic bone marrow transplant <b>OR</b> for mobilization of hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis <b>OR</b> for peripheral stem cell transplant patients who have received myeloablative chemotherapy.</p> <p><b>Acute myeloid leukemia (AML):</b> Patients diagnosed with AML following induction or consolidation chemotherapy.</p> <p><b>Primary prophylaxis of chemotherapy-induced febrile neutropenia (CFN):</b> Patients receiving chemotherapy associated with greater than 20% incidence of febrile neutropenia <b>OR</b> selected chemotherapy regimen associated with 10-20% incidence of febrile neutropenia <b>AND</b> one or more risk factors associated with chemotherapy-induced infection, febrile neutropenia, or neutropenia.</p> <p><b>Secondary prophylaxis of febrile neutropenia:</b> Patient has a history of febrile neutropenia with previous chemotherapy <b>AND</b> is receiving myelosuppressive chemotherapy associated with neutropenia (ANC less than 500 cells/mm<sup>3</sup>).</p> <p><b>Neutropenia associated with dose dense chemotherapy (NDDC):</b> Patient is receiving National Cancer Institute’s Breast Intergroup, INT C9741 dose dense chemotherapy protocol for primary breast cancer <b>OR</b> patient is receiving a dose-dense chemotherapy regimen and the incidence of febrile neutropenia is unknown.</p> <p><b>Severe chronic neutropenia (SCN):</b> Diagnosed with congenital, cyclic, and idiopathic neutropenia with chronic ANC less than or equal to 500 cells/mm<sup>3</sup>.</p> <p><b>Febrile Neutropenia (FN):</b> Patient receiving myelosuppressive chemotherapy associated with neutropenia (ANC less than or equal to 500 cells/mm<sup>3</sup>) <b>AND</b> is at high risk for infection-associated complications.</p>

<b>PA Criteria</b>	<b>Criteria Details</b>
	<b>Acute radiation syndrome (ARS):</b> Patient is/was acutely exposed to myelosuppressive doses of radiation.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Prescribed by hematologist or oncologist.
<b>Coverage Duration</b>	<b>Initial:</b> 12 months. <b>Renewal:</b> 12 months.
<b>Renewal Criteria</b>	Documented positive clinical response to therapy

Effective Date:	
P&T Approval Date:	
P&T Revision Date:	

# Fingolimod (GILENYA)

**Products Affected**

- GILENYA

PA Criteria	Criteria Details
<b>Required Medical Information</b>	Diagnosis of relapsing forms of multiple sclerosis
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Neurologist
<b>Coverage Duration</b>	<b>Initial:</b> 12 months. <b>Renewal:</b> 12 months.
<b>Renewal Criteria</b>	Documented positive clinical response to therapy

Effective Date:	
P&T Approval Date:	
P&T Revision Date:	

# Fluorouracil, topical (EFUDEX, FLUOROPLEX)

**Products Affected**

- FLUOROURACIL **CRE 5%**
- FLUOROURACIL **SOL 2%**
- FLUOROURACIL **SOL 5%**

PA Criteria	Criteria Details
<b>Required Medical Information</b>	Diagnosis of superficial basal cell carcinoma with multiple lesions and/or difficult to treat areas.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	<b>Initial:</b> 12 months. <b>Renewal:</b> 12 months.
<b>Renewal Criteria</b>	Documented positive clinical response to therapy

Effective Date:	
P&T Approval Date:	
P&T Revision Date:	

# Galcanezumab-gnlm (EMGALITY)

## Products Affected

- Emgality 120MG dose
- Emgality 300MG dose

PA Criteria	Criteria Details
<b>Required Medical Information</b>	<p><b>Diagnosis of cluster headache:</b> None of the following exclusions: ECG abnormalities compatible with an acute CV event, history of unstable angina, percutaneous coronary intervention, coronary artery bypass grafting, deep vein thrombosis, or pulmonary embolism within the past 6 months, history of stroke, intracranial or carotid aneurysm, intracranial hemorrhage, vasospastic angina, peripheral vascular disease <b>AND</b> tried and failed a 3-month trial of verapamil and topiramate.</p> <p><b>Migraine prophylaxis:</b> Experiences at least 4 migraines per month <b>AND</b> trial and failure (defined as at least an 8-week trial) of 3 prophylactic medications from at least 2 different therapeutic classes including beta blockers, antidepressants, and anticonvulsants (e.g. propranolol, amitriptyline, topiramate). If the member has a diagnosis of chronic migraine (<math>\geq 15</math> headache days &amp; 8 migraine episodes per month) then trial and failure or intolerance to Botox.</p>
<b>Age Restrictions</b>	18 years of age and older
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a neurologist
<b>Coverage Duration</b>	<b>Initial:</b> 3 months <b>Renewal:</b> 6 months
<b>Renewal Criteria</b>	<p><b>Cluster Headache:</b> Documented positive clinical response to therapy</p> <p><b>Migraine:</b> shows reduction in monthly headache days by at least 2 days from pre-CGRP treatment baseline. Clinical documented improvement in migraine-related disability.</p>

Effective Date:	
P&T Approval Date:	
P&T Revision Date:	

# General Oncology

## Products Affected

- AKEEGA TAB
- AUGTYRO CAP
- BRUKINSA CAP
- CABOMETYX TAB
- CALQUENCE TAB
- COTELLIC TAB
- EMCYT CAP
- ERLOTINIB TAB
- EVEROLIMUS
- EXKIVITY CAP
- FOTIVDA CAP
- FRUZAQLA CAP
- GLEOSTINE CAP
- HYCAMTIN CAP
- IBRANCE CAP
- IBRANCE TAB
- IMBRUVICA CAP
- IMBRUVICA TAB
- IMBRUVICA SUSP
- JAYPIRCA TAB
- KISQALI TAB
- KRAZATI TAB
- LENALIDOMIDE CAP
- LENVIMA CAP
- LEUKERAN TAB
- LONSURF TAB
- LORBRENA TAB
- LUMAKRAS TAB
- LYNPARZA TAB
- LYNPARZA TAB
- LYTGABI TAB
- MEKINIST TAB
- NINLARO CAP
- OGSIVEO TAB
- PEMAZYRE TAB
- RETEVMO TAB
- REZLIDHIA CAP
- ROZLYTREK CAP
- RYDAPT CAP
- SCEMBLIX TAB
- SORAFENIB TAB
- SPRYCEL TAB
- SUNITINIB CAP
- TALZENNA CAP
- TAFINLAR CAP
- TASIGNA CAP
- TEPMETKO TAB
- THALOMID CAP
- TIBSOVO TAB
- TRUSELTIQ CAP
- TRUQAP TAB
- TUKYSA TAB
- VANFLYTA TAB
- VERZENIO TAB
- VONJO CAP
- VOTRIENT TAB
- XALKORI CAP
- ZOLINZA TAB

PA Criteria	Criteria Details
<b>Required Medical Information</b>	Medication is being used for an FDA approved age <b>AND</b> Medication is being used for FDA approved indication <b>OR</b> Medication is being used according to National Comprehensive Cancer Network (NCCN) guidelines
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Prescribed by oncologist
<b>Coverage Duration</b>	<b>Initial:</b> 3 months. <b>Renewal:</b> up to 6 months.
<b>Renewal Criteria</b>	Clinical documentation of provider follow-up indicating safety and efficacy with medication adherence over previous approval duration.

Effective Date:	7/1/2024
P&T Approval Date:	5/14/2024
P&T Revision Date:	5/1/2024, 03/01/2024, 01/09/2024, 11/1/2023, 09/01/2023, 7/11/2023, 05/09/2023, 03/14/2023, 01/10/2023, 10/01/2022,

# Glatiramer (GLATOPA)

---

## Products Affected

- GLATIRAMER INJ 20MG/ML
- GLATIRAMER INJ 40MG/ML

PA Criteria	Criteria Details
Required Medical Information	Diagnosis of relapsing forms of multiple sclerosis
Age Restrictions	
Prescriber Restrictions	Prescribed by Neurologist
Coverage Duration	<b>Initial:</b> 12 months. <b>Renewal:</b> up to 12 months.
Renewal Criteria	Documented positive clinical response to therapy

Effective Date:	02/01/2023
P&T Approval Date:	01/10/2023
P&T Revision Date:	01/10/2023



# Glucagon-Like Peptide-1 (GLP-s) Receptor Agonist

**Products Affected**

- BYDUREON BCISE
- BYETTA 10 MCG PEN
- BYETTA 5 MCG PEN
- TRULICITY
- VICTOZA

PA Criteria	Criteria Details
<b>Required Medical Information</b>	<p><b>Type 2 diabetes:</b></p> <ul style="list-style-type: none"> <li>• Documentation of clinically diagnosed Type 2 Diabetes.</li> <li>• Documentation of adequate trial of maximally tolerated dose of metformin.</li> <li>• Documentation of trial and failure of an SGLT-2 inhibitor or a DPP-4 inhibitor (or contraindication to both).</li> </ul>
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	<b>Initial:</b> 12 months, <b>Renewal:</b> 12 months.
<b>Renewal Criteria</b>	Documented positive clinical response to therapy

Effective Date:	
P&T Approval Date:	
P&T Revision Date:	

# Golimumab (SIMPONI)

## Products Affected

- SIMPONI 50/0.5ML, 100MG/ML

PA Criteria	Criteria Details
<p><b>Required Medical Information</b></p>	<p><b>All diagnoses:</b></p> <ul style="list-style-type: none"> <li>• Initial testing for latent TB and treatment, if necessary, before starting treatment.</li> <li>• No current active infection at initiation of therapy.</li> <li>• Risks and benefits documented in cases of chronic or recurrent infection.</li> <li>• Will NOT be used in combination with another biologic or Otezla</li> </ul> <p><b>Ankylosing Spondylitis/Axial Spondyloarthritis (AS/SpA):</b></p> <ul style="list-style-type: none"> <li>• Documentation of moderate-to-severe ankylosing spondylitis or axial spondyloarthritis as defined by:               <ul style="list-style-type: none"> <li>○ Back pain and stiffness for more than 3 months AND</li> <li>○ Signs of active inflammation on MRI OR radiological evidence of sacroiliitis OR HLA-B27 positive AND</li> <li>○ BASDAI score of <math>\geq 4</math></li> </ul> </li> <li>• The member is transitioning to the requested treatment from a different biologic product previously approved by the plan OR Documented failure of conventional therapy with both of the following:               <ul style="list-style-type: none"> <li>○ At least two NSAIDs for 3 months at maximum recommended or tolerated anti-inflammatory dose unless contraindicated, AND</li> <li>○ Physical therapy/exercise program</li> </ul> </li> <li>• Trial and failure of both infliximab and adalimumab</li> </ul> <p><b>Psoriatic Arthritis (PsA):</b></p> <ul style="list-style-type: none"> <li>• Documentation of psoriatic arthritis based on at least 3 out of 5 of the following:               <ul style="list-style-type: none"> <li>○ Psoriasis (1 point for personal or family history, 2 points for current)</li> <li>○ Psoriatic nail dystrophy</li> <li>○ Negative test result for RF</li> <li>○ Dactylitis (current or history)</li> <li>○ Radiological evidence of juxta-articular new bone formation</li> </ul> </li> <li>• The member is transitioning to the requested treatment from a different biologic product previously approved by the plan OR documented failure of conventional therapy with both of the following:</li> </ul>

PA Criteria	Criteria Details
	<ul style="list-style-type: none"> <li>○ NSAIDs for 3 months at maximum recommended or tolerated anti-inflammatory dose unless contraindicated, AND</li> <li>○ Methotrexate or other DMARD such as leflunomide, sulfasalazine, or cyclosporine</li> <li>● Trial and failure of both infliximab and adalimumab</li> </ul> <p><b>Rheumatoid Arthritis (RA):</b></p> <ul style="list-style-type: none"> <li>● Documentation of a baseline of moderate to high disease activity of rheumatoid arthritis measured as such by an accepted assessment instrument (PAS, PASII, RAPID3, CDAI, DAS28, SDAI)</li> <li>● The member is transitioning to the requested treatment from a different biologic product previously approved by the plan OR documented failure of nonbiologic DMARD therapy: methotrexate (dosed at least 20mg per week for at least 8 weeks), leflunomide or sulfasalazine</li> <li>● Trial and failure of both infliximab and adalimumab</li> </ul> <p><b>Ulcerative Colitis (UC):</b></p> <ul style="list-style-type: none"> <li>● Documentation of moderate-to-severe ulcerative colitis</li> <li>● The member is transitioning to the requested treatment from a different biologic product previously approved by the plan OR documented failure of at least 1 of the following: <ul style="list-style-type: none"> <li>○ Mesalamine, sulfasalazine OR</li> <li>○ Mercaptopurine, azathioprine, OR</li> <li>○ Corticosteroids (prednisone, methylprednisolone)</li> <li>○ Trial and failure of both infliximab and adalimumab</li> </ul> </li> </ul>
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	<p><b>Ulcerative Colitis:</b> Gastroenterologist.  <b>Psoriatic Arthritis:</b> Dermatologist or Rheumatologist.  <b>Rheumatoid Arthritis:</b> Rheumatologist.  <b>Ankylosing Spondylitis, Axial Spondyloarthritis:</b> Rheumatologist.</p>
<b>Coverage Duration</b>	<b>Initial:</b> 6 months. <b>Renewal:</b> 12 months.
<b>Renewal Criteria</b>	<p><b>AS/SpA:</b> Evidence of significant improvement in signs and symptoms of AS/SpA and/or functioning, such as ASAS40 or 2-point improvement in BASDAI.</p> <p><b>PsA:</b> Evidence of a 20% or greater improvement in tender joint count and swollen joint count.</p>

PA Criteria	Criteria Details
	<p><b>RA:</b> Evidence of a 20% or greater improvement in tender joint count and swollen joint count.</p> <p><b>UC:</b> Evidence of a significant response such as a decrease in bloody stools per day or elimination of signs of toxicity.</p>

Effective Date:	9/1/2023
P&T Approval Date:	7/11/2023
P&T Revision Date:	

# Gonadotropin-Releasing Hormone Agonists

## Products Affected

- Lupron

PA Criteria	Criteria Details
<p><b>Required Medical Information</b></p>	<p><b>Endometriosis</b></p> <ul style="list-style-type: none"> <li>• One of the following:           <ul style="list-style-type: none"> <li>○ History of inadequate pain control response following and trial of at least 6 months or history of intolerance or contraindication to one of the following:               <ul style="list-style-type: none"> <li>▪ Danazol</li> <li>▪ Combination (estrogen/progestin) oral contraceptive</li> <li>▪ Progestins</li> </ul> </li> <li>○ Patient has had surgical ablation to prevent recurrence</li> </ul> </li> </ul> <p><b>Uterine Leiomyomata (Fibroids) – For the reduction of the size of fibroids</b></p> <ul style="list-style-type: none"> <li>• For use prior to surgery to reduce the size of fibroids to facilitate a surgical procedure (e.g., myomectomy, hysterectomy)</li> </ul> <p><b>Uterine Leiomyomata (Fibroids) – Anemia</b></p> <ul style="list-style-type: none"> <li>• Anemia is caused by uterine leiomyomata (fibroids)</li> <li>• Patient has tried and had an inadequate response to at least 1 month of monotherapy with iron</li> <li>• Used in combination with iron therapy</li> <li>• For use prior to surgery</li> </ul> <p><b>Central Precocious Puberty (CPP)</b></p> <ul style="list-style-type: none"> <li>• Diagnosis of central precocious puberty (idiopathic or neurogenic)</li> <li>• Early onset of secondary sexual characteristics in one of the following:           <ul style="list-style-type: none"> <li>○ Females less than 8 years of age</li> <li>○ Males less than 9 years of age</li> </ul> </li> <li>• Advanced bone age of at least one year compared with chronological age</li> <li>• One of the following:           <ul style="list-style-type: none"> <li>○ Patient has undergone gonadotropin-releasing hormone agonist (GnRHa) testing and peak luteinizing hormone (LH) level above pre-pubertal range</li> <li>○ Patient has a random LH level in the pubertal range</li> </ul> </li> <li>• One of the following:</li> </ul>

PA Criteria	Criteria Details
	<ul style="list-style-type: none"> <li>○ Patient had one of the following diagnostic evaluations to rule out tumors, when suspected: <ul style="list-style-type: none"> <li>▪ Diagnostic imaging of the brain (MRI or CT scan) (in patients with symptoms suggestive of a brain tumor or in those 6 years of age or younger</li> <li>▪ Pelvic/testicular/adrenal ultrasound (if steroid levels suggest suspicion)</li> <li>▪ Adrenal steroids to rule out congenital adrenal hyperplasia (when pubarche precedes thelarche or gonadarche)</li> </ul> </li> <li>○ Patient has no suspected tumors</li> </ul> <p><b>Prostate Cancer</b></p> <ul style="list-style-type: none"> <li>• Diagnosis of advanced or metastatic prostate cancer</li> </ul> <p><b>Gender Dysphoria/Gender Incongruence</b></p> <ul style="list-style-type: none"> <li>• Using gonadotropin for suppression of puberty</li> <li>• Diagnosis of gender dysphoria/gender incongruence</li> </ul>
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	<b>Central Precocious Puberty (CPP):</b> Pediatric endocrinologist
<b>Coverage Duration</b>	<p><b>Endometriosis: Initial:</b> 6 months. <b>Renewal:</b> up to 6 months.  <b>Uterine Leiomyomata (Fibroids Reduction): Initial:</b> 4 months.  <b>Uterine Leiomyomata (Fibroids Anemia): Initial:</b> 3 months.  <b>Central Precocious Puberty (CPP): Initial:</b> 12 months. <b>Renewal:</b> up to 12 months.  <b>Prostate Cancer: Initial:</b> 12 months. <b>Renewal:</b> up to 12 months.  <b>Gender Dysphoria: Initial:</b> 12 months.</p>
<b>Renewal Criteria</b>	<p><b>Endometriosis:</b> Recurrence of symptoms following a trial of at least 6 months with leuprolide acetate AND used in combination with one of the following: Norethindrone 5mg daily, other “add-back” sex-hormones (e.g. estrogen, medroxyprogesterone), other bone-sparing agents (e.g., bisphosphonates).</p> <p><b>Central Precocious Puberty (CPP):</b> LH levels have been suppressed to pre-pubertal levels.</p> <p><b>Prostate Cancer:</b> Patient does not show evidence of progressive disease while on therapy.</p>

Effective Date:	07/01/2024
P&T Approval Date:	05/14/2024
P&T Revision Date:	05/14/2024, 01/10/2023

# Grass Pollen Allergen Extract -Timothy Grass (GRASTEK)

**Products Affected**

- GRASTEK

PA Criteria	Criteria Details
<b>Required Medical Information</b>	Patient has a diagnosis of grass pollen-induced allergic rhinitis.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Prescribed by an Allergy or Immunology specialist.
<b>Coverage Duration</b>	<b>Initial:</b> 3 months. <b>Renewal:</b> 3 months.
<b>Renewal Criteria</b>	Documented positive clinical response to therapy

Effective Date:	
P&T Approval Date:	
P&T Revision Date:	





# Insulin Degludec (TRESIBA)

## Products Affected

- TRESIBA FLEXTOUCH

PA Criteria	Criteria Details
<b>Required Medical Information</b>	<b>(both U-100 &amp; U-200)</b> Must have tried and failed insulin glargine or have documented intolerance or contraindication to insulin glargine <b>AND</b> have significant barriers to standardized administration requiring flexibility in dose timing. <b>(U-200)</b> Patient must require greater than 160 units of insulin per dose <b>AND</b> have difficulty with multiple daily injections.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	<b>Initial:</b> 12 months. <b>Renewal:</b> 12 months.
<b>Renewal Criteria</b>	Documented positive clinical response to therapy

Effective Date:	5/1/2024
P&T Approval Date:	3/12/2024
P&T Revision Date:	3/12/2024

# Interferon beta-1a (AVONEX)

**Products Affected**

- AVONEX PEN
- AVONEX PREFILLED

PA Criteria	Criteria Details
<b>Required Medical Information</b>	Diagnosis of a relapsing form of Multiple Sclerosis <b>AND</b> Trial and failure, contraindication, or intolerance to all of the following: <ul style="list-style-type: none"> <li>• dimethyl fumarate</li> <li>• fingolimod</li> <li>• glatiramer acetate/glatopa</li> </ul>
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a neurologist
<b>Coverage Duration</b>	<b>Initial:</b> 12 months. <b>Renewal:</b> 12 months.
<b>Renewal Criteria</b>	Documented positive clinical response to therapy

Effective Date:	02/01/2023
P&T Approval Date:	01/10/2023
P&T Revision Date:	01/10/2023

# Interferon beta-1a (REBIF)

**Products Affected**

- REBIF INJ 22/0.5ML
- REBIF INJ 44/0.5ML
- REBIF REBIDO INJ 22/0.5
- REBIF REBIDO INJ 44/0.5

PA Criteria	Criteria Details
<b>Required Medical Information</b>	Diagnosis of relapsing forms of multiple sclerosis <b>AND</b> trial and failure, contraindication, or intolerance to all of the following: dimethyl fumarate, fingolimod, glatiramer acetate/glatopa, avonex.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Neurologist
<b>Coverage Duration</b>	<b>Initial:</b> 12 months. <b>Renewal:</b> 12 months.
<b>Renewal Criteria</b>	Documented positive clinical response to therapy

Effective Date:	02/01/2023
P&T Approval Date:	01/10/2023
P&T Revision Date:	01/10/2023

# Interferon beta-1b (EXTAVIA)

**Products Affected**

- EXTAVIA INJ 0.3MG

PA Criteria	Criteria Details
<b>Required Medical Information</b>	Diagnosis of relapsing forms of multiple sclerosis <b>AND</b> trial and failure, contraindication, or intolerance to all of the following: dimethyl fumarate, fingolimod, glatiramer acetate/glatopa.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Neurologist
<b>Coverage Duration</b>	<b>Initial:</b> 12 months. <b>Renewal:</b> 12 months.
<b>Renewal Criteria</b>	Documented positive clinical response to therapy

Effective Date:	02/01/2023
P&T Approval Date:	01/10/2023
P&T Revision Date:	01/10/2023

# Itraconazole (SPORANOX)

## Products Affected

- ITRACONAZOLE ORAL SOLUTION

PA Criteria	Criteria Details
<b>Required Medical Information</b>	<p><b>Tinea Unguim:</b></p> <ul style="list-style-type: none"> <li>• Patient is experiencing pain which limits normal activity (i.e, unable to wear shoes, difficulty walking, etc), <b>OR</b> Patient has diabetes, <b>OR</b> patient has peripheral vascular disease, <b>OR</b> patient is immunocompromised.</li> </ul> <p><b>All other conditions:</b></p> <ul style="list-style-type: none"> <li>• Diagnosis is supported by compendia and is an above the line condition.</li> </ul>
<b>Age Restrictions</b>	Member is under age 10 or unable to use tablets
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	<b>Initial:</b> 3 months. <b>Renewal:</b> 3 months.
<b>Renewal Criteria</b>	Documented positive clinical response to therapy

Effective Date:	5/1/2024
P&T Approval Date:	3/12/2024
P&T Revision Date:	3/12/2024

# Iron sulfate (Ferrous Sulfate)

---

## Products Affected

- Ferrous Sulfate 300mg/5mL

PA Criteria	Criteria Details
Required Medical Information	Documentation of inability to use ferrous sulfate tabs or 200mg/5mL liquid
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Lifetime approval
Renewal Criteria	

Effective Date:	01/01/2024
P&T Approval Date:	11/14/2023
P&T Revision Date:	

# Ivacaftor (KALYDECO)

---

## Products Affected

- KALYDECO

PA Criteria	Criteria Details
<b>Required Medical Information</b>	Diagnosis of Cystic Fibrosis with documentation showing at least one CFTR gene mutation that has shown to be responsive to Kalydeco.
<b>Age Restrictions</b>	6 months of age and older
<b>Prescriber Restrictions</b>	Prescribed by pulmonologist
<b>Coverage Duration</b>	<b>Initial:</b> 3 months <b>Renewal:</b> 6 months
<b>Renewal Criteria</b>	Documentation of improved or stable lung function, shown by FEV1 improvement or a reduction in pulmonary exacerbations

Effective Date:	
P&T Approval Date:	
P&T Revision Date:	



# Ivermectin (STROMECTOL)

---

## Products Affected

- IVERMECTIN

PA Criteria	Criteria Details
<b>Required Medical Information</b>	Treatment of FDA approved diagnosis including Strongyloidiasis, Onchocerciasis, Infestation by Phthirus pubis, Scabies, Enterobiasis.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	6 months, <b>Renewals:</b> reinfection 6 months
<b>Renewal Criteria</b>	Documented positive clinical response to therapy

Effective Date:	
P&T Approval Date:	
P&T Revision Date:	

# Ixekizumab (TALTZ)

## Products Affected

- TALTZ 80MG/ML (auto-injector and prefilled syringe)

PA Criteria	Criteria Details
<p><b>Required Medical Information</b></p>	<p><b>All diagnoses:</b></p> <ul style="list-style-type: none"> <li>• Initial testing for latent TB and treatment, if necessary, before starting treatment.</li> <li>• No current active infection at initiation of therapy.</li> <li>• Risks and benefits documented in cases of chronic or recurrent infection.</li> <li>• Will NOT be used in combination with another biologic or Otezla</li> </ul> <p><b>Ankylosing Spondylitis/Axial Spondyloarthritis (AS/SpA):</b></p> <ul style="list-style-type: none"> <li>• Documentation of moderate-to-severe ankylosing spondylitis or axial spondyloarthritis as defined by:               <ul style="list-style-type: none"> <li>○ Back pain and stiffness for more than 3 months AND</li> <li>○ Signs of active inflammation on MRI OR radiological evidence of sacroiliitis OR HLA-B27 positive AND</li> <li>○ BASDAI score of <math>\geq 4</math></li> </ul> </li> <li>• The member is transitioning to the requested treatment from a different biologic product previously approved by the plan OR Documented failure of conventional therapy with both of the following:               <ul style="list-style-type: none"> <li>○ At least two NSAIDs for 3 months at maximum recommended or tolerated anti-inflammatory dose unless contraindicated, AND</li> <li>○ Physical therapy/exercise program</li> </ul> </li> <li>• Trial and failure of both infliximab and adalimumab</li> </ul> <p><b>Plaque Psoriasis (PP):</b></p> <ul style="list-style-type: none"> <li>• Documentation of severe plaque psoriasis, defined as having functional impairment as indicated by Dermatology Life Quality Index (DLQI) = 11 or Children's Dermatology Life Quality Index (CDLQI) = 13 (or severe score on other validated tool) AND one or more of the following:               <ul style="list-style-type: none"> <li>○ At least 10% of body surface area involved</li> <li>○ Hand, foot, face, or mucous membrane involvement</li> </ul> </li> <li>• The member is transitioning to the requested treatment from a different biologic product previously approved by the plan OR documented failure of all the following:</li> </ul>

PA Criteria	Criteria Details
	<ul style="list-style-type: none"> <li>○ High-potency topical corticosteroids (augmented betamethasone, clobetasol, etc.)</li> <li>○ At least one other topical agent (calcipotriene, tazarotene, anthralin, tar, etc.)</li> <li>○ PUVA or UVB Phototherapy</li> <li>○ Methotrexate</li> <li>○ At least 1 other second line systemic agent such as cyclosporine or acitretin</li> <li>● Trial and failure of both infliximab and adalimumab</li> </ul> <p><b>Psoriatic Arthritis (PsA):</b></p> <ul style="list-style-type: none"> <li>● Documentation of psoriatic arthritis based on at least 3 out of 5 of the following: <ul style="list-style-type: none"> <li>○ Psoriasis (1 point for personal or family history, 2 points for current)</li> <li>○ Psoriatic nail dystrophy</li> <li>○ Negative test result for RF</li> <li>○ Dactylitis (current or history)</li> <li>○ Radiological evidence of juxta-articular new bone formation</li> </ul> </li> <li>● The member is transitioning to the requested treatment from a different biologic product previously approved by the plan OR documented failure of conventional therapy with both of the following: <ul style="list-style-type: none"> <li>○ NSAIDs for 3 months at maximum recommended or tolerated anti-inflammatory dose unless contraindicated, AND</li> <li>○ Methotrexate or other DMARD such as leflunomide, sulfasalazine, or cyclosporine</li> </ul> </li> <li>● Trial and failure of both infliximab and adalimumab</li> </ul>
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	<p><b>Plaque Psoriasis:</b> Dermatologist.</p> <p><b>Psoriatic Arthritis:</b> Dermatologist or Rheumatologist.</p> <p><b>Ankylosing Spondylitis, Axial Spondyloarthritis:</b> Rheumatologist.</p>
<b>Coverage Duration</b>	<b>Initial:</b> 6 months. <b>Renewal:</b> 12 months.
<b>Renewal Criteria</b>	<p><b>AS/SpA:</b> Evidence of significant improvement in signs and symptoms of AS/SpA and/or functioning, such as ASAS40 or 2-point improvement in BASDAI.</p> <p><b>PP:</b> Evidence of positive clinical response to therapy as evidenced by ONE of the following: reduction of body surface area (BSA) involvement from</p>

PA Criteria	Criteria Details
	<p>baseline, improvement in symptoms (e.g. pruritus, inflammation) from baseline, or evidence of functional improvement.</p> <p><b>PsA:</b> Evidence of a 20% or greater improvement in tender joint count and swollen joint count.</p>

Effective Date:	9/1/2023
P&T Approval Date:	7/11/2023
P&T Revision Date:	

# Lacosamide (VIMPAT)

---

## Products Affected

- Lacosamide **TAB 50MG, 100MG, 150MG, 200MG**
- Lacosamide **Solution 10MG/ML**

PA Criteria	Criteria Details
<b>Required Medical Information</b>	<b>Focal seizures OR Primary generalized tonic-clonic seizures:</b> <ul style="list-style-type: none"> <li>• Documented epilepsy or seizure disorder</li> </ul>
<b>Age Restrictions</b>	<b>Solution only:</b> Member is under age 10 or unable to use tablets
<b>Neurology</b>	Neurologist
<b>Coverage Duration</b>	<b>Initial:</b> 12 months. <b>Renewal:</b> 12 months.
<b>Renewal Criteria</b>	Documentation of positive clinical response to therapy.

Effective Date:	5/1/2024
P&T Approval Date:	3/12/2024
P&T Revision Date:	7/11/2023

# Lanthanum Carbonate (FOSRENOL)

---

## Products Affected

- Lanthanum carbonate **500MG**
- Lanthanum carbonate **750MG**
- Lanthanum carbonate **1000MG**

PA Criteria	Criteria Details
<b>Required Medical Information</b>	Diagnosis of hyperphosphatemia in chronic kidney disease <b>AND</b> trial and failure, contraindication, or intolerance (at least 6 weeks) to both maximally tolerated calcium acetate and sevelamer carbonate
<b>Age Restrictions</b>	6 years or older
<b>Prescriber Restrictions</b>	Nephrologist
<b>Coverage Duration</b>	<b>Lifetime</b>
<b>Renewal Criteria</b>	Documentation of positive clinical response to therapy.

Effective Date:	07/01/2023
P&T Approval Date:	05/09/2023
P&T Revision Date:	05/09/2023

# Lasmiditan (REYVOW)

## Products Affected

- Reyvow **50MG TAB**
- Reyvow **100MG TAB**

PA Criteria	Criteria Details
<b>Required Medical Information</b>	Diagnosis of migraine <b>AND</b> documentation patient is on preventative therapy <b>AND</b> trial and failure (defined as trial period of 6 weeks per agent) or contraindication to at least 3 generic oral formulary triptans use at up to the maximally indicated dosing and in combination with NSAID therapy (naproxen)
<b>Age Restrictions</b>	Patient is 18 years of age or older
<b>Prescriber Restrictions</b>	Prescribed by neurologist or headache specialist
<b>Coverage Duration</b>	<b>Initial:</b> 3 months <b>Renewal:</b> 6 months
<b>Renewal Criteria</b>	Documented positive clinical response to therapy

Effective Date:	07/01/2023
P&T Approval Date:	05/09/2023
P&T Revision Date:	05/09/2023

# Lenacapavir (SUNLENCA)

**Products Affected**

- SUNLENCA THERAPY PACK
- SUNLENCA SUBCUTANEOUS 463.5MG/1.5mL (*must be billed to medical benefit*)

PA Criteria	Criteria Details
<b>Required Medical Information</b>	Diagnosis of MDR HIV-1 infection with resistance to at least two drugs in each of at least three of the following classes: NRTIs, NNRTIs, PIs, and INSTIs <b>AND</b> will be used in combination with an optimized baseline regimen (OBR) <b>AND</b> current ARV regimen has been stable for at least 2 months and HIV-1 RNA is $\geq 400$ copies/mL
<b>Age Restrictions</b>	$\geq 18$ years
<b>Prescriber Restrictions</b>	HIV Specialist
<b>Coverage Duration</b>	<b>Initial:</b> 6 months. <b>Renewal:</b> 12 months.
<b>Renewal Criteria</b>	<ul style="list-style-type: none"> <li>• Continues to be used in combination with an optimized background regimen (OBR)</li> <li>• Provider states that patient continues to receive clinical benefit from the treatment</li> </ul>

Effective Date:	4/1/2023
P&T Approval Date:	03/14/2023
P&T Revision Date:	03/14/2023



# Lidocaine Topical Anesthetic (LIDODERM)

---

**Products Affected**

- LIDOCAINE EXTERNAL PATCH

PA Criteria	Criteria Details
<b>Required Medical Information</b>	Diagnosis of post-herpetic neuralgia.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	<b>Initial:</b> 3 months. <b>Renewal:</b> 3 months.
<b>Renewal Criteria</b>	Documented positive clinical response to therapy

Effective Date:	
P&T Approval Date:	
P&T Revision Date:	

# Lisdexamfetamine (VYVANSE)

**Products Affected**

- LISDEXAMFETAMINE CAPS

PA Criteria	Criteria Details
<b>Required Medical Information</b>	<p><b>ADHD:</b> Clinical documentation of trial and failure (defined as at least 6 weeks of treatment) of generic Adderall XR, generic Concerta, and generic Focalin XR in the treatment of ADHD. In cases of concern of stimulant abuse, must provide clinical documentation of trial and failure of one long-acting formulary stimulant <b>OR</b> clinical justification as to why formulary long-acting stimulants are contraindicated for the patient.</p> <p><b>BED:</b> Clinical documentation confirming binge eating disorder diagnosis per DSM-5 criteria. Trial and failure of at least two therapeutic alternatives including SSRIs, topiramate, and/or methylphenidate.</p>
<b>Age Restrictions</b>	<b>BED:</b> 18 years of age or older
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	<b>Initial:</b> 12 months. <b>Renewal:</b> 12 months.
<b>Renewal Criteria</b>	Documented positive clinical response to therapy

Effective Date:	
P&T Approval Date:	
P&T Revision Date:	

# Long Acting Opiates and Dolophine

## Products Affected

- FENTANYL PATCH 72 HOUR **100 MCG/HR; 12 MCG/HR; 25 MCG/HR; 37.5 MCG/HR; 50 MCG/HR; 62.5 MCG/HR; 75 MCG/HR; 87.5 MCG/HR TRANSDERMAL**
- HYDROCODONE BITARTRATE ER CAPSULE EXTENDED RELEASE 12 HOUR **10 MG; 15 MG; 20 MG; 30 MG; 40 MG; 50 MG ORAL**
- HYDROCODONE BITARTRATE ER ORAL TABLET ER 24 HOUR ABUSE-DETERRENT
- HYDROMORPHONE HCL ER
- METHADONE HCL ORAL TABLET
- MORPHINE SULFATE ER BEADS CAPSULE EXTENDED RELEASE 24 HOUR **120 MG; 30 MG; 45 MG; 60 MG; 75 MG; 90 MG**
- MORPHINE SULFATE ER ORAL CAPSULE EXTENDED RELEASE 24 HOUR
- MORPHINE SULFATE ER ORAL TABLET EXTENDED RELEASE
- NUCYNTA ER
- OXYCODONE HCL ER
- OXYCONTIN
- OXYMORPHONE HCL ER
- XTAMPZA ER

PA Criteria	Criteria Details
<b>Required Medical Information</b>	<p><b>Cancer, end of life, or palliative care:</b> No coverage restrictions.</p> <p><b>Non-cancer/end of life care:</b> Documented use of current and/or recent usage of short-acting opioids for at least 15 days prior to long-acting opioids.</p> <ul style="list-style-type: none"> <li>• For opioid naive (14 or fewer days filled in previous 120 days): 7-day maximum quantity limit; equal to or less than 50 MED [morphine equivalents per day].</li> <li>• For opioid experienced (greater than or equal to 15 days filled in previous 120 days): equal to or less than 90 MED [morphine equivalents per day].</li> <li>• Restricted to 2 fills in a 60-day period for both naive and experienced.</li> </ul>
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	<b>Initial:</b> 12 months. <b>Renewal:</b> 12 months.
<b>Renewal Criteria</b>	Documented positive clinical response to therapy

Effective Date:	
P&T Approval Date:	
P&T Revision Date:	

# Lotilaner (Xdemyv)

## Products Affected

- Xdemyv 0.25% Ophthalmic solution

PA Criteria	Criteria Details
<b>Required Medical Information</b>	<b>Diagnosis:</b> Demodex Blepharitis <ul style="list-style-type: none"> <li>• Documentation of at least mild erythema of the upper eyelid margin</li> <li>• Presence of mites upon examination of eyelashes by light microscopy or presence of collarettes on slit lamp examination</li> </ul>
<b>Age Restrictions</b>	18 years of age and older
<b>Prescriber Restrictions</b>	Optometrist or Ophthalmologist
<b>Coverage Duration</b>	<b>Initial:</b> 6 weeks. <b>Renewal:</b> No renewals allowed
<b>Renewal Criteria</b>	N/A

Effective Date:	5/1/2024
P&T Approval Date:	3/12/2024
P&T Revision Date:	

# Lumacaftor/ivacaftor (ORKAMBI)

## Products Affected

- ORKAMBI GRA 100-125
- ORKAMBI GRA 150-188
- ORKAMBI TAB 100-125
- ORKAMBI TAB 200-125

PA Criteria	Criteria Details
<b>Required Medical Information</b>	Clinical documentation of cystic fibrosis diagnosis with homozygous F508del mutation.
<b>Age Restrictions</b>	2 years of age and older
<b>Prescriber Restrictions</b>	Prescribed by pulmonologist
<b>Coverage Duration</b>	<b>Initial:</b> 3 months <b>Renewal:</b> 6 months
<b>Renewal Criteria</b>	Documented positive clinical response to therapy

Effective Date:	
P&T Approval Date:	
P&T Revision Date:	

# Mefloquine (LARIAM)

---

## Products Affected

- MEFLOQUINE HCL

PA Criteria	Criteria Details
Required Medical Information	Malaria treatment.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Initial: 1 month.
Renewal Criteria	Documented positive clinical response to therapy

Effective Date:	
P&T Approval Date:	
P&T Revision Date:	

# Memantine Hydrochloride (NAMENDA)

**Products Affected**

- MEMANTINE HCL

PA Criteria	Criteria Details
<b>Required Medical Information</b>	Treatment of moderate-to-severe dementia of the Alzheimer's type. <b>Solution only:</b> Documentation that member can't use tablets/capsules and is under the age of 10
<b>Age Restrictions</b>	<b>Solution only:</b> Documentation that member can't use tablets/capsules and is under the age of 10
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	<b>Initial:</b> 12 months. <b>Renewal:</b> 12 months.
<b>Renewal Criteria</b>	Documented positive clinical response to therapy

Effective Date:	5/1/2024
P&T Approval Date:	3/12/2024
P&T Revision Date:	3/12/2024



# Mirikizumab-mrkz (OMVOH)

## Products Affected

- Omvoh

PA Criteria	Criteria Details
<b>Required Medical Information</b>	<p><b>All diagnoses:</b></p> <ul style="list-style-type: none"> <li>• Initial testing for latent TB and treatment, if necessary, before starting treatment.</li> <li>• No current active infection at initiation of therapy.</li> <li>• Risks and benefits documented in cases of chronic or recurrent infection.</li> <li>• Will NOT be used in combination with another biologic or Otezla</li> </ul> <p><b>Ulcerative Colitis (UC):</b></p> <ul style="list-style-type: none"> <li>• Documentation of moderate-to-severe ulcerative colitis</li> <li>• The member is transitioning to the requested treatment from a different biologic product previously approved by the plan OR documented failure of at least 1 of the following:               <ul style="list-style-type: none"> <li>• Mesalamine, sulfasalazine OR</li> <li>• Mercaptopurine, azathioprine, OR</li> <li>• Corticosteroids (prednisone, methylprednisolone)</li> <li>• Trial and failure of both infliximab and adalimumab</li> </ul> </li> </ul>
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Prescribed by or in consultations with a Gastroenterologist.
<b>Coverage Duration</b>	<b>Initial:</b> 6 months. <b>Renewal:</b> 12 months.
<b>Renewal Criteria</b>	Evidence of a significant response such as a decrease in bloody stools per day or elimination of signs of toxicity.

Effective Date:	07/01/2024
P&T Approval Date:	05/14/2024
P&T Revision Date:	



# Mitapivat (PYRUKYND)

## Products Affected

- Pyrukynd

PA Criteria	Criteria Details
<b>Required Medical Information</b>	Diagnosis of PKD with at least two mutations within the PKLR gene, including a missense mutation <b>AND</b> confirmation of current hemoglobin is $\leq$ 10mg/dL <b>AND</b> patient is not homozygous for the R479H mutation <b>AND</b> does not have two non-missense variants in the PKLR gene, without the presence of another missense variant <b>AND</b> patient has had at least 6 RBC transfusions within the previous year for hemolytic anemia due to PKD <b>AND</b> prescriber confirmed concomitant use of daily folic acid <b>AND</b> confirmation that the patient does not have moderate or severe hepatic dysfunction.
<b>Age Restrictions</b>	At least 18 years of age
<b>Prescriber Restrictions</b>	Prescribed by or in consultations with a hematologist
<b>Coverage Duration</b>	<b>Initial:</b> 3 months. <b>Renewal:</b> 6 months.
<b>Renewal Criteria</b>	Clinical documentation showing an increase in Hb at least 1.5 mg/dL over baseline and/or a reduction in frequency of transfusions.

Effective Date:	08/01/2022
P&T Approval Date:	07/12/2022
P&T Revision Date:	

# Mometasone (NASONEX)

## Products Affected

- MOMETASONE FUROATE NASAL

PA Criteria	Criteria Details
<b>Required Medical Information</b>	Diagnosis of asthma or an above the line comorbid condition that may worsen if not treated <b>AND</b> inadequate treatment response, intolerance, or contraindication to fluticasone nasal spray, <b>AND</b> budesonide nasal spray <b>AND</b> triamcinolone nasal spray.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	<b>Initial:</b> 12 months. <b>Renewal:</b> 12 months.
<b>Renewal Criteria</b>	Documented positive clinical response to therapy

Effective Date:	12/01/2022
P&T Approval Date:	11/08/2022
P&T Revision Date:	

# Naltrexone (VIVITROL)

**Products Affected**

- Vivitrol Inj.

PA Criteria	Criteria Details
<b>Required Medical Information</b>	The drug will be dispensed directly to the provider and not the member.
<b>Coverage Duration</b>	<b>Initial:</b> 12 months <b>Renewal:</b> 12 months

Effective Date:	5/1/2024
P&T Approval Date:	3/12/2024
P&T Revision Date:	7/12/2022

## Non-Formulary Criteria (standard criteria for non-formulary medication)

### Products Affected

- All Non-formulary medications

PA Criteria	Criteria Details
<b>Required Medical Information</b>	<ul style="list-style-type: none"> <li>• The requested medication being used to treat an above the line diagnosis on the OHA Prioritized list OR the member has an above the line comorbid condition that will be treated indirectly by the requested medication OR the member under the age of 21.</li> <li>• The requested medication is being used for an FDA-approved indication OR being used for an off-label indication with well-established, clinical evidence supporting its use.</li> <li>• All appropriate formulary alternatives have been tried and failed or are contraindicated.</li> <li>• <b>If the request for a non-formulary medication to allow for an alternative dosage form of a formulary agent with ALL the following criteria being met:</b> <ul style="list-style-type: none"> <li>○ <b>For a child age 10 years old or younger, or the member has documented inability to swallow formulary tablets/capsules</b></li> <li>○ <b>formulary equivalent (tablet/capsule) does not require PA OR member meets coverage criteria for formulary equivalent (tablet/capsule)</b></li> </ul> </li> </ul>
<b>Age Restrictions</b>	FDA indicated age limits (vary by drug)
<b>Prescriber Restrictions</b>	Appropriate Specialist (vary by drug)
<b>Coverage Duration</b>	<b>Initial:</b> 6 months <b>Renewal:</b> 12 months
<b>Renewal Criteria</b>	Clinical documentation of follow-up indicating safety, efficacy and medication adherence over previous approval duration.

Effective Date:	
P&T Approval Date:	

P&T Revision Date:	
--------------------	--





# Omalizumab (XOLAIR)

## Products Affected

- XOLAIR

PA Criteria	Criteria Details
<b>Required Medical Information</b>	<p><b>Severe asthma:</b> Confirmed diagnosis of moderate to severe persistent asthma <b>AND</b> documentation of smoking status <b>AND</b> positive skin test or RAST to a perennial aeroallergen <b>AND</b> baseline IgE serum level within FDA label <b>AND</b> documentation of steps taken to avoid within reason environmental allergens and other triggers <b>AND</b> documented trial and failure of : High dose inhaled corticosteroid with a long acting beta agonist (e.g. Advair), Long acting anti-muscarinic (e.g. Spiriva), Leukotriene Inhibitor (e.g. Singulair) <b>AND</b> documented trial and failure of, or contraindication to allergen immunotherapy <b>AND</b> medical or claims history of compliance/adherence with prescribed asthma medications</p> <p><b>Nasal Polyps:</b> Documentation of recurrent nasal polyps after prior sinus surgery <b>AND</b> trial and failure of at least 2 intranasal corticosteroids and Sinuva nasal implant <b>AND</b> documented adherence to a nasal corticosteroid with Xolair intended as adjunct therapy <b>AND</b> documented risk of another sinus surgery, or a statement why sinus surgery is not medically appropriate</p> <p><b>Idiopathic chronic urticaria- refractory:</b> Documentation of chronic spontaneous or idiopathic urticaria <b>AND</b> documented trial and failure (including dose escalation of both first and second-generation antihistamines) for at least 6 weeks</p> <ul style="list-style-type: none"> <li>○ (1<sup>st</sup> generation – doxepin, hydroxyzine)</li> <li>○ (2<sup>nd</sup> generation – Cetirizine, Levocetirizine, Fexofenadine, Loratadine, Desloratadine)</li> <li>○ Documented trial and failure of an H2 antihistamine (e.g. Famotidine, Cimetidine)</li> <li>○ Documented trial and failure (at least 4 weeks) of, or contraindication to a leukotriene inhibitor (e.g., Montelukast, Zafirlukast)</li> </ul>
<b>Age Restrictions</b>	<p><b>Asthma:</b> 6 years of age and older</p> <p><b>CIU:</b> 12 years of age and older</p> <p><b>Nasal Polyps:</b> 18 years of age and older</p>

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Prescriber Restrictions</b>	<b>Asthma:</b> Prescribed by or in consultation with a pulmonologist or immunologist <b>CIU:</b> Prescribed by or in consultation with an immunologist <b>Nasal Polyps:</b> Prescribed by or in consultation with an allergist or ENT
<b>Coverage Duration</b>	<b>SA/NP Initial:</b> 6 months. <b>Renewal:</b> 6 months. <b>CIU Initial:</b> 4 months. <b>Renewal:</b> 3 months.
<b>Renewal Criteria</b>	Documentation of clinically significant improvement in symptoms.

Effective Date:	
P&T Approval Date:	
P&T Revision Date:	

## **Pancrelipase (CREON) (PANCREAZE)**

### Products Affected

- Creon Capsules
- Pancreaze Capsules

PA Criteria	Criteria Details
<b>Required Medical Information</b>	Confirmed diagnosis of cystic fibrosis <b>OR</b> history of pancreatectomy <b>OR</b> diagnosis of exocrine pancreatic cancer <b>OR</b> diagnosis of chronic pancreatitis confirmed by imaging <b>OR</b> confirmed diagnosis of pancreatic insufficiency confirmed with one of the following methods: <ul style="list-style-type: none"> <li>• Steatorrhea with fecal fat determination <b>OR</b></li> <li>• Measurement of fecal elastase <b>OR</b></li> <li>• Secretin or CCK pancreatic function testing <b>OR</b></li> <li>• Two of the following CFTR mutations (G542X, W1282X, R553X, 621+1G&gt;T, 1717-1G&gt;A, 3120+1G&gt;A, R1162X, 3659delC, 1898+1G&gt;A, 2184delA, 711+1G&gt;T, F508del, I507del, G551D, N1303K, R560T)</li> </ul>
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	<b>Initial:</b> 12 months. <b>Renewal:</b> 12 months
<b>Renewal Criteria</b>	Documented positive clinical response to therapy

Effective Date:	
P&T Approval Date:	
P&T Revision Date:	

# PEANUT POWDER (PALFORZIA)

## Products Affected

- PALFORZIA (12 MG DAILY DOSE)
- PALFORZIA (120 MG DAILY DOSE)
- PALFORZIA (160 MG DAILY DOSE)
- PALFORZIA (20 MG DAILY DOSE)
- PALFORZIA (200 MG DAILY DOSE)
- PALFORZIA (240 MG DAILY DOSE)
- PALFORZIA (3 MG DAILY DOSE)
- PALFORZIA (300 MG MAINTENANCE)
- PALFORZIA (300 MG TITRATION)
- PALFORZIA (40 MG DAILY DOSE)
- PALFORZIA (6 MG DAILY DOSE)
- PALFORZIA (80 MG DAILY DOSE)
- PALFORZIA INITIAL ESCALATION

PA Criteria	Criteria Details
<b>Required Medical Information</b>	Confirmed positive skin test or peanut-specific serum IgE greater than 0.35 kUA/L Concurrent prescription with injectable epinephrine Medical justification supports necessity for oral immunotherapy despite peanut avoidance.
<b>Age Restrictions</b>	Patient must be between 4 and 17 at therapy initiation
<b>Prescriber Restrictions</b>	Prescribed by allergist or immunologist enrolled in Palforzia REMS program
<b>Coverage Duration</b>	<b>Initial:</b> 12 months. <b>Renewal:</b> 12 months.
<b>Renewal Criteria</b>	Reauthorization: Currently receiving medication byway of previously approved SHP authorization or documents showing <b>Initial</b> approval criteria was or has been met. For patients who required use of injectable epinephrine while on Palforzia, must have medical justification that supports continued need for Palforzia. If less than 18 years old, must have medical justification that supports continued need for oral immunotherapy despite peanut avoidance and documentation that <b>Initial</b> dose escalation happened between age 4 and 17.

Effective Date:	
P&T Approval Date:	
P&T Revision Date:	

# Pramipexole Dihydrochloride (MIRAPEX)

---

## Products Affected

- PRAMIPEXOLE DIHYDROCHLORIDE

PA Criteria	Criteria Details
Required Medical Information	For the treatment of Parkinson's Disease.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	<b>Initial:</b> 12 months. <b>Renewal:</b> 12 months.
Renewal Criteria	Documented positive clinical response to therapy

Effective Date:	
P&T Approval Date:	
P&T Revision Date:	

# Potassium Binders

## Products Affected

- Lokelma Powder Pak: 5g, 10g
- Veltassa Packet: 8.4g, 16.8g, 25.2g

PA Criteria	Criteria Details
<b>Required Medical Information</b>	<p><b>Hyperkalemia</b></p> <ul style="list-style-type: none"> <li>• Being used for the treatment of hyperkalemia based on current potassium labs</li> <li>• Failed all of the following:               <ul style="list-style-type: none"> <li>○ Dietary changes (potassium restriction)</li> <li>○ Dose modification/discontinuation of ACE-inhibitor, ARB, or other hyperkalemia causing agents</li> <li>○ Diuretics titrated to maximum tolerated dose</li> </ul> </li> <li>• If the request is for Lokelma or does the member have a trial and failure or contraindication to Lokelma therapy (Lokelma is not recommended in those with heart failure or are on sodium restriction)</li> </ul>
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	<b>Initial:</b> 6 months; <b>Renewal:</b> 12 months
<b>Renewal Criteria</b>	<p>Documented positive clinical response to therapy by either of the following:</p> <ul style="list-style-type: none"> <li>• Potassium level returning to normal on therapy</li> <li>• Significant drop in potassium level from baseline on therapy</li> </ul>

Effective Date:	07/01/2024
P&T Approval Date:	05/14/2024
P&T Revision Date:	09/13/2022

# Quantity Limit Exception Criteria (standard criteria for quantity exception)

## Products Affected

- All drugs with quantity limits

PA Criteria	Criteria Details
<b>Required Medical Information</b>	<ul style="list-style-type: none"> <li>• The requested medication being used to treat an above the line diagnosis on the OHA Prioritized list OR the member has an above the line comorbid condition that will be treated indirectly by the requested medication OR the member under the age of 21.</li> <li>• The requested medication is being used for an FDA-approved indication OR being used for an off-label indication with well-established, clinical evidence supporting its use.</li> <li>• Documentation of failure of the requested medication within quantity limits, including failure of different strengths of the requested medication.</li> <li>• All appropriate alternative treatments have been tried and failed.</li> </ul>
<b>Age Restrictions</b>	FDA indicated age limits (vary by drug)
<b>Prescriber Restrictions</b>	Appropriate Specialist (vary by drug)
<b>Coverage Duration</b>	Will vary by drug and situation.
<b>Renewal Criteria</b>	Documented positive clinical response to therapy

Effective Date:	
P&T Approval Date:	
P&T Revision Date:	

# Resmetirom (REZDIFFRA)

## Products Affected

- Rezdiffra 60MG/80MG/100MG TAB

PA Criteria	Criteria Details
<b>Required Medical Information</b>	<ul style="list-style-type: none"> <li>• Diagnosis of metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH)</li> <li>• Patient does not have cirrhosis (e.g. decompensated cirrhosis)</li> <li>• Submission of medical records (e.g. chart notes) showing diagnosis has been confirmed by one of the following:               <ul style="list-style-type: none"> <li>○ FibroScan-aspartate aminotransferase (FAST)</li> <li>○ MRI-aspartate aminotransferase (MAST)</li> <li>○ Liver biopsy</li> </ul> </li> <li>• Submission of medical records (e.g. chart notes) showing disease is fibrosis stage F2 or F3 as confirmed by one of the following:               <ul style="list-style-type: none"> <li>○ FibroScan</li> <li>○ Fibrosis-4 index (FIB-4)</li> <li>○ Magnetic resonance Elastography (MRE)</li> </ul> </li> <li>• Presence of greater than or equal to 3 metabolic risk factors (e.g., Type 2 diabetes, hypertension, obesity)</li> <li>• Submission of medical records (e.g. chart notes) confirming drug is used as an adjunct to lifestyle modification (e.g., dietary or caloric restriction, exercise, behavioral support, community based program)</li> </ul>
<b>Age Restrictions</b>	For patients ≥18 years old
<b>Prescriber Restrictions</b>	Gastroenterologist; Hepatologist
<b>Coverage Duration</b>	Initial: 6 months; Renewal: 12 months
<b>Renewal Criteria</b>	Renewal Criteria: Patient demonstrates positive response to therapy (e.g., MASH resolution, fibrosis stage improvement, etc.) AND Submission of medical records (e.g., chart notes) confirming drug will continue to be used as an adjunct to lifestyle modification (e.g., dietary or caloric restriction, exercise, behavioral support, community-based program)



Effective Date:	
P&T Approval Date:	
P&T Revision Date:	

# Rifapentine (Priftin)

## Products Affected

- Priftin 150mg tablets

PA Criteria	Criteria Details
<b>Required Medical Information</b>	<p><b>Latent tuberculosis:</b></p> <ul style="list-style-type: none"> <li>• Used in combination with isoniazid (INH).</li> </ul> <p><b>Active tuberculosis:</b></p> <ul style="list-style-type: none"> <li>• Used as part of a multi-drug regimen.</li> </ul>
<b>Exclusion Criteria</b>	Prescribed by a county clinic with a state funded TB program (for these programs the drug is funded directly through the state).
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	<b>Active tuberculosis:</b> Infectious disease specialist required for multidrug resistant cases only
<b>Coverage Duration</b>	<p><b>Latent TB:</b> 3 months</p> <p><b>Active TB:</b> 6 months</p>
<b>Renewal Criteria</b>	N/A

Effective Date:	5/1/2024
P&T Approval Date:	3/12/2024
P&T Revision Date:	

# Rifaximin (XIFAXAN)

## Products Affected

- XIFAXAN

PA Criteria	Criteria Details
<b>Required Medical Information</b>	<b>Diagnosis of Hepatic Encephalopathy:</b> must have one of the following: used as add-on therapy to lactulose <b>AND</b> unable to achieve an optimal clinical response with lactulose monotherapy <b>OR</b> a history of contraindication or intolerance to lactulose.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	<b>Initial:</b> 12 months. <b>Renewal:</b> 12 months.
<b>Renewal Criteria</b>	Documented positive clinical response to therapy

Effective Date:	
P&T Approval Date:	
P&T Revision Date:	

# Risdiplam (EVERYSDI)

## Products Affected

- Evrysdi SOL 0.75 MG/ML

PA Criteria	Criteria Details
<b>Required Medical Information</b>	<b>Spinal Muscular Atrophy (SMA):</b> <ul style="list-style-type: none"> <li>• Confirmed (via genetic testing) diagnosis of 5q-autosomal recessive SMA (type 1, 2 or 3)</li> <li>• Patient is not dependent on invasive ventilation or tracheostomy OR use of non-invasive ventilation beyond uses for sleeping</li> <li>• Is not receiving concomitant chronic SMN modifying therapy such as Spinraza</li> <li>• Patient has not previously received gene replacement therapy for the treatment of SMA (e.g. Zolgensma)</li> </ul>
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a neurologist with expertise in the treatment of SMA
<b>Coverage Duration</b>	<b>Initial:</b> 12 months. <b>Renewal:</b> up to 12 months.
<b>Renewal Criteria</b>	Documentation of clinical improvement from baseline in motor functionality confirmed by standard exams (e.g. BSID-III, CHOP INTEND, HINE-2, RULM test)

Effective Date:	9/1/2023
P&T Approval Date:	7/11/2023
P&T Revision Date:	

# Rituximab (RITUXIMAB)

## Products Affected

- RUXIENCE INJ (100/10ML & 500/50ML)
- RIABNI SOL (100/10ML & 500/50ML)
- TRUXIMA INJ (100/10ML & 500/50ML)
- RITUXAN INJ (100MG & 500MG)

PA Criteria	Criteria Details
<b>Required Medical Information</b>	<p><b>Rheumatoid Arthritis</b></p> <ul style="list-style-type: none"> <li>• Diagnosis of moderately to severely active rheumatoid arthritis</li> <li>• One of the following               <ul style="list-style-type: none"> <li>○ The member is transitioning to the requested treatment from a different biologic product previously approved by the plan</li> <li>○ Trial and failure, contraindication or intolerance to one of the following: Methotrexate, Leflunomide, Sulfasalazine</li> </ul> </li> <li>• Trial and failure to infliximab and adalimumab</li> </ul> <p><b>Non-Hodgkin's Lymphoma</b></p> <ul style="list-style-type: none"> <li>• One of the following               <ul style="list-style-type: none"> <li>○ Diagnosis of diffuse large B-cell, CD20-positive, non-Hodgkin's lymphoma and used as a first-line treatment in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) or other anthracycline-based chemotherapy regimens</li> <li>○ Diagnosis of follicular, CD20-positive, B-cell non-Hodgkin's lymphoma and used as a first-line treatment in combination with chemotherapy.</li> <li>○ Diagnosis of follicular, CD20-positive, B-cell non-Hodgkin's lymphoma and patient achieved a complete or partial response to a rituximab product in combination with chemotherapy and followed by rituximab used as monotherapy for maintenance therapy.</li> <li>○ Diagnosis of low-grade, CD20-positive, B-cell non-Hodgkin's lymphoma and patient has stable disease following first-line treatment with CVP (cyclophosphamide, vincristine, prednisolone/ prednisone) chemotherapy and patient achieved a partial or complete response following first-line treatment with CVP (cyclophosphamide, vincristine, prednisolone/ prednisone) chemotherapy</li> <li>○ Diagnosis of relapsed or refractory, low grade or follicular CD20-positive, B-cell non-Hodgkin's lymphoma</li> </ul> </li> </ul>

PA Criteria	Criteria Details
	<ul style="list-style-type: none"> <li>○ Diagnosis of one of the following previously untreated, advanced stage indications: <ul style="list-style-type: none"> <li>▪ CD-20-positive diffuse large B-cell lymphoma (DLBCL)</li> <li>▪ Burkitt lymphoma (BL)</li> <li>▪ Burkitt-like lymphoma (BLL)</li> <li>▪ Mature B-cell acute leukemia (B-AL)</li> </ul> </li> <li>● Used in combination with chemotherapy</li> </ul> <p><b>Chronic Lymphocytic Leukemia</b></p> <ul style="list-style-type: none"> <li>● Diagnosis of chronic lymphocytic leukemia</li> <li>● Used in combination with fludarabine and cyclophosphamide</li> </ul> <p><b>Immune or Idiopathic Thrombocytopenic Purpura (Off-Label)</b></p> <ul style="list-style-type: none"> <li>● Diagnosis of immune or idiopathic thrombocytopenic purpura (off-label)</li> <li>● Trial and failure, contraindication, or intolerance to at least ONE of the following: <ul style="list-style-type: none"> <li>○ Glucocorticoids (e.g., prednisone, methylprednisolone)</li> <li>○ Immunoglobulins (e.g., IVIg)</li> <li>○ Splenectomy</li> </ul> </li> <li>● Documented platelet count of less than <math>50 \times 10^9 / L</math></li> </ul> <p><b>Pemphigus Vulgaris</b></p> <ul style="list-style-type: none"> <li>● Diagnosis of moderate to severe Pemphigus Vulgaris</li> </ul> <p><b>Waldenstrom’s macroglobulinemia</b></p> <ul style="list-style-type: none"> <li>● Diagnosis of relapsed/refractory Waldenstrom’s macroglobulinemia</li> </ul> <p><b>Wegener’s Granulomatosis and Microscopic Polyangiitis</b></p> <ul style="list-style-type: none"> <li>● One of the following <ul style="list-style-type: none"> <li>○ Granulomatosis with Polyangiitis (GPA) (Wegener’s Granulomatosis)</li> <li>○ Microscopic Polyangiitis</li> </ul> </li> <li>● Used in combination with glucocorticoids (e.g., prednisone)</li> </ul>
<b>Age Restrictions</b>	<b>Non-Hodgkin’s Lymphoma:</b> 6 months of age or older
<b>Prescriber Restrictions</b>	<b>Rheumatoid Arthritis:</b> Prescribed by or in consultation with rheumatologist

PA Criteria	Criteria Details
<b>Coverage Duration</b>	<b>Rheumatoid Arthritis: Initial:</b> 6 months. <b>Renewal:</b> up to 12 months. <b>Non-Hodgkin’s Lymphoma: Initial:</b> 12 months. <b>Chronic Lymphocytic Leukemia: Initial:</b> 12 months. <b>Immune or Idiopathic Thrombocytopenic Purpura: Initial:</b> 12 months. <b>Pemphigus Vulgaris: Initial:</b> 12 months. <b>Renewal:</b> 12 months. <b>Waldenstrom’s macroglobulinemia: Initial:</b> 12 months. <b>Wegener’s Granulomatosis and Microscopic Polyangiitis: Initial:</b> 3 months
<b>Renewal Criteria</b>	<b>Pemphigus Vulgaris:</b> Documentation of positive clinical response to Rituxan therapy

Effective Date:	10/1/2023
P&T Approval Date:	
P&T Revision Date:	

# Roflumilast (DALIRESP)

## Products Affected

- DALIRESP

PA Criteria	Criteria Details
<b>Required Medical Information</b>	Diagnosis of moderate to severe COPD and patient has chronic bronchitis and patient has tried and failed or has an intolerance or contraindication to two previous COPD therapies.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	COPD <b>Initial</b> : 12 months. COPD <b>Renewal</b> : 12 months.
<b>Renewal Criteria</b>	Documentation of positive clinical response to Daliresp therapy.

Effective Date:	
P&T Approval Date:	
P&T Revision Date:	



# Ropinirole Hydrochloride (REQUIP)

---

## Products Affected

- ROPINIROLE HCL

PA Criteria	Criteria Details
Required Medical Information	For the treatment of Parkinson's Disease.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	<b>Initial:</b> 12 months. <b>Renewal:</b> 12 months.
Renewal Criteria	Documented positive clinical response to therapy

Effective Date:	
P&T Approval Date:	
P&T Revision Date:	

# Sacubitril/Valsartan (ENTRESTO)

**Products Affected**

- ENTRESTO

PA Criteria	Criteria Details
<b>Required Medical Information</b>	The patient has a diagnosis of New York Heart Association class II to IV heart failure <b>AND</b> the patient is receiving concomitant therapy with one of the following beta blockers: carvedilol, bisoprolol, sustained-released metoprolol, unless unable to tolerate or contraindicated <b>AND</b> the patient will discontinue use of any concomitant ACE inhibitor or ARB before initiating therapy. ACE inhibitors must be discontinued at least 36 hours prior to ENTRESTO.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Cardiologist or in consultation with a cardiologist
<b>Coverage Duration</b>	<b>Initial:</b> 12 months <b>Renewal:</b> 12 months
<b>Renewal Criteria</b>	Documented positive clinical response to therapy

Effective Date:	
P&T Approval Date:	
P&T Revision Date:	

# Sargramostim (LEUKINE)

**Products Affected**

- LEUKINE INJ 250MCG

PA Criteria	Criteria Details
<p><b>Required Medical Information</b></p>	<p><b>Acute myelogenous leukemia (AML):</b> To shorten time to neutrophil recovery and to reduce the incidence of severe and life-threatening infections and infections resulting in death following induction chemotherapy in older adults (greater than or equal to 55 years of age).</p> <p><b>Bone marrow transplant (allogeneic or autologous):</b> For graft failure or engraftment delay.</p> <p><b>Myeloid reconstitution after allogeneic bone marrow transplantation:</b> To accelerate myeloid recovery following transplantation in non-Hodgkin lymphoma (NHL), acute lymphoblastic leukemia (ALL), Hodgkin lymphoma. Febrile neutropenia Primary prophylaxis of neutropenia in patients receiving chemotherapy (outside transplant and AML) or who are at high risk for neutropenic fever.</p> <p><b>Peripheral stem cell transplantation:</b> Mobilization of hematopoietic progenitor cells for leukapheresis and myeloid reconstitution following autologous peripheral stem cell transplantation.</p> <p><b>Acute Radiation Syndrome:</b> Treatment of radiation induced myelosuppression of the bone marrow.</p>
<p><b>Age Restrictions</b></p>	
<p><b>Prescriber Restrictions</b></p>	<p>Requested by a specialist.</p>
<p><b>Coverage Duration</b></p>	<p><b>Initial:</b> 12 months. <b>Renewal:</b> 12 months.</p>
<p><b>Renewal Criteria</b></p>	<p>Documented positive clinical response to therapy</p>

Effective Date:	
P&T Approval Date:	
P&T Revision Date:	

# Secukinumab SC (COSENTYX)

**Products Affected**

- COSENTYX (300 MG DOSE)
- COSENTYX SENSOREADY (300 MG)

PA Criteria	Criteria Details
<p><b>Required Medical Information</b></p>	<p><b>All diagnoses:</b></p> <ul style="list-style-type: none"> <li>• Initial testing for latent TB and treatment, if necessary, before starting treatment.</li> <li>• No current active infection at initiation of therapy.</li> <li>• Risks and benefits documented in cases of chronic or recurrent infection.</li> <li>• Will NOT be used in combination with another biologic or Otezla</li> </ul> <p><b>Ankylosing Spondylitis/Axial Spondyloarthritis (AS/SpA):</b></p> <ul style="list-style-type: none"> <li>• Documentation of moderate-to-severe ankylosing spondylitis or axial spondyloarthritis as defined by:               <ul style="list-style-type: none"> <li>○ Back pain and stiffness for more than 3 months AND</li> <li>○ Signs of active inflammation on MRI OR radiological evidence of sacroiliitis OR HLA-B27 positive AND</li> <li>○ BASDAI score of <math>\geq 4</math></li> </ul> </li> <li>• The member is transitioning to the requested treatment from a different biologic product previously approved by the plan OR Documented failure of conventional therapy with both of the following:               <ul style="list-style-type: none"> <li>○ At least two NSAIDs for 3 months at maximum recommended or tolerated anti-inflammatory dose unless contraindicated, AND</li> <li>○ Physical therapy/exercise program</li> </ul> </li> <li>• Trial and failure of both infliximab and adalimumab</li> </ul> <p><b>Juvenile Idiopathic Arthritis (JIA):</b></p> <ul style="list-style-type: none"> <li>• Documentation of juvenile idiopathic arthritis with active systemic features of JIA, with a physician global assessment of 5 or higher (or any systemic activity in the absence of active joint involvement) or JIA without active systemic features</li> <li>• The member is transitioning to the requested treatment from a different biologic product previously approved by the plan OR documented failure of the following:               <ul style="list-style-type: none"> <li>○ NSAIDs for 3 months at maximum recommended or tolerated anti-inflammatory dose unless contraindicated, AND</li> <li>○ At least 6 months of 2 of Methotrexate, leflunomide, sulfasalazine, hydroxychloroquine, or systemic corticosteroids</li> </ul> </li> </ul>

PA Criteria	Criteria Details
	<ul style="list-style-type: none"> <li>• Documented intolerance or contraindication to DMARDs OR DMARD will be continued</li> <li>• Trial and failure of both infliximab and adalimumab</li> </ul> <p><b>Plaque Psoriasis (PP):</b></p> <ul style="list-style-type: none"> <li>• Documentation of severe plaque psoriasis, defined as having functional impairment as indicated by Dermatology Life Quality Index (DLQI) = 11 or Children's Dermatology Life Quality Index (CDLQI) = 13 (or severe score on other validated tool) AND one or more of the following: <ul style="list-style-type: none"> <li>○ At least 10% of body surface area involved</li> <li>○ Hand, foot, face, or mucous membrane involvement</li> </ul> </li> <li>• The member is transitioning to the requested treatment from a different biologic product previously approved by the plan OR documented failure of all the following: <ul style="list-style-type: none"> <li>○ High-potency topical corticosteroids (augmented betamethasone, clobetasol, etc.)</li> <li>○ At least one other topical agent (calcipotriene, tazarotene, anthralin, tar, etc.)</li> <li>○ PUVA or UVB Phototherapy</li> <li>○ Methotrexate</li> <li>○ At least 1 other second line systemic agent such as cyclosporine or acitretin</li> </ul> </li> <li>• Trial and failure of both infliximab and adalimumab</li> </ul> <p><b>Psoriatic Arthritis (PsA):</b></p> <ul style="list-style-type: none"> <li>• Documentation of psoriatic arthritis based on at least 3 out of 5 of the following: <ul style="list-style-type: none"> <li>○ Psoriasis (1 point for personal or family history, 2 points for current)</li> <li>○ Psoriatic nail dystrophy</li> <li>○ Negative test result for RF</li> <li>○ Dactylitis (current or history)</li> <li>○ Radiological evidence of juxta-articular new bone formation</li> </ul> </li> <li>• The member is transitioning to the requested treatment from a different biologic product previously approved by the plan OR documented failure of conventional therapy with both of the following: <ul style="list-style-type: none"> <li>○ NSAIDs for 3 months at maximum recommended or tolerated anti-inflammatory dose unless contraindicated, AND</li> <li>○ Methotrexate or other DMARD such as leflunomide, sulfasalazine, or cyclosporine</li> </ul> </li> <li>• Trial and failure of both infliximab and adalimumab</li> </ul>

PA Criteria	Criteria Details
	<p><b>Hidradenitis Suppurativa (HS):</b></p> <ul style="list-style-type: none"> <li>• Documentation of one of the following: <ul style="list-style-type: none"> <li>• Moderate to severe hidradenitis suppurative (Hurley Stage II or Hurley Stage III)</li> <li>• Patient is on a current biologic product and experiencing intolerable side effects.</li> </ul> </li> <li>• The patient is transitioning to the requested treatment from a different biologic product previously approved by the plan OR documented failure of the following: <ul style="list-style-type: none"> <li>○ 90-day trial of conventional therapy (e.g. oral antibiotics)</li> </ul> </li> <li>• Trial and failure of both infliximab and adalimumab</li> </ul>
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	<p><b>Plaque Psoriasis:</b> Dermatologist.  <b>Psoriatic Arthritis:</b> Dermatologist or Rheumatologist.  <b>Juvenile Idiopathic Arthritis:</b> Rheumatologist.  <b>Ankylosing Spondylitis, Axial Spondyloarthritis:</b> Rheumatologist.</p>
<b>Coverage Duration</b>	<b>Initial:</b> 6 months. <b>Renewal:</b> 12 months.
<b>Renewal Criteria</b>	<p><b>AS/SpA:</b> Evidence of significant improvement in signs and symptoms of AS/SpA and/or functioning, such as ASAS40 or 2-point improvement in BASDAI.</p> <p><b>JIA:</b> Evidence of 20% or greater improvement in tender joint count and swollen joint count or has there been an improvement in functional ability.</p> <p><b>PP:</b> Evidence of positive clinical response to therapy as evidenced by ONE of the following: reduction of body surface area (BSA) involvement from baseline, improvement in symptoms (e.g. pruritus, inflammation) from baseline, or evidence of functional improvement.</p> <p><b>PsA:</b> Evidence of a 20% or greater improvement in tender joint count and swollen joint count.</p>

Effective Date:	7/1/2024
P&T Approval Date:	5/14/2024
P&T Revision Date:	9/1/2023, 07/11/2023, 01/11/2022

# Semaglutide (WEYGOVY)

## Products Affected

- Wegovy

PA Criteria	Criteria Details
<b>Required Medical Information</b>	<ul style="list-style-type: none"> <li>• Wegovy is being used to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established cardiovascular disease and either obesity or overweight</li> <li>• Wegovy is being used as adjunct to lifestyle modification (e.g. dietary or caloric restriction, exercise, behavioral support, community-based program)</li> <li>• Patient has established cardiovascular disease as evidenced by one of the following: prior MI, prior stroke, peripheral arterial disease (e.g. intermittent claudication with ankle-brachial index &lt;0.85, peripheral arterial revascularization procedure, or amputation due to atherosclerotic disease)</li> <li>• BMI greater than or equal to 27 kg/m<sup>2</sup></li> </ul>
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a cardiologist
<b>Coverage Duration</b>	<b>Initial:</b> 6 months. <b>Renewal:</b> 6 months.
<b>Renewal Criteria</b>	<ul style="list-style-type: none"> <li>• Documentation of treatment success (BMI reduction of 5% or more)</li> <li>• Documentation of continuation of lifestyle modification program with reduced calorie diet and regular physical activity alongside continuous Wegovy use (80% adherence)</li> </ul>

Effective Date:	7/1/2024
P&T Approval Date:	5/13/2024
P&T Revision Date:	5/13/2024

# Sildenafil Citrate (REVATIO)

---

## Products Affected

- SILDENAFIL CITRATE 20MG TAB

PA Criteria	Criteria Details
Required Medical Information	Clinical diagnosis of pulmonary arterial hypertension (PAH).
Age Restrictions	
Prescriber Restrictions	Prescribed by or in consultation with a cardiologist or pulmonologist.
Coverage Duration	<b>Initial:</b> 12 months. <b>Renewal:</b> 12 months.
Renewal Criteria	Documented positive clinical response to therapy

Effective Date:	
P&T Approval Date:	
P&T Revision Date:	



# Sirolimus (RAPAMUNE)

---

## Products Affected

- SIROLIMUS ORAL SOLUTION

PA Criteria	Criteria Details
Required Medical Information	Lymphangi leiomyomatosis, Renal transplant rejection prophylaxis.
Age Restrictions	Member is under age 10 or unable to use tablets
Prescriber Restrictions	
Coverage Duration	<b>Initial:</b> 12 months. <b>Renewal:</b> 12 months.
Renewal Criteria	Documented positive clinical response to therapy

Effective Date:	5/1/2024
P&T Approval Date:	3/12/2024
P&T Revision Date:	3/12/2024

# Sparsentan (FILSPARI)

## Products Affected

- Filspari TAB 200MG , 400MG

PA Criteria	Criteria Details
<b>Required Medical Information</b>	<b>Primary immunoglobulin A nephropathy:</b> <ul style="list-style-type: none"> <li>Urine protein-to-creatinine ratio (UPCR) <math>\geq 1.5</math> and eGFR <math>\geq 30</math> mL/min/1.73 m<sup>2</sup></li> <li>Biopsy-verified primary IgA nephropathy</li> <li>No history of kidney transplant and not currently receiving dialysis</li> <li>Member has failed to achieve a reduction in proteinuria to under 1 gram/day while receiving maximally tolerated doses of an ACE inhibitor or ARB for at least 12 weeks</li> </ul>
<b>Age Restrictions</b>	18 or older
<b>Prescriber Restrictions</b>	Nephrologist
<b>Coverage Duration</b>	<b>Initial:</b> 6 months. <b>Renewal:</b> 12 months.
<b>Renewal Criteria</b>	Improved or stable kidney function compared to baseline <b>OR</b> reduction in proteinuria

Effective Date:	9/1/2023
P&T Approval Date:	7/11/2023
P&T Revision Date:	

# Sodium-Glucose Co-Transporter 2 (Sglt2) Inhibitors

## Products Affected

- FARXIGA TABLET 5MG; 10 MG ORAL
- INVOKANA TABLET 100 MG; 300 MG ORAL
- JARDIANCE TABLET 10 MG, 25 MG ORAL

PA Criteria	Criteria Details
<b>Required Medical Information</b>	<p><b>T2DM:</b> Trial and failure of or contraindication to metformin <b>AND</b> trial and failure or reason why it is inappropriate to use a sulfonylurea or pioglitazone.</p> <p><b>CKD (Farxiga):</b> Concurrent therapy with an ACEi or ARB at maximum tolerated doses, or documented contraindication to both <b>AND</b> eGFR of 25 to 75 mL/min/1.73 m<sup>2</sup> or stage 2, 3, or 4 CKD <b>AND</b> no previous use of dialysis <b>AND</b> no history of polycystic kidney disease, type 1 diabetes, lupus nephritis, or antineutrophil cytoplasmic antibody-associate vasculitis.</p> <p><b>HFrEF:</b> Patient must be stabilized and titrated to maximally tolerated or target dose of ACEi, ARB, or ARNI <b>AND</b> patient must be stabilized and titrated to maximally tolerated or target dose of either carvedilol, metoprolol succinate, or bisoprolol <b>OR</b> have a contraindication to beta blocker use <b>AND</b> NYHA class II-IV (EF≤40%) <b>AND</b> eGFR &gt;30 mL/min/1.73m<sup>2</sup>.</p> <p><b>HFpEF (Jardiance only):</b> eGFR &gt;30 mL/min/1.73<sup>2</sup></p>
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	HFrEF & HFpEF: Cardiologist
<b>Coverage Duration</b>	<b>Initial:</b> Lifetime Approval. <b>Renewal:</b> Lifetime Approval
<b>Renewal Criteria</b>	

Effective Date:	04/01/2022
P&T Approval Date:	03/08/2022
P&T Revision Date:	03/08/2022

# Somatropin, E-Coli Derived (HUMATROPE)

**Products Affected**

- HUMATROPE

PA Criteria	Criteria Details
<p><b>Required Medical Information</b></p>	<p>Documentation of goals of therapy and objective baseline assessment (e.g., quality of life, exercise capacity, height, body composition improvements, etc.)</p> <p><b>For patients under the age of 18:</b></p> <ul style="list-style-type: none"> <li>• Growth Hormone Deficiency (GHD)</li> <li>• Prader-Willi Syndrome               <ul style="list-style-type: none"> <li>○ Patient does not have concurrent severe obesity nor history of upper airway obstruction nor sleep apnea nor severe respiratory impairment</li> </ul> </li> <li>• Noonan Syndrome</li> <li>• Turner Syndrome</li> <li>• Idiopathic Short Stature</li> <li>• Growth Failure secondary to chronic kidney disease (CKD)</li> <li>• Small for gestational age</li> <li>• Short stature homeobox-containing (SHOX) gene deficiency</li> <li>• HIV Associated Cachexia</li> </ul> <p><b>For Adults aged 18 years and older</b></p> <ul style="list-style-type: none"> <li>• Growth hormone deficiency (GHD)               <ul style="list-style-type: none"> <li>○ Prescribed by or in consultation with an endocrinologist; <b>AND</b></li> <li>○ Either                   <ul style="list-style-type: none"> <li>▪ Growth hormone deficiency is confirmed by a negative response to a growth hormone stimulation test (e.g., serum GH levels of &lt;5 ng/mL on stimulation testing with either of the following: glucagon or insulin); <b>OR</b></li> <li>▪ Patient has had the pituitary removed or destroyed or has had panhypopituitarism since birth; <b>AND</b></li> </ul> </li> <li>○ The prescriber certifies that the growth hormone is not being prescribed for anti-aging therapy or to enhance athletic ability or body building</li> </ul> </li> </ul>

<b>PA Criteria</b>	<b>Criteria Details</b>
	<ul style="list-style-type: none"> <li>• HIV associated cachexia</li> <li>• Short Bowel Syndrome (SBS)</li> </ul>
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	An endocrinologist for adults or a pediatric endocrinologist or pediatric nephrologist for children/adolescents
<b>Coverage Duration</b>	<b>Initial:</b> up to 12 months. <b>Renewal:</b> up to 12 months.
<b>Renewal Criteria</b>	<ul style="list-style-type: none"> <li>• Treatment with agent initiated in a patient prior to reaching adulthood (&lt;18 years of age) was to improve growth velocity or height; <b>AND</b> <ul style="list-style-type: none"> <li>○ Growth velocity greater than 2.5 cm per year; <b>OR</b></li> <li>○ Growth velocity less than 2.5 cm per year <ul style="list-style-type: none"> <li>▪ Documentation that benefits of therapy continue to outweigh risks</li> </ul> </li> </ul> </li> <li>• Documentation of improvement from baseline as assessed by the prescribing provider</li> </ul>

Effective Date:	04/01/2023
P&T Approval Date:	03/14/2023
P&T Revision Date:	03/14/2023

# SUPREP Bowel Prep

**Products Affected**

- na sulfate-k sulfate-mg sulf solution

PA Criteria	Criteria Details
<b>Required Medical Information</b>	Bowel cleansing prior to GI examination. Prior use of formulary agent, golytely solution, must be tried and failed <b>OR</b> patient is having Bariatric surgery.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	<b>Initial:</b> 1 treatment.
<b>Renewal Criteria</b>	

Effective Date:	
P&T Approval Date:	
P&T Revision Date:	

# Tacrolimus (PROTOPIC)

## Products Affected

- TACROLIMUS OINT

PA Criteria	Criteria Details
<b>Required Medical Information</b>	<p><b>Atopic Dermatitis:</b> Clinically diagnosed moderate-to-severe atopic dermatitis: (10 percent BSA, hand, foot or mucous membrane involvement, or functional impairment). Trial and failure of topical steroids, UVB phototherapy, or reason why they would not be medically appropriate.</p> <p><b>Psoriasis:</b> diagnosis of moderate to severe Psoriasis (10 percent BSA, hand, foot or mucous membrane involvement, or functional impairment). Trial and failure or contraindication to a high potency topical corticosteroid and/or UVB phototherapy.</p>
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Psoriasis: prescribed by or in consultation with a dermatologist.
<b>Coverage Duration</b>	<b>Initial:</b> 12 months. <b>Renewal:</b> 12 months
<b>Renewal Criteria</b>	Documented positive clinical response to therapy

Effective Date:	
P&T Approval Date:	
P&T Revision Date:	

# Tadalafil (CIALIS)

---

**Products Affected**

- TADALAFIL (PAH) 20MG TAB

PA Criteria	Criteria Details
<b>Required Medical Information</b>	Clinical diagnosis of pulmonary arterial hypertension (PAH).
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a cardiologist or pulmonologist.
<b>Coverage Duration</b>	<b>Initial:</b> 12 months. <b>Renewal:</b> 12 months.
<b>Renewal Criteria</b>	Documented positive clinical response to therapy
Effective Date:	
P&T Approval Date:	
P&T Revision Date:	



# Tazarotene (AVAGE) (TAZORAC)

## Products Affected

- Tazarotene 0.1% cream

PA Criteria	Criteria Details
<b>Required Medical Information</b>	<p><b>Psoriasis:</b> diagnosis of moderate to severe Psoriasis (10% BSA, hand, foot or mucous membrane involvement and functional impairment (IHN). Trial and failure of high potency topical corticosteroids or medical reason why they would be inappropriate</p> <p><b>Other FDA approved indications that are above the line</b> (i.e., severe acne): trial and failure/contraindication to two formulary alternatives used to treat the approved indication.</p>
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	<b>Initial:</b> 12 months. <b>Renewal:</b> 12 months.
<b>Renewal Criteria</b>	Documented positive clinical response to therapy

Effective Date:	
P&T Approval Date:	
P&T Revision Date:	



# Terbinafine Hydrochloride (LAMISIL)

## Products Affected

- TERBINAFINE CREAM 1%

PA Criteria	Criteria Details
<b>Required Medical Information</b>	Treatment of onychomycosis of the toenail or fingernail due to dermatophytes (tinea unguium) <b>AND</b> one of the following: Patient is experiencing pain which limits normal activity (i.e., unable to wear shoes, difficulty walking, etc.) <b>OR</b> patient has diabetes <b>OR</b> Patient has peripheral vascular disease <b>OR</b> patient is immunocompromised. Treatment of tinea corporis or tinea cruris in a patient who is immunocompromised or has extensive or complicated infection.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	<b>Initial:</b> 3 months. <b>Renewal:</b> 3 months.
<b>Renewal Criteria</b>	Documented positive clinical response to therapy

Effective Date:	
P&T Approval Date:	
P&T Revision Date:	



# Tiagabine (GABITRIL)

**Products Affected**

- TIAGABINE HCL TABLET 12 MG ORAL
- TIAGABINE HCL TABLET 16 MG ORAL

PA Criteria	Criteria Details
<b>Required Medical Information</b>	For the treatment of Partial seizures as adjunct therapy.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	<b>Initial:</b> 12 months. <b>Renewal:</b> 12 months.
<b>Renewal Criteria</b>	Documented positive clinical response to therapy

Effective Date:	
P&T Approval Date:	
P&T Revision Date:	



# Testosterone

**Products Affected**

- Testosterone 1% Gel (25mg & 50mg)
  - Testosterone 1% Gel pump
- Testosterone ethanate 200mg/mL

PA Criteria	Criteria Details
<b>Required Medical Information</b>	Diagnosis of: Gender dysphoria <b>OR</b> aids wasting syndrome <b>OR</b> post-menopausal breast cancer <b>OR</b> hypogonadism <b>AND</b> trial and failure or contraindication to injectable testosterone.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Gender dysphoria, aids wasting syndrome, post-menopausal breast cancer <b>Initial:</b> Indefinite  Hypogonadism: <b>Initial:</b> 12 months; <b>Renewal:</b> 12 months
<b>Renewal Criteria</b>	Documented positive clinical response to therapy

Effective Date:	07/01/2024
P&T Approval Date:	05/14/2024
P&T Revision Date:	09/13/2022

# Tenapanor (XPHOZA)

## Products Affected

- Xphoza 20MG
- Xphoza 30MG

PA Criteria	Criteria Details
<b>Required Medical Information</b>	<p><b>Add on therapy for hyperphosphatemia in chronic kidney disease, on chronic hemodialysis:</b></p> <ul style="list-style-type: none"> <li>• On chronic maintenance hemodialysis 3x per week for at least 3 months or chronic peritoneal dialysis for a minimum of 6 months</li> <li>• Other contributing factors for hyperphosphatemia have been addressed: <ul style="list-style-type: none"> <li>○ On a stable dose of calcimimetic or active vitamin D for at least 4 weeks</li> <li>○ Serum parathyroid hormone is &lt;1200 pg/mL</li> <li>○ Dietary restrictions are in place to limit phosphate intake</li> </ul> </li> <li>• Serum phosphate levels remain elevated despite use of at least 3 different phosphate binder agents (calcium acetate, sevelamer, lanthanum) used at therapeutic doses with adherence to therapy (at least 80% adherence based on fill history)</li> <li>• Medication will be used as add-on therapy with phosphate binder treatment</li> </ul>
<b>Age Restrictions</b>	Must be at least 18 years of age
<b>Prescriber Restrictions</b>	Prescribed by or in collaboration with a Nephrologist
<b>Coverage Duration</b>	<b>Initial:</b> 6 months; <b>Renewal:</b> 12 months
<b>Renewal Criteria</b>	Clinical documentation of provider follow-up indicating safety and efficacy with medication adherence over previous approval duration

Effective Date:	03/01/2024
P&T Approval Date:	01/09/2024
P&T Revision Date:	





# Tezacaftor/ivacaftor and ivacaftor (SYMDEKO)

---

## Products Affected

- SYMDEKO

PA Criteria	Criteria Details
<b>Required Medical Information</b>	Clinical documentation of cystic fibrosis diagnosis with homozygous F508del mutation.
<b>Age Restrictions</b>	6 years of age and older
<b>Prescriber Restrictions</b>	Prescribed by a pulmonologist
<b>Coverage Duration</b>	<b>Initial:</b> 3 months <b>Renewal:</b> 6 months
<b>Renewal Criteria</b>	Documented positive clinical response to therapy

Effective Date:	
P&T Approval Date:	
P&T Revision Date:	

# Ticagrelor (BRILINTA)

## Products Affected

- Brilinta TAB 60MG, 90MG

PA Criteria	Criteria Details
<b>Required Medical Information</b>	<b>Acute Coronary Syndrome</b> <ul style="list-style-type: none"> <li>• Patient has acute coronary syndrome (ACS) <ul style="list-style-type: none"> <li>○ Either NSTEMI-ACS or STEMI and has had a coronary stent implanted OR</li> <li>○ Patient has NSTEMI-ACS and is treated with medical therapy alone (i.e., has not had revascularization)?</li> </ul> </li> </ul>
<b>Age Restrictions</b>	18 or older
<b>Prescriber Restrictions</b>	Gynecologist
<b>Coverage Duration</b>	<b>Initial:</b> 12 months. <b>Renewal:</b> 12 months.
<b>Renewal Criteria</b>	Documentation of positive clinical response to therapy.

Effective Date:	9/1/2023
P&T Approval Date:	7/11/2023
P&T Revision Date:	

# Tranexamic Acid

## Products Affected

- Tranexamic Acid 650MG TAB

PA Criteria	Criteria Details
<b>Required Medical Information</b>	<p><b>Hemophilia Diagnosis</b></p> <ul style="list-style-type: none"> <li>• Intending to use for hemorrhage prophylaxis for tooth extraction(s)</li> </ul> <p><b>Abnormal Uterine Bleeding</b></p> <ul style="list-style-type: none"> <li>• Currently using or documented trial and failure or contradiction to ALL the following treatments:               <ul style="list-style-type: none"> <li>○ Cobombined Oral Contraceptive therapy</li> <li>○ Profestin therapy (oral or LM) or Levonogrestrel IUD</li> <li>○ NSAID therapy</li> </ul> </li> </ul>
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Hematologist, Hemophilia specialist, Dentist, Gynecologist
<b>Coverage Duration</b>	<b>Initial:</b> 12 months. <b>Renewal:</b> 12 months.
<b>Renewal Criteria</b>	Documentation of positive clinical response to therapy.

Effective Date:	7/1/2024
P&T Approval Date:	5/14/2024
P&T Revision Date:	

# Vonoprazan (VONQUEZNA)

## Products Affected

- Voquezna 10mg
- Voquezna 20mg

PA Criteria	Criteria Details
<b>Required Medical Information</b>	<p><b>Erosive esophagitis-</b></p> <ul style="list-style-type: none"> <li>• Imaging confirmed LA Classification Grade C/D erosive esophagitis AND</li> <li>• Documented contraindication, intolerance, or inadequate response to 2 or more PPIs (i.e., lansoprazole, omeprazole, esomeprazole, etc.) at maximum tolerated twice-daily dosing for at least 8 weeks each.</li> </ul> <p><b>H.pylori eradication –</b></p> <ul style="list-style-type: none"> <li>• Confirmed H. pylori positive infection AND</li> <li>• Documented contraindication, intolerance, or inadequate response to standard first-line therapies for H.pylori infection (e.g. PPI (standard or double dose), clarithromycin, amoxicillin (or metronidazole)) AND</li> <li>• Documented contraindication, intolerance, or inadequate response to a quadruple bismuth regimen (e.g. standard twice daily dose PPI, bismuth subsalicylate, tetracycline, metronidazole) AND</li> <li>• Co-prescribed in combination with antibiotics.</li> </ul>
<b>Age Restrictions</b>	Must be at least 18 years of age
<b>Prescriber Restrictions</b>	Prescribed by or in collaboration with a Gastroenterologist or Infectious Disease specialist
<b>Coverage Duration</b>	<p><b>Initial healing of erosive esophagitis:</b> 2 months</p> <p><b>Maintenance of healing of erosive esophagitis:</b> 6 months</p> <p><b>H. Pylori eradication:</b> 14 days</p>
<b>Renewal Criteria</b>	Renewals past the above timelines are not allowed

Effective Date:	03/01/2024
P&T Approval Date:	01/09/2024
P&T Revision Date:	

# Tocilizumab SC (ACTEMRA)

## Products Affected

- Actemra INJ 162mg/0.9ml
- Actemra INJ ACTPEN

PA Criteria	Criteria Details
<b>Required Medical Information</b>	<p><b>All diagnoses:</b></p> <ul style="list-style-type: none"> <li>• Initial testing for latent TB and treatment, if necessary, before starting treatment.</li> <li>• No current active infection at initiation of therapy.</li> <li>• Risks and benefits documented in cases of chronic or recurrent infection.</li> <li>• Will NOT be used in combination with another biologic or Otezla</li> </ul> <p><b>Juvenile Idiopathic Arthritis (JIA):</b></p> <ul style="list-style-type: none"> <li>• Documentation of juvenile idiopathic arthritis with active systemic features of JIA, with a physician global assessment of 5 or higher (or any systemic activity in the absence of active joint involvement) or JIA without active systemic features</li> <li>• The member is transitioning to the requested treatment from a different biologic product previously approved by the plan OR documented failure of the following:               <ul style="list-style-type: none"> <li>○ NSAIDs for 3 months at maximum recommended or tolerated anti-inflammatory dose unless contraindicated, AND</li> <li>○ At least 6 months of 2 of Methotrexate, leflunomide, sulfasalazine, hydroxychloroquine, or systemic corticosteroids</li> </ul> </li> <li>• Documented intolerance or contraindication to DMARDs OR DMARD will be continued</li> <li>• Trial and failure of both infliximab and adalimumab</li> </ul> <p><b>Rheumatoid Arthritis (RA):</b></p> <ul style="list-style-type: none"> <li>• Documentation of a baseline of moderate to high disease activity of rheumatoid arthritis measured as such by an accepted assessment instrument (PAS, PASII, RAPID3, CDAI, DAS28, SDAI)</li> <li>• The member is transitioning to the requested treatment from a different biologic product previously approved by the plan OR documented failure of nonbiologic DMARD therapy: methotrexate (dosed at least 20mg per week for at least 8 weeks), leflunomide or sulfasalazine</li> <li>• Trial and failure of both infliximab and adalimumab</li> </ul>
<b>Age Restrictions</b>	

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Prescriber Restrictions</b>	<b>Rheumatoid Arthritis, Juvenile Idiopathic Arthritis:</b> Rheumatologist.
<b>Coverage Duration</b>	<b>Initial:</b> 6 months. <b>Renewal:</b> 12 months.
<b>Renewal Criteria</b>	<p><b>JIA:</b> Evidence of 20% or greater improvement in tender joint count and swollen joint count or has there been an improvement in functional ability.</p> <p><b>RA:</b> Evidence of a 20% or greater improvement in tender joint count and swollen joint count.</p>

Effective Date:	9/1/2023
P&T Approval Date:	7/11/2023
P&T Revision Date:	

# Tofacitinib (XELJANZ)

## Products Affected

- Xeljanz

- Xeljanz XR

PA Criteria	Criteria Details
<p><b>Required Medical Information</b></p>	<p><b>All diagnoses:</b></p> <ul style="list-style-type: none"> <li>• Initial testing for latent TB and treatment, if necessary, before starting treatment.</li> <li>• No current active infection at initiation of therapy.</li> <li>• Risks and benefits documented in cases of chronic or recurrent infection.</li> <li>• Will NOT be used in combination with another biologic or Otezla</li> </ul> <p><b>Ankylosing Spondylitis/Axial Spondyloarthritis (AS/SpA):</b></p> <ul style="list-style-type: none"> <li>• Documentation of moderate-to-severe ankylosing spondylitis or axial spondyloarthritis as defined by:               <ul style="list-style-type: none"> <li>○ Back pain and stiffness for more than 3 months AND</li> <li>○ Signs of active inflammation on MRI OR radiological evidence of sacroiliitis OR HLA-B27 positive AND</li> <li>○ BASDAI score of <math>\geq 4</math></li> </ul> </li> <li>• The member is transitioning to the requested treatment from a different biologic product previously approved by the plan OR Documented failure of conventional therapy with both of the following:               <ul style="list-style-type: none"> <li>○ At least two NSAIDs for 3 months at maximum recommended or tolerated anti-inflammatory dose unless contraindicated, AND</li> <li>○ Physical therapy/exercise program</li> </ul> </li> <li>• Trial and failure of both infliximab and adalimumab</li> <li>• Trial and failure of Cosentyx and Taltz or a reason they can't be used</li> </ul> <p><b>Juvenile Idiopathic Arthritis (JIA):</b></p> <ul style="list-style-type: none"> <li>• Documentation of juvenile idiopathic arthritis with active systemic features of JIA, with a physician global assessment of 5 or higher (or any systemic activity in the absence of active joint involvement) or JIA without active systemic features</li> <li>• The member is transitioning to the requested treatment from a different biologic product previously approved by the plan OR documented failure of the following:               <ul style="list-style-type: none"> <li>○ NSAIDs for 3 months at maximum recommended or tolerated anti-inflammatory dose unless contraindicated, AND</li> <li>○ At least 6 months of 2 of Methotrexate, leflunomide, sulfasalazine, hydroxychloroquine, or systemic corticosteroids</li> </ul> </li> </ul>



PA Criteria	Criteria Details
	<ul style="list-style-type: none"> <li>• Documented intolerance or contraindication to DMARDs OR DMARD will be continued</li> <li>• Trial and failure of both infliximab and adalimumab</li> <li>• Trial and failure of Actemra and Orencia</li> </ul> <p><b>Psoriatic Arthritis (PsA):</b></p> <ul style="list-style-type: none"> <li>• Documentation of psoriatic arthritis based on at least 3 out of 5 of the following: <ul style="list-style-type: none"> <li>○ Psoriasis (1 point for personal or family history, 2 points for current)</li> <li>○ Psoriatic nail dystrophy</li> <li>○ Negative test result for RF</li> <li>○ Dactylitis (current or history)</li> <li>○ Radiological evidence of juxta-articular new bone formation</li> </ul> </li> <li>• The member is transitioning to the requested treatment from a different biologic product previously approved by the plan OR documented failure of conventional therapy with both of the following: <ul style="list-style-type: none"> <li>○ NSAIDs for 3 months at maximum recommended or tolerated anti-inflammatory dose unless contraindicated, AND</li> <li>○ Methotrexate or other DMARD such as leflunomide, sulfasalazine, or cyclosporine</li> </ul> </li> <li>• Trial and failure of both infliximab and adalimumab</li> <li>• Trial and failure of Cosentyx, Otezla, Stelara, Orencia, and Taltz</li> </ul> <p><b>Rheumatoid Arthritis (RA):</b></p> <ul style="list-style-type: none"> <li>• Documentation of a baseline of moderate to high disease activity of rheumatoid arthritis measured as such by an accepted assessment instrument (PAS, PASII, RAPID3, CDAI, DAS28, SDAI)</li> <li>• The member is transitioning to the requested treatment from a different biologic product previously approved by the plan OR documented failure of nonbiologic DMARD therapy: methotrexate (dosed at least 20mg per week for at least 8 weeks), leflunomide or sulfasalazine</li> <li>• Trial and failure of both infliximab and adalimumab</li> <li>• Trial and failure of Actemra, Cimzia, Kineret, Orencia, and rituximab</li> </ul> <p><b>Ulcerative Colitis (UC):</b></p> <ul style="list-style-type: none"> <li>• Documentation of moderate-to-severe ulcerative colitis</li> <li>• The member is transitioning to the requested treatment from a different biologic product previously approved by the plan OR documented failure of at least 1 of the following:</li> </ul>

PA Criteria	Criteria Details
	<ul style="list-style-type: none"> <li>○ Mesalamine, sulfasalazine OR</li> <li>○ Mercaptopurine, azathioprine, OR</li> <li>○ Corticosteroids (prednisone, methylprednisolone)</li> <li>○ Trial and failure of both infliximab and adalimumab</li> <li>○ Trial and failure of Entyvio and Stelara</li> </ul>
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	<p><b>Ulcerative Colitis:</b> Gastroenterologist.</p> <p><b>Psoriatic Arthritis:</b> Dermatologist or Rheumatologist.</p> <p><b>Rheumatoid Arthritis, Juvenile Idiopathic Arthritis:</b> Rheumatologist.</p> <p><b>Ankylosing Spondylitis, Axial Spondyloarthritis:</b> Rheumatologist.</p>
<b>Coverage Duration</b>	<b>Initial:</b> 6 months. <b>Renewal:</b> up to 12 months.
<b>Renewal Criteria</b>	<p><b>AS/SpA:</b> Evidence of significant improvement in signs and symptoms of AS/SpA and/or functioning, such as ASAS40 or 2-point improvement in BASDAI.</p> <p><b>JIA:</b> Evidence of 20% or greater improvement in tender joint count and swollen joint count or has there been an improvement in functional ability.</p> <p><b>PsA:</b> Evidence of a 20% or greater improvement in tender joint count and swollen joint count.</p> <p><b>RA:</b> Evidence of a 20% or greater improvement in tender joint count and swollen joint count.</p> <p><b>UC:</b> Evidence of a significant response such as a decrease in bloody stools per day or elimination of signs of toxicity.</p>

Effective Date:	9/1/2023
P&T Approval Date:	7/11/2023
P&T Revision Date:	07/11/2023, 01/11/2022

# Topical Antifungal Agents

## Products Affected

Ciclopirox 8% solution  
Econazole 1% cream

Selenium Sulfide 2.5% Lotion  
Ketoconazole 2% Cream & Shampoo

PA Criteria	Criteria Details
<b>Required Medical Information</b>	The following alternatives have been tried and failed or are not appropriate for use: clotrimazole 1% cream, miconazole 2% (cream, aerosol, or powder), terbinafine 1%, cream, terbinafine tablets, nystatin 100,000 units/gram (ointment, cream, or powder).
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	<b>Initial:</b> 3 months. <b>Renewal:</b> 12 months.
<b>Renewal Criteria</b>	Documented positive clinical response to therapy

Effective Date:	9/1/2023
P&T Approval Date:	7/11/2023
P&T Revision Date:	07/11/2023, 01/11/2022

# Treprostinil diolamine (ORENITRAM)

## Products Affected

- ORENITRAM

PA Criteria	Criteria Details
<b>Required Medical Information</b>	Confirmed diagnosis of pulmonary arterial hypertension with right heart catheterization and WHO functional class II through IV <b>AND</b> evidence of either an unfavorable acute response to vasodilators or evidence of being refractory to or unable to tolerate calcium channel blockers (e.g., extended release nifedipine or extended-release diltiazem) <b>AND</b> documented failure or incomplete response to sildenafil or tadalafil/ambrisentan combination <b>AND</b> trial and failure of Remodulin or clinical justification for the need of an alternative route of administration.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a cardiologist or pulmonologist.
<b>Coverage Duration</b>	<b>Initial:</b> 12 months. <b>Renewal:</b> 12 months.
<b>Renewal Criteria</b>	Documented positive clinical response to therapy

Effective Date:	
P&T Approval Date:	
P&T Revision Date:	



# Treprostinil sodium (REMODULIN)

## Products Affected

- TREPROSTINIL

PA Criteria	Criteria Details
<b>Required Medical Information</b>	Confirmed diagnosis of pulmonary arterial hypertension with right heart catheterization and WHO functional class II through IV <b>AND</b> evidence of either an unfavorable acute response to vasodilators or evidence of being refractory to or unable to tolerate calcium channel blockers (e.g., extended release nifedipine or extended-release diltiazem) <b>AND</b> documented failure or incomplete response to sildenafil or tadalafil/ambriasantan combination.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a cardiologist or pulmonologist.
<b>Coverage Duration</b>	<b>Initial:</b> 12 months. <b>Renewal:</b> 12 months.
<b>Renewal Criteria</b>	Documented positive clinical response to therapy

Effective Date:	
P&T Approval Date:	
P&T Revision Date:	



# Treprostinil (TYVASO)

**Products Affected**

- TYVASO
- TYVASO REFILL
- TYVASO STARTER

PA Criteria	Criteria Details
<b>Required Medical Information</b>	Confirmed diagnosis of pulmonary hypertension associated with interstitial lung disease (WHO Group 3).  Any other indication would be required to try and fail formulary alternatives.
<b>Age Restrictions</b>	18 years of age or older
<b>Prescriber Restrictions</b>	Prescribed by pulmonologist or cardiologist.
<b>Coverage Duration</b>	<b>Initial:</b> 12 months. <b>Renewal:</b> 12 months.
<b>Renewal Criteria</b>	Documented positive clinical response to therapy

Effective Date:	
P&T Approval Date:	
P&T Revision Date:	





# Ubrogепant (UBRELVY)

## Products Affected

- Ubrelvy

PA Criteria	Criteria Details
<b>Required Medical Information</b>	Diagnosis of migraine <b>AND</b> documentation patient is on preventative therapy <b>AND</b> trial and failure (defined as trial period of 6 weeks per agent) or contraindication to at least 3 generic oral formulary triptans used at up to maximally indicated dosing combined with NSAIDs
<b>Age Restrictions</b>	18 years of age and older
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	<b>Initial:</b> 3 months <b>Renewal:</b> 6 months
<b>Renewal Criteria</b>	Documented positive clinical response to therapy

Effective Date:	07/01/2023
P&T Approval Date:	05/09/2023
P&T Revision Date:	05/09/2023





# Upadacitinib (RINVOQ)

## Products Affected

- Rinvoq TAB 15MG ER, 30MG ER, 45MG ER

PA Criteria	Criteria Details
<p><b>Required Medical Information</b></p>	<p><b>All diagnoses:</b></p> <ul style="list-style-type: none"> <li>• Initial testing for latent TB and treatment, if necessary, before starting treatment.</li> <li>• No current active infection at initiation of therapy.</li> <li>• Risks and benefits documented in cases of chronic or recurrent infection.</li> <li>• Will NOT be used in combination with another biologic or Otezla</li> </ul> <p><b>Ankylosing Spondylitis/Axial Spondyloarthritis (AS/SpA):</b></p> <ul style="list-style-type: none"> <li>• Documentation of moderate-to-severe ankylosing spondylitis or axial spondyloarthritis as defined by:               <ul style="list-style-type: none"> <li>○ Back pain and stiffness for more than 3 months AND</li> <li>○ Signs of active inflammation on MRI OR radiological evidence of sacroiliitis OR HLA-B27 positive AND</li> <li>○ BASDAI score of <math>\geq 4</math></li> </ul> </li> <li>• The member is transitioning to the requested treatment from a different biologic product previously approved by the plan OR Documented failure of conventional therapy with both of the following:               <ul style="list-style-type: none"> <li>○ At least two NSAIDs for 3 months at maximum recommended or tolerated anti-inflammatory dose unless contraindicated, AND</li> <li>○ Physical therapy/exercise program</li> </ul> </li> <li>• Trial and failure of both infliximab and adalimumab Trial and failure of Cosentyx and Taltz or a reason they can't be used</li> </ul> <p><b>Atopic Dermatitis (AD):</b></p> <ul style="list-style-type: none"> <li>• Documentation of severe atopic dermatitis, defined as having functional impairment as indicated by Dermatology Life Quality Index (DLQI) = 11 or Children's Dermatology Life Quality Index (CDLQI) = 13 (or severe score on other validated tool) AND one or more of the following:               <ul style="list-style-type: none"> <li>○ At least 10% of body surface area involved</li> <li>○ Hand, foot, face, or mucous membrane involvement</li> </ul> </li> <li>• Documented contraindication or failed trial to ALL of the following:               <ul style="list-style-type: none"> <li>○ Moderate-high potency corticosteroid (e.g., clobetasol, fluocinonide, fluticasone)</li> </ul> </li> </ul>

PA Criteria	Criteria Details
	<ul style="list-style-type: none"> <li>○ Topical calcineurin inhibitor (e.g. tacrolimus)</li> <li>○ Oral immunomodulator therapy (e.g. cyclosporine, methotrexate, azathioprine, mycophenolate mofetil).</li> <li>● Failure of Dupixent</li> </ul> <p><b>Crohn’s Disease (CD):</b></p> <ul style="list-style-type: none"> <li>● Documentation of moderate-to-severe Crohn’s Disease</li> <li>● The member is transitioning to the requested treatment from a different biologic product previously approved by the plan OR Documented trial and failure of at least 1 of the following: 6-mercaptopurine, azathioprine, corticosteroid, methotrexate</li> <li>● Trial and failure of both infliximab and adalimumab</li> <li>● Trial and failure of Cimzia, Entyvio, Stelara</li> </ul> <p><b>Psoriatic Arthritis (PsA):</b></p> <ul style="list-style-type: none"> <li>● Documentation of psoriatic arthritis based on at least 3 out of 5 of the following: <ul style="list-style-type: none"> <li>○ Psoriasis (1 point for personal or family history, 2 points for current)</li> <li>○ Psoriatic nail dystrophy</li> <li>○ Negative test result for RF</li> <li>○ Dactylitis (current or history)</li> <li>○ Radiological evidence of juxta-articular new bone formation</li> </ul> </li> <li>● The member is transitioning to the requested treatment from a different biologic product previously approved by the plan OR documented failure of conventional therapy with both of the following: <ul style="list-style-type: none"> <li>○ NSAIDs for 3 months at maximum recommended or tolerated anti-inflammatory dose unless contraindicated, AND</li> <li>○ Methotrexate or other DMARD such as leflunomide, sulfasalazine, or cyclosporine</li> </ul> </li> <li>● Trial and failure of both infliximab and adalimumab</li> <li>● Trial and failure of Cosentyx, Otezla, Stelara, Orencia, and Taltz</li> </ul> <p><b>Rheumatoid Arthritis (RA):</b></p> <ul style="list-style-type: none"> <li>● Documentation of a baseline of moderate to high disease activity of rheumatoid arthritis measured as such by an accepted assessment instrument (PAS, PASII, RAPID3, CDAI, DAS28, SDAI)</li> <li>● The member is transitioning to the requested treatment from a different biologic product previously approved by the plan OR documented failure of nonbiologic DMARD therapy: methotrexate</li> </ul>

PA Criteria	Criteria Details
	<p>(dosed at least 20mg per week for at least 8 weeks), leflunomide or sulfasalazine</p> <ul style="list-style-type: none"> <li>• Trial and failure of both infliximab and adalimumab</li> <li>• Trial and failure of Actemra, Cimzia, Kineret, Orencia, and rituximab</li> </ul> <p><b>Ulcerative Colitis (UC):</b></p> <ul style="list-style-type: none"> <li>• Documentation of moderate-to-severe ulcerative colitis</li> <li>• The member is transitioning to the requested treatment from a different biologic product previously approved by the plan OR documented failure of at least 1 of the following: <ul style="list-style-type: none"> <li>○ Mesalamine, sulfasalazine OR</li> <li>○ Mercaptopurine, azathioprine, OR</li> <li>○ Corticosteroids (prednisone, methylprednisolone)</li> </ul> </li> <li>• Trial and failure of both infliximab and adalimumab</li> <li>• Trial and failure of Entyvio and Stelara</li> </ul>
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	<p><b>Atopic Dermatitis:</b> Dermatologist  <b>Crohns Disease and Ulcerative Colitis:</b> Gastroenterologist.  <b>Psoriatic Arthritis:</b> Dermatologist or Rheumatologist.  <b>Rheumatoid Arthritis:</b> Rheumatologist.  <b>Ankylosing Spondylitis, Axial Spondyloarthritis:</b> Rheumatologist.</p>
<b>Coverage Duration</b>	<b>Initial:</b> 6 months. <b>Renewal:</b> 12 months.
<b>Renewal Criteria</b>	<p><b>AS/SpA:</b> Evidence of significant improvement in signs and symptoms of AS/SpA and/or functioning, such as ASAS40 or 2-point improvement in BASDAI.</p> <p><b>AD:</b> Evidence of positive clinical response to therapy as evidenced by ONE of the following: reduction of body surface area (BSA) involvement from baseline, improvement in symptoms (e.g. pruritus, inflammation) from baseline, or evidence of functional improvement.</p> <p><b>CD:</b> Evidence of a decrease in symptoms, reduction in enterocutaneous fistulas or clinical remission.</p> <p><b>PsA:</b> Evidence of a 20% or greater improvement in tender joint count and swollen joint count.</p>

PA Criteria	Criteria Details
	<p><b>RA:</b> Evidence of a 20% or greater improvement in tender joint count and swollen joint count.</p> <p><b>UC:</b> Evidence of a significant response such as a decrease in bloody stools per day or elimination of signs of toxicity.</p>

Effective Date:	9/1/2023
P&T Approval Date:	7/11/2023
P&T Revision Date:	07/11/2023, 01/11/2022





# Ustekinumab SC (STELARA)

## Products Affected

- STELARA 45MG/0.5ML, 90 MG/ML

PA Criteria	Criteria Details
<p><b>Required Medical Information</b></p>	<p><b>All diagnoses:</b></p> <ul style="list-style-type: none"> <li>• Initial testing for latent TB and treatment, if necessary, before starting treatment.</li> <li>• No current active infection at initiation of therapy.</li> <li>• Risks and benefits documented in cases of chronic or recurrent infection.</li> <li>• Will NOT be used in combination with another biologic or Otezla</li> </ul> <p><b>Crohn's Disease (CD):</b></p> <ul style="list-style-type: none"> <li>• Documentation of moderate-to-severe Crohn's Disease</li> <li>• The member is transitioning to the requested treatment from a different biologic product previously approved by the plan OR Documented trial and failure of at least 1 of the following: 6-mercaptopurine, azathioprine, corticosteroid, methotrexate</li> <li>• Trial and failure of both infliximab and adalimumab</li> </ul> <p><b>Plaque Psoriasis (PP):</b></p> <ul style="list-style-type: none"> <li>• Documentation of severe plaque psoriasis, defined as having functional impairment as indicated by Dermatology Life Quality Index (DLQI) = 11 or Children's Dermatology Life Quality Index (CDLQI) = 13 (or severe score on other validated tool) AND one or more of the following: <ul style="list-style-type: none"> <li>○ At least 10% of body surface area involved</li> <li>○ Hand, foot, face, or mucous membrane involvement</li> </ul> </li> <li>• The member is transitioning to the requested treatment from a different biologic product previously approved by the plan OR documented failure of all the following: <ul style="list-style-type: none"> <li>○ High-potency topical corticosteroids (augmented betamethasone, clobetasol, etc.)</li> <li>○ At least one other topical agent (calcipotriene, tazarotene, anthralin, tar, etc.)</li> <li>○ PUVA or UVB Phototherapy</li> <li>○ Methotrexate</li> <li>○ At least 1 other second line systemic agent such as cyclosporine or acitretin</li> </ul> </li> </ul>

PA Criteria	Criteria Details
	<ul style="list-style-type: none"> <li>• Trial and failure of both infliximab and adalimumab</li> </ul> <p><b>Psoriatic Arthritis (PsA):</b></p> <ul style="list-style-type: none"> <li>• Documentation of psoriatic arthritis based on at least 3 out of 5 of the following: <ul style="list-style-type: none"> <li>○ Psoriasis (1 point for personal or family history, 2 points for current)</li> <li>○ Psoriatic nail dystrophy</li> <li>○ Negative test result for RF</li> <li>○ Dactylitis (current or history)</li> <li>○ Radiological evidence of juxta-articular new bone formation</li> </ul> </li> <li>• The member is transitioning to the requested treatment from a different biologic product previously approved by the plan OR documented failure of conventional therapy with both of the following: <ul style="list-style-type: none"> <li>○ NSAIDs for 3 months at maximum recommended or tolerated anti-inflammatory dose unless contraindicated, AND</li> <li>○ Methotrexate or other DMARD such as leflunomide, sulfasalazine, or cyclosporine</li> </ul> </li> <li>• Trial and failure of both infliximab and adalimumab</li> </ul> <p><b>Ulcerative Colitis (UC):</b></p> <ul style="list-style-type: none"> <li>• Documentation of moderate-to-severe ulcerative colitis</li> <li>• The member is transitioning to the requested treatment from a different biologic product previously approved by the plan OR documented failure of at least 1 of the following: <ul style="list-style-type: none"> <li>○ Mesalamine, sulfasalazine OR</li> <li>○ Mercaptopurine, azathioprine, OR</li> <li>○ Corticosteroids (prednisone, methylprednisolone)</li> </ul> </li> <li>• Trial and failure of both infliximab and adalimumab</li> </ul>
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	<p><b>Crohns Disease and Ulcerative Colitis:</b> Gastroenterologist.  <b>Plaque Psoriasis:</b> Dermatologist.  <b>Psoriatic Arthritis:</b> Dermatologist or Rheumatologist.</p>
<b>Coverage Duration</b>	<b>Initial:</b> 6 months. <b>Renewal:</b> 12 months.
<b>Renewal Criteria</b>	<b>CD:</b> Evidence of a decrease in symptoms, reduction in enterocutaneous fistulas or clinical remission.

PA Criteria	Criteria Details
	<p><b>PP:</b> Evidence of positive clinical response to therapy as evidenced by ONE of the following: reduction of body surface area (BSA) involvement from baseline, improvement in symptoms (e.g. pruritus, inflammation) from baseline, or evidence of functional improvement.</p> <p><b>PsA:</b> Evidence of a 20% or greater improvement in tender joint count and swollen joint count.</p> <p><b>UC:</b> Evidence of a significant response such as a decrease in bloody stools per day or elimination of signs of toxicity.</p>

Effective Date:	9/1/2023
P&T Approval Date:	7/11/2023
P&T Revision Date:	07/11/2023, 01/11/2022

# Voriconazole (VFEND)

**Products Affected**

- VORICONAZOLE

PA Criteria	Criteria Details
<b>Required Medical Information</b>	Approved for treatment of invasive aspergillosis and treatment of serious fungal infections in patients intolerant of, or refractory to other therapy.
<b>Age Restrictions</b>	<b>Suspension only:</b> Member is under age 10 or unable to use tablets
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	<b>Initial:</b> 3 months. <b>Renewal:</b> 3 months.
<b>Renewal Criteria</b>	Documented positive clinical response to therapy

Effective Date:	5/1/2024
P&T Approval Date:	3/12/2024
P&T Revision Date:	3/12/2024



# Zafirlukast (ACCOLATE)

**Products Affected**

- ZAFIRLUKAST

PA Criteria	Criteria Details
<b>Required Medical Information</b>	Patient has a diagnosis of asthma <b>AND</b> Patient has experienced suboptimal control with combined use of an inhaled steroid and beta agonist.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	<b>Initial:</b> 12 months. <b>Renewal:</b> 12 months.
<b>Renewal Criteria</b>	Documented positive clinical response to therapy

Effective Date:	
P&T Approval Date:	
P&T Revision Date:	